diff --git a/.gitignore b/.gitignore
index fe49e6b..3eb9de7 100644
--- a/.gitignore
+++ b/.gitignore
@@ -16,3 +16,9 @@ output/
 # IDE
 .vscode/
 .idea/
+
+# 런타임 DB
+*.db
+
+# 개발/디버깅 스크립트
+_dev_scripts/
diff --git a/anipharm_api.py b/anipharm_api.py
new file mode 100644
index 0000000..035d4f4
--- /dev/null
+++ b/anipharm_api.py
@@ -0,0 +1,379 @@
+#!/usr/bin/env python
+# -*- coding: utf-8 -*-
+"""
+애니팜 투약지도서 API
+- 동물약 PDF 생성 API
+- 포트: 7002
+"""
+
+from flask import Flask, request, jsonify, send_file, render_template_string
+from flask_cors import CORS
+import os
+import tempfile
+import uuid
+import sqlite3
+from datetime import datetime
+
+from animal_med.renderer_v2 import AnimalMedRendererV2
+
+app = Flask(__name__)
+CORS(app)
+
+# 렌더러 인스턴스 (싱글톤)
+renderer = AnimalMedRendererV2()
+
+# 출력 디렉토리
+OUTPUT_DIR = os.path.join(os.path.dirname(__file__), 'output')
+os.makedirs(OUTPUT_DIR, exist_ok=True)
+
+# ─────────────────────────────────────────────────────────────
+# SQLite 접속 로그 DB
+# ─────────────────────────────────────────────────────────────
+LOGS_DB = os.path.join(os.path.dirname(__file__), 'lecture_logs.db')
+
+def init_logs_db():
+    """접속 로그 DB 초기화"""
+    conn = sqlite3.connect(LOGS_DB)
+    c = conn.cursor()
+    c.execute('''
+        CREATE TABLE IF NOT EXISTS lecture_views (
+            id INTEGER PRIMARY KEY AUTOINCREMENT,
+            lecture_id INTEGER NOT NULL,
+            ip_address TEXT,
+            user_agent TEXT,
+            referer TEXT,
+            viewed_at TIMESTAMP DEFAULT CURRENT_TIMESTAMP
+        )
+    ''')
+    c.execute('CREATE INDEX IF NOT EXISTS idx_lecture_id ON lecture_views(lecture_id)')
+    c.execute('CREATE INDEX IF NOT EXISTS idx_viewed_at ON lecture_views(viewed_at)')
+    conn.commit()
+    conn.close()
+
+def log_lecture_view(lecture_id, ip, user_agent, referer):
+    """강의 조회 로깅"""
+    try:
+        conn = sqlite3.connect(LOGS_DB)
+        c = conn.cursor()
+        c.execute('''
+            INSERT INTO lecture_views (lecture_id, ip_address, user_agent, referer)
+            VALUES (?, ?, ?, ?)
+        ''', (lecture_id, ip, user_agent[:500] if user_agent else None, referer[:500] if referer else None))
+        conn.commit()
+        conn.close()
+    except Exception as e:
+        print(f"[LOG ERROR] {e}")
+
+# DB 초기화
+init_logs_db()
+
+
+@app.route('/health', methods=['GET'])
+def health():
+    """헬스체크"""
+    return jsonify({
+        'status': 'ok',
+        'service': 'anipharm-api',
+        'timestamp': datetime.now().isoformat()
+    })
+
+
+@app.route('/api/products', methods=['GET'])
+def list_products():
+    """등록된 약품 목록 조회"""
+    products = renderer.list_drugs()
+    return jsonify({
+        'success': True,
+        'count': len(products),
+        'products': products
+    })
+
+
+@app.route('/api/guide/pdf', methods=['POST'])
+def generate_pdf():
+    """
+    투약지도서 PDF 생성
+    
+    Request Body:
+    {
+        "product_ids": ["nexgard_spectra", "heartsaver", ...],
+        "patient_name": "김남곤",
+        "pet_name": "뽀삐",
+        "pet_species": "푸들",
+        "pet_age": "3세",
+        "pharmacy_name": "청춘약국 동물약 전문상담",  // optional
+        "pharmacy_tel": "033-481-0384"  // optional
+    }
+    
+    Response: PDF 파일 (application/pdf)
+    """
+    try:
+        data = request.get_json()
+        
+        if not data:
+            return jsonify({'success': False, 'error': 'No JSON data'}), 400
+        
+        product_ids = data.get('product_ids', [])
+        if not product_ids:
+            return jsonify({'success': False, 'error': 'product_ids required'}), 400
+        
+        # 파일명 생성
+        timestamp = datetime.now().strftime('%Y%m%d_%H%M%S')
+        filename = f"guide_{timestamp}_{uuid.uuid4().hex[:8]}.pdf"
+        output_path = os.path.join(OUTPUT_DIR, filename)
+        
+        # PDF 생성
+        result = renderer.render_to_pdf(
+            product_ids=product_ids,
+            output_path=output_path,
+            patient_name=data.get('patient_name', '보호자'),
+            pet_name=data.get('pet_name', '반려동물'),
+            pet_species=data.get('pet_species', ''),
+            pet_age=data.get('pet_age', ''),
+            pharmacy_name=data.get('pharmacy_name', '청춘약국 동물약 전문상담'),
+            pharmacy_tel=data.get('pharmacy_tel', '033-481-0384')
+        )
+        
+        if result['success']:
+            return send_file(
+                output_path,
+                mimetype='application/pdf',
+                as_attachment=True,
+                download_name=f"투약지도서_{timestamp}.pdf"
+            )
+        else:
+            return jsonify({
+                'success': False,
+                'error': result.get('error', 'Unknown error')
+            }), 500
+            
+    except Exception as e:
+        return jsonify({
+            'success': False,
+            'error': str(e)
+        }), 500
+
+
+@app.route('/api/guide/preview', methods=['POST'])
+def preview_guide():
+    """
+    투약지도서 미리보기 (메타데이터만 반환)
+    
+    Request Body: generate_pdf와 동일
+    Response: JSON (약품 정보 + 예상 페이지 수)
+    """
+    try:
+        data = request.get_json()
+        
+        if not data:
+            return jsonify({'success': False, 'error': 'No JSON data'}), 400
+        
+        product_ids = data.get('product_ids', [])
+        if not product_ids:
+            return jsonify({'success': False, 'error': 'product_ids required'}), 400
+        
+        # 약품 정보 조회
+        drugs = []
+        for pid in product_ids:
+            drug = renderer.get_drug(pid)
+            if drug:
+                drugs.append({
+                    'id': pid,
+                    'name': drug.get('name'),
+                    'category': drug.get('category'),
+                    'has_image': bool(drug.get('image_url') or drug.get('apc_code'))
+                })
+        
+        # 페이지 수 계산 (4개/페이지)
+        page_count = (len(drugs) + 3) // 4
+        
+        return jsonify({
+            'success': True,
+            'drug_count': len(drugs),
+            'page_count': page_count,
+            'drugs': drugs
+        })
+        
+    except Exception as e:
+        return jsonify({
+            'success': False,
+            'error': str(e)
+        }), 500
+
+
+# ─────────────────────────────────────────────────────────────
+# 동물약 강의 콘텐츠 라우트
+# ─────────────────────────────────────────────────────────────
+LECTURES_DIR = os.path.join(os.path.dirname(__file__), 'static', 'lectures')
+os.makedirs(LECTURES_DIR, exist_ok=True)
+
+@app.route('/lecture/<int:lecture_id>')
+def serve_lecture(lecture_id):
+    """동물약 강의 콘텐츠 서빙 (카카오톡 og 태그 포함) + 접속 로깅"""
+    from flask import send_from_directory
+    
+    # 접속 로깅
+    ip = request.headers.get('X-Forwarded-For', request.remote_addr)
+    user_agent = request.headers.get('User-Agent', '')
+    referer = request.headers.get('Referer', '')
+    log_lecture_view(lecture_id, ip, user_agent, referer)
+    
+    filename = f'lecture_{lecture_id:02d}.html'
+    return send_from_directory(LECTURES_DIR, filename)
+
+
+# ─────────────────────────────────────────────────────────────
+# 관리자 페이지 - 강의 접속 통계
+# ─────────────────────────────────────────────────────────────
+ADMIN_HTML = '''
+<!DOCTYPE html>
+<html lang="ko">
+<head>
+    <meta charset="UTF-8">
+    <meta name="viewport" content="width=device-width, initial-scale=1.0">
+    <title>📊 강의 접속 통계 - 애니팜</title>
+    <style>
+        * { box-sizing: border-box; }
+        body { font-family: 'Pretendard', -apple-system, sans-serif; background: #f5f7fa; margin: 0; padding: 20px; }
+        .container { max-width: 1000px; margin: 0 auto; }
+        h1 { color: #008BD5; margin-bottom: 30px; }
+        .card { background: white; border-radius: 12px; padding: 24px; margin-bottom: 20px; box-shadow: 0 2px 8px rgba(0,0,0,0.08); }
+        .card h2 { margin-top: 0; color: #333; font-size: 1.2em; border-bottom: 2px solid #008BD5; padding-bottom: 10px; }
+        .stat-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(200px, 1fr)); gap: 16px; margin-bottom: 20px; }
+        .stat-box { background: linear-gradient(135deg, #008BD5, #00a8e8); color: white; padding: 20px; border-radius: 10px; text-align: center; }
+        .stat-box .number { font-size: 2.5em; font-weight: bold; }
+        .stat-box .label { font-size: 0.9em; opacity: 0.9; }
+        table { width: 100%; border-collapse: collapse; }
+        th, td { padding: 12px; text-align: left; border-bottom: 1px solid #eee; }
+        th { background: #f8f9fa; color: #666; font-weight: 600; }
+        tr:hover { background: #f8f9fa; }
+        .ip { font-family: monospace; color: #666; font-size: 0.9em; }
+        .time { color: #888; font-size: 0.85em; }
+        .ua { color: #999; font-size: 0.75em; max-width: 300px; overflow: hidden; text-overflow: ellipsis; white-space: nowrap; }
+        .badge { display: inline-block; padding: 4px 10px; border-radius: 20px; font-size: 0.8em; font-weight: 600; }
+        .badge-lecture { background: #e3f2fd; color: #1976d2; }
+        .refresh-btn { background: #008BD5; color: white; border: none; padding: 10px 20px; border-radius: 8px; cursor: pointer; font-size: 1em; }
+        .refresh-btn:hover { background: #0077b6; }
+    </style>
+</head>
+<body>
+    <div class="container">
+        <h1>📊 강의 접속 통계</h1>
+        
+        <div class="stat-grid">
+            <div class="stat-box">
+                <div class="number">{{ total_views }}</div>
+                <div class="label">총 조회수</div>
+            </div>
+            <div class="stat-box">
+                <div class="number">{{ today_views }}</div>
+                <div class="label">오늘 조회수</div>
+            </div>
+            <div class="stat-box">
+                <div class="number">{{ unique_ips }}</div>
+                <div class="label">순 방문자 (IP)</div>
+            </div>
+        </div>
+        
+        <div class="card">
+            <h2>📈 강의별 조회수</h2>
+            <table>
+                <thead>
+                    <tr><th>강의</th><th>조회수</th><th>최근 조회</th></tr>
+                </thead>
+                <tbody>
+                {% for row in lecture_stats %}
+                    <tr>
+                        <td><span class="badge badge-lecture">Lecture {{ row[0] }}</span></td>
+                        <td><strong>{{ row[1] }}</strong>회</td>
+                        <td class="time">{{ row[2] }}</td>
+                    </tr>
+                {% endfor %}
+                </tbody>
+            </table>
+        </div>
+        
+        <div class="card">
+            <h2>🕐 최근 접속 로그 (50건)</h2>
+            <table>
+                <thead>
+                    <tr><th>시간</th><th>강의</th><th>IP</th><th>Referer</th></tr>
+                </thead>
+                <tbody>
+                {% for row in recent_logs %}
+                    <tr>
+                        <td class="time">{{ row[0] }}</td>
+                        <td><span class="badge badge-lecture">Lecture {{ row[1] }}</span></td>
+                        <td class="ip">{{ row[2] }}</td>
+                        <td class="ua">{{ row[3] or '-' }}</td>
+                    </tr>
+                {% endfor %}
+                </tbody>
+            </table>
+        </div>
+        
+        <button class="refresh-btn" onclick="location.reload()">🔄 새로고침</button>
+    </div>
+</body>
+</html>
+'''
+
+@app.route('/admin/lectures')
+def admin_lectures():
+    """강의 접속 통계 관리자 페이지"""
+    conn = sqlite3.connect(LOGS_DB)
+    c = conn.cursor()
+    
+    # 총 조회수
+    c.execute('SELECT COUNT(*) FROM lecture_views')
+    total_views = c.fetchone()[0]
+    
+    # 오늘 조회수
+    c.execute("SELECT COUNT(*) FROM lecture_views WHERE date(viewed_at) = date('now', 'localtime')")
+    today_views = c.fetchone()[0]
+    
+    # 순 방문자 (unique IP)
+    c.execute('SELECT COUNT(DISTINCT ip_address) FROM lecture_views')
+    unique_ips = c.fetchone()[0]
+    
+    # 강의별 통계
+    c.execute('''
+        SELECT lecture_id, COUNT(*) as cnt, MAX(viewed_at) as last_view
+        FROM lecture_views
+        GROUP BY lecture_id
+        ORDER BY cnt DESC
+    ''')
+    lecture_stats = c.fetchall()
+    
+    # 최근 로그 50건
+    c.execute('''
+        SELECT viewed_at, lecture_id, ip_address, referer
+        FROM lecture_views
+        ORDER BY viewed_at DESC
+        LIMIT 50
+    ''')
+    recent_logs = c.fetchall()
+    
+    conn.close()
+    
+    return render_template_string(ADMIN_HTML,
+        total_views=total_views,
+        today_views=today_views,
+        unique_ips=unique_ips,
+        lecture_stats=lecture_stats,
+        recent_logs=recent_logs
+    )
+
+
+if __name__ == '__main__':
+    print("=" * 50)
+    print("🐾 애니팜 투약지도서 API")
+    print("=" * 50)
+    print(f"📍 http://localhost:7002")
+    print(f"📋 GET  /health - 헬스체크")
+    print(f"📋 GET  /api/products - 약품 목록")
+    print(f"📋 POST /api/guide/pdf - PDF 생성")
+    print(f"📋 POST /api/guide/preview - 미리보기")
+    print("=" * 50)
+    
+    app.run(host='0.0.0.0', port=7002, debug=False, threaded=True)
diff --git a/data/master/actibet.json b/data/master/actibet.json
index b29cf05..ae92c21 100644
--- a/data/master/actibet.json
+++ b/data/master/actibet.json
@@ -1,58 +1,386 @@
 {
   "product_id": "MASTER-016",
-  "apc_code": "0519-ACTIBET",
+  "apc_code": "9240043910403",
   "name": "액티벳정",
   "english_name": "Actibet (Amoxicillin + Clavulanate)",
   "manufacturer": "홍익메디케어",
   "category": "antibiotic",
   "category_display": "항생제 (β-Lactam)",
-  "target_animal": ["개", "고양이"],
+  "drug_class": "Aminopenicillin + β-Lactamase 억제제",
+  "ema_ameg_category": "D (Prudence) — 1차 선택 가능",
+  "who_classification": "CIA (Critically Important Antimicrobials) - High Priority",
+  "target_animal": [
+    "개",
+    "고양이"
+  ],
   "administration": "경구 (정제)",
-
-  "indication": "광범위 세균 감염 (피부, 호흡기, 요로, 치주)",
-  
+  "composition": {
+    "amoxicillin_mg": 40,
+    "potassium_clavulanate_mg": 10,
+    "ratio": "4:1",
+    "description": "아목시실린 40mg + 클라불란산칼륨 10mg (1정 기준)"
+  },
   "mechanism": {
-    "amoxicillin": "40mg - PBP 결합 → 세포벽 합성 억제 → 살균",
-    "clavulanate": "10mg - β-Lactamase 억제 → 내성균 커버 확장",
-    "ratio": "4:1 (Amoxicillin:Clavulanate)"
+    "amoxicillin": "세균 세포벽 합성 효소(PBP)에 결합 → Peptidoglycan 교차결합 억제 → 세포벽 파괴 → 살균",
+    "clavulanate": "β-Lactamase 효소에 비가역적 결합 → 아목시실린 분해 방지 → 내성균 커버 확장",
+    "killing_type": "살균성(bactericidal), 시간 의존적(time-dependent)",
+    "clinical_implication": "MIC 이상 농도 유지 시간이 효능 결정 → 1일 2회 분할 투여 필수"
+  },
+  "spectrum": {
+    "gram_positive_aerobic": [
+      "Staphylococcus pseudintermedius (MSSP)",
+      "Staphylococcus aureus (MSSA)",
+      "Streptococcus spp.",
+      "Enterococcus faecalis"
+    ],
+    "gram_negative_aerobic": [
+      "Escherichia coli",
+      "Proteus mirabilis",
+      "Klebsiella spp.",
+      "Pasteurella multocida"
+    ],
+    "anaerobes": [
+      "Bacteroides spp.",
+      "Fusobacterium spp.",
+      "Clostridium spp. (일부)"
+    ],
+    "resistant_organisms": [
+      "MRSP (메티실린 내성 S. pseudintermedius)",
+      "MRSA",
+      "Pseudomonas aeruginosa",
+      "Mycoplasma spp.",
+      "Bordetella bronchiseptica (일부)"
+    ]
+  },
+  "indications": {
+    "summary": "광범위 세균 감염 (피부, 요로, 호흡기, 연조직, 구강)",
+    "detailed": [
+      {
+        "name": "피부감염 (농피증)",
+        "description": "표재성 및 심부 세균성 피부감염",
+        "iscaid_position": "전신 항생제 1차 선택 (국소치료 실패 시)"
+      },
+      {
+        "name": "요로감염 (방광염, 신우신염)",
+        "description": "단순 산발성 방광염부터 복잡성 상부 UTI까지",
+        "iscaid_position": "1차 선택"
+      },
+      {
+        "name": "호흡기 감염",
+        "description": "상·하부 호흡기 세균 감염 (폐렴 포함)",
+        "iscaid_position": "대안 1차 (Doxycycline 불가 시)"
+      },
+      {
+        "name": "연조직 감염",
+        "description": "농양, 항문낭염, 교상(물린 상처)",
+        "iscaid_position": "1차 선택"
+      },
+      {
+        "name": "구강/치주 감염",
+        "description": "치주질환, 구강 내 혼합감염",
+        "iscaid_position": "2차 (Clindamycin이 1차)"
+      }
+    ]
   },
-
   "dosage": {
-    "standard": "12.5mg/kg 1일 2회",
-    "formula": "체중 4kg당 1정",
-    "duration": "5~7일 (질환별 상이)"
+    "standard": "12.5mg/kg (복합) 1일 2회 (q12h)",
+    "formula": "체중 4kg당 1정, 12시간 간격",
+    "per_kg": {
+      "amoxicillin": "10mg/kg/회",
+      "clavulanate": "2.5mg/kg/회"
+    }
   },
-
   "dosage_table": [
-    {"weight": "4kg", "tablets": "1정 × 2회"},
-    {"weight": "8kg", "tablets": "2정 × 2회"},
-    {"weight": "12kg", "tablets": "3정 × 2회"},
-    {"weight": "20kg", "tablets": "5정 × 2회"}
+    {
+      "weight": "2kg",
+      "tablets_per_dose": "0.5정",
+      "frequency": "1일 2회",
+      "daily_amoxicillin": "40mg",
+      "daily_clavulanate": "10mg"
+    },
+    {
+      "weight": "4kg",
+      "tablets_per_dose": "1정",
+      "frequency": "1일 2회",
+      "daily_amoxicillin": "80mg",
+      "daily_clavulanate": "20mg"
+    },
+    {
+      "weight": "6kg",
+      "tablets_per_dose": "1.5정",
+      "frequency": "1일 2회",
+      "daily_amoxicillin": "120mg",
+      "daily_clavulanate": "30mg"
+    },
+    {
+      "weight": "8kg",
+      "tablets_per_dose": "2정",
+      "frequency": "1일 2회",
+      "daily_amoxicillin": "160mg",
+      "daily_clavulanate": "40mg"
+    },
+    {
+      "weight": "10kg",
+      "tablets_per_dose": "2.5정",
+      "frequency": "1일 2회",
+      "daily_amoxicillin": "200mg",
+      "daily_clavulanate": "50mg"
+    },
+    {
+      "weight": "12kg",
+      "tablets_per_dose": "3정",
+      "frequency": "1일 2회",
+      "daily_amoxicillin": "240mg",
+      "daily_clavulanate": "60mg"
+    },
+    {
+      "weight": "16kg",
+      "tablets_per_dose": "4정",
+      "frequency": "1일 2회",
+      "daily_amoxicillin": "320mg",
+      "daily_clavulanate": "80mg"
+    },
+    {
+      "weight": "20kg",
+      "tablets_per_dose": "5정",
+      "frequency": "1일 2회",
+      "daily_amoxicillin": "400mg",
+      "daily_clavulanate": "100mg"
+    }
   ],
-
-  "indications_by_disease": {
-    "skin_pyoderma": "5~7일 (표재성) / 3~4주 (심부)",
-    "uti": "7~14일",
-    "respiratory": "7~10일",
-    "dental": "수술 전후 5~7일"
+  "duration_by_indication": [
+    {
+      "indication": "단순 방광염",
+      "duration": "3~5일",
+      "note": "ISCAID 2019 권장. 증상 소실 후에도 완료",
+      "source": "ISCAID UTI Guidelines 2019"
+    },
+    {
+      "indication": "신우신염 (상부 UTI)",
+      "duration": "10~14일",
+      "note": "전신 증상 동반 시. 배양검사 권장",
+      "source": "ISCAID UTI Guidelines 2019"
+    },
+    {
+      "indication": "표재성 농피증",
+      "duration": "2주 + 재평가",
+      "note": "국소치료 실패 시만 전신투여. 임상호전 후 1주 추가",
+      "source": "ISCAID Pyoderma Guidelines 2025"
+    },
+    {
+      "indication": "심부 농피증",
+      "duration": "3주 + 재평가",
+      "note": "배양검사 권장. 증상 소실 후 최소 1주 연장",
+      "source": "ISCAID Pyoderma Guidelines 2025"
+    },
+    {
+      "indication": "상부 호흡기 감염",
+      "duration": "7~10일",
+      "note": "Mycoplasma 의심 시 Doxycycline 선택",
+      "source": "ISCAID Respiratory Guidelines 2017"
+    },
+    {
+      "indication": "하부 호흡기/폐렴 (개)",
+      "duration": "14일",
+      "note": "경증~중등도 폐렴",
+      "source": "ISCAID Respiratory Guidelines 2017"
+    },
+    {
+      "indication": "하부 호흡기/폐렴 (고양이)",
+      "duration": "21일",
+      "note": "고양이는 재발률 높아 장기 투여",
+      "source": "ISCAID Respiratory Guidelines 2017"
+    },
+    {
+      "indication": "연조직 감염/교상",
+      "duration": "5~7일",
+      "note": "Pasteurella + 혐기성균 동시 커버",
+      "source": "ISCAID"
+    },
+    {
+      "indication": "치주/구강 감염",
+      "duration": "5~7일",
+      "note": "수술 전후 예방적 투여 포함",
+      "source": "General practice"
+    }
+  ],
+  "administration_instructions": {
+    "timing": [
+      "1일 2회, 12시간 간격 유지 (예: 아침 8시, 저녁 8시)",
+      "시간 의존적 살균제 → 일정한 간격이 효과에 중요"
+    ],
+    "with_food": {
+      "recommended": true,
+      "reason": "음식과 함께 투여 시 위장관 부작용 감소",
+      "note": "공복 투여도 가능하나 구토/설사 위험 증가"
+    },
+    "completion_importance": {
+      "message": "증상이 나아져도 처방 기간 끝까지 복용 완료",
+      "reason": "불완전 투약 시 남은 세균이 내성을 획득할 위험",
+      "warning": "임의 중단은 항생제 내성 유발의 주요 원인"
+    },
+    "missed_dose": "1회분을 놓쳤을 경우 기억난 즉시 투여. 다음 투약 시간이 가까우면 건너뛰고 다음 회차에 정상 용량 투여 (2배 용량 투여 금지)"
   },
-
+  "side_effects": {
+    "common": [
+      {
+        "symptom": "구토",
+        "frequency": "흔함",
+        "management": "음식과 함께 투여. 지속 시 수의사 상담"
+      },
+      {
+        "symptom": "설사",
+        "frequency": "흔함",
+        "management": "장내균총 교란 가능. 프로바이오틱스 병행 고려 (투약 2시간 간격)"
+      },
+      {
+        "symptom": "식욕 부진",
+        "frequency": "흔함",
+        "management": "대부분 일시적. 지속 시 수의사 상담"
+      }
+    ],
+    "uncommon": [
+      {
+        "symptom": "알레르기 반응 (두드러기, 안면부종, 호흡곤란)",
+        "frequency": "드묾",
+        "management": "즉시 투약 중단 및 응급 처치 필요",
+        "severity": "심각"
+      },
+      {
+        "symptom": "아나필락시스",
+        "frequency": "매우 드묾",
+        "management": "응급 상황. 에피네프린 투여 필요",
+        "severity": "생명 위협"
+      }
+    ],
+    "when_to_stop": [
+      "심한 구토/설사가 지속될 때",
+      "두드러기, 안면 부종, 호흡 곤란 발생 시 (알레르기)",
+      "혈변, 극심한 복통 등 심각한 증상 시"
+    ]
+  },
+  "contraindications": [
+    {
+      "condition": "페니실린 계열 알레르기",
+      "severity": "절대 금기",
+      "note": "과거 페니실린/세팔로스포린 과민반응 이력 있는 경우"
+    },
+    {
+      "condition": "중증 신부전",
+      "severity": "주의 필요",
+      "note": "용량 조절 또는 투여 간격 연장 필요. 수의사 판단"
+    }
+  ],
   "warnings": [
-    "⚠️ 페니실린 알레르기 과거력 확인",
-    "⚠️ 소형견/고양이 정확한 체중 투여",
-    "⚠️ 시간 의존적 살균 → 분할 투여 필수",
-    "⚠️ 장기 투여 시 내성균 모니터링"
+    "⚠️ 페니실린 알레르기 과거력 반드시 확인",
+    "⚠️ 소형견/고양이는 체중에 정확히 비례하여 투여 (과량 주의)",
+    "⚠️ 시간 의존적 살균제 → 1일 2회 분할 투여 필수 (1일 1회 투여 금지)",
+    "⚠️ 사람용 오그멘틴(Augmentin) 임의 투여 금지 (비율/용량 다름)",
+    "⚠️ 장기 투여 시 내성균 발생 모니터링 필요",
+    "⚠️ 치료 실패 시 배양검사 시행 (경험적 재처방 지양)"
   ],
-
-  "clinical_notes": [
-    "EMA AMEG Category D: 1차 선택 가능",
-    "β-Lactamase 생산균까지 커버 (단독 AMX 대비)",
-    "MIC 이상 농도 유지 시간이 핵심 → BID 분할"
-  ],
-
-  "source": {
-    "guidelines": ["ISCAID (수의 피부과)", "AAHA"]
+  "antibiotic_stewardship": {
+    "importance": "항생제 내성은 인수공통 문제. 동물에서의 오남용은 사람에게도 영향",
+    "principles": [
+      "처방된 기간 끝까지 복용 완료 (조기 중단 금지)",
+      "남은 약 보관 후 자가 투약 금지",
+      "증상 재발 시 수의사 재진 (같은 약 임의 복용 금지)",
+      "가능하면 배양검사 후 처방 (특히 재발/치료 실패 시)"
+    ],
+    "resistance_warning": "불완전 투약, 과소/과다 용량, 불필요한 처방은 내성균 선택의 주요 원인",
+    "iscaid_effect": "ISCAID 가이드라인 준수 결과 이탈리아에서 E.coli의 AMX-CLV 내성률이 52.6%→25.6%로 감소 (PMID:41012835)"
   },
-
-  "storage": "25°C 이하, 건조, 차광 보관"
-}
+  "drug_interactions": [
+    {
+      "drug": "Methotrexate",
+      "effect": "Methotrexate 배설 감소 → 독성 증가 가능",
+      "recommendation": "병용 시 모니터링 필요"
+    },
+    {
+      "drug": "Probenecid",
+      "effect": "아목시실린 신장 배설 억제 → 혈중 농도 상승",
+      "recommendation": "용량 조절 고려"
+    },
+    {
+      "drug": "구충제 (일반)",
+      "effect": "대부분 병용 가능",
+      "recommendation": "펜벤다졸, 이버멕틴 등 일반 구충제와 병용 안전"
+    },
+    {
+      "drug": "프로바이오틱스",
+      "effect": "항생제로 인한 장내균총 교란 완화",
+      "recommendation": "병용 가능. 투약 시간 2시간 간격 권장"
+    }
+  ],
+  "susceptibility_data": [
+    {
+      "pathogen": "E. coli (개 UTI)",
+      "susceptibility": "92%",
+      "source": "KuKanich 2020 (PMID:31777977)",
+      "region": "미국 중서부"
+    },
+    {
+      "pathogen": "E. coli (이탈리아, 2019 이후)",
+      "susceptibility": "74.4%",
+      "source": "Tagliasacchi 2025 (PMID:41012835)",
+      "note": "ISCAID 가이드라인 도입 후 내성률 25.6%로 감소"
+    },
+    {
+      "pathogen": "S. pseudintermedius (MSSP, 유럽)",
+      "susceptibility": "≥88.5%",
+      "source": "ComPath 2020 (PMID:32924232)",
+      "note": "피부 분리주"
+    },
+    {
+      "pathogen": "S. pseudintermedius (MRSP)",
+      "susceptibility": "내성 (일반)",
+      "source": "Pirolo 2023 (PMID:37294541)",
+      "note": "Low-level MRSP 일부는 임상 반응"
+    }
+  ],
+  "clinical_notes": [
+    "EMA AMEG Category D: 경험적 처방 허용되는 1차 선택 항생제",
+    "β-Lactamase 생산균까지 커버 (Amoxicillin 단독 대비 스펙트럼 확장)",
+    "시간 의존적 살균 → MIC 이상 농도 유지가 핵심 → BID 분할 필수",
+    "ISCAID 가이드라인이 항생제 내성률 감소에 실질적 효과 입증됨",
+    "치료 실패 시 Category C (Cephalexin 등) → B (Fluoroquinolone) 순으로 상향"
+  ],
+  "pharmacy_counseling": {
+    "key_messages": [
+      "체중 4kg당 1정, 하루 2번 (12시간 간격)",
+      "음식과 함께 드리면 위장 부작용 감소",
+      "증상 나아져도 처방 기간 끝까지 복용 완료 (내성 예방)",
+      "구토/설사 심하거나 알레르기 증상(부종, 호흡곤란) 시 즉시 중단"
+    ],
+    "common_questions": [
+      {
+        "question": "며칠이나 먹여야 하나요?",
+        "answer": "질환에 따라 다릅니다. 방광염 3~5일, 피부감염 2~3주, 호흡기 7~21일. 수의사 처방 기간 준수하세요."
+      },
+      {
+        "question": "증상이 나았는데 계속 먹여야 하나요?",
+        "answer": "네, 반드시요. 증상만 나아지고 세균은 남아있을 수 있습니다. 중간에 끊으면 내성균이 생깁니다."
+      },
+      {
+        "question": "사람용 오그멘틴 줘도 되나요?",
+        "answer": "안 됩니다. 용량과 비율이 다릅니다. 동물 전용 제품만 사용하세요."
+      },
+      {
+        "question": "부작용은 없나요?",
+        "answer": "구토, 설사 같은 위장 증상이 흔합니다. 음식과 함께 주면 줄어듭니다. 알레르기 반응(부종, 호흡곤란)은 드물지만 발생 시 즉시 중단하세요."
+      }
+    ]
+  },
+  "source": {
+    "guidelines": [
+      "ISCAID UTI Guidelines 2019 (PMID:30971357)",
+      "ISCAID Pyoderma Guidelines 2025 (PMID:40338805)",
+      "ISCAID Respiratory Guidelines 2017 (PMC5354050)",
+      "AAHA/AAFP Antimicrobial Stewardship Guidelines 2022"
+    ],
+    "golden_pattern": "actibet_amoxicillin_clavulanate.md (2026-03-02)"
+  },
+  "storage": "25°C 이하, 건조, 차광 보관",
+  "last_updated": "2026-03-19",
+  "indication": "광범위 세균 감염 (피부, 요로, 호흡기, 연조직, 구강)"
+}
\ No newline at end of file
diff --git a/data/master/antelmin.json b/data/master/antelmin.json
index d3d8583..f9a12c1 100644
--- a/data/master/antelmin.json
+++ b/data/master/antelmin.json
@@ -1,64 +1,101 @@
 {
   "product_id": "MASTER-014",
-  "apc_code": "0519-ANTELMIN",
+  "apc_code": "0230237810109",
   "name": "안텔민 뽀삐/킹",
   "english_name": "Antelmin (Mebendazole + Praziquantel)",
   "manufacturer": "대성",
   "category": "antiparasitic",
   "category_display": "광범위 내부구충제",
-  "target_animal": ["개", "고양이"],
+  "target_animal": [
+    "개",
+    "고양이"
+  ],
   "administration": "경구 (정제)",
-
   "indication": "회충, 조충(촌충), 십이지장충(구충), 편충 구제",
-  
   "coverage_summary": {
-    "covered": ["회충", "조충(촌충)", "구충(십이지장충)", "편충"],
-    "not_covered": ["벼룩", "진드기", "심장사상충"],
+    "covered": [
+      "회충",
+      "조충(촌충)",
+      "구충(십이지장충)",
+      "편충"
+    ],
+    "not_covered": [
+      "벼룩",
+      "진드기",
+      "심장사상충"
+    ],
     "gap_solution": "넥스가드/셀라이트의 조충 갭 보완용"
   },
-
   "mechanism": {
     "mebendazole": "벤즈이미다졸계 → 회충, 구충, 편충 구제",
     "praziquantel": "프라지노이소퀴놀린계 → 조충(촌충) 구제"
   },
-
   "dosing": {
     "interval": "3개월마다 (연 4회)",
     "interval_reason": "ESCCAP/CAPC 가이드라인 기반, 기생충 prepatent period 고려",
     "puppy_kitten": "6개월 미만: 2주~1개월 간격",
     "minimum_age": "제한 없음"
   },
-
   "dosage_table": [
-    {"product": "뽀삐 정", "weight": "~5kg", "tablets": "1정"},
-    {"product": "킹 정 5kg", "weight": "5kg", "tablets": "1정"},
-    {"product": "킹 정 10kg", "weight": "10kg", "tablets": "2정"},
-    {"product": "킹 정 15kg", "weight": "15kg", "tablets": "3정"},
-    {"product": "킹 정 20kg", "weight": "20kg", "tablets": "4정"}
+    {
+      "product": "뽀삐 정",
+      "weight": "~5kg",
+      "tablets": "1정"
+    },
+    {
+      "product": "킹 정 5kg",
+      "weight": "5kg",
+      "tablets": "1정"
+    },
+    {
+      "product": "킹 정 10kg",
+      "weight": "10kg",
+      "tablets": "2정"
+    },
+    {
+      "product": "킹 정 15kg",
+      "weight": "15kg",
+      "tablets": "3정"
+    },
+    {
+      "product": "킹 정 20kg",
+      "weight": "20kg",
+      "tablets": "4정"
+    }
   ],
-
   "prepatent_periods": [
-    {"parasite": "십이지장충", "period": "14~18일"},
-    {"parasite": "개회충", "period": "2~5주"},
-    {"parasite": "조충(벼룩매개)", "period": "~3주"},
-    {"parasite": "편충", "period": "10~12주"}
+    {
+      "parasite": "십이지장충",
+      "period": "14~18일"
+    },
+    {
+      "parasite": "개회충",
+      "period": "2~5주"
+    },
+    {
+      "parasite": "조충(벼룩매개)",
+      "period": "~3주"
+    },
+    {
+      "parasite": "편충",
+      "period": "10~12주"
+    }
   ],
-
   "warnings": [
     "⚠️ 공복 투여 권장 (효과 증가)",
     "⚠️ 다두 사육 시 동시 투약 (교차 감염 방지)",
     "⚠️ 유기동물: 즉시 투약 + 2주 후 재투약"
   ],
-
   "clinical_notes": [
     "넥스가드 스펙트라/셀라이트의 조충 미커버 보완",
     "3개월 간격 정기 투약 권장 (ESCCAP/CAPC)",
     "벼룩 관리 필수 (조충 중간숙주)"
   ],
-
   "source": {
-    "guidelines": ["ESCCAP GL01 7th Ed (2025)", "CAPC Guidelines"]
+    "guidelines": [
+      "ESCCAP GL01 7th Ed (2025)",
+      "CAPC Guidelines"
+    ]
   },
-
   "storage": "실온 보관"
-}
+}
\ No newline at end of file
diff --git a/data/master/asikaff_carprofen.json b/data/master/asikaff_carprofen.json
index b4931eb..2892479 100644
--- a/data/master/asikaff_carprofen.json
+++ b/data/master/asikaff_carprofen.json
@@ -1,38 +1,58 @@
 {
   "product_id": "MASTER-002",
-  "apc_code": "0232617800004",
+  "apc_code": "0232635710103",
   "name": "아시카프 츄어블정",
   "english_name": "Asikaff Chewable (Carprofen 50mg)",
   "manufacturer": "미상",
   "category": "nsaid",
   "category_display": "진통소염제 (NSAIDs)",
-  "target_animal": ["개"],
+  "target_animal": [
+    "개"
+  ],
   "administration": "경구 (츄어블정)",
-  "image_url": "/images/asikaff.png",
-
   "indication": "개의 관절염, 수술 후 통증, 근골격계 염증 완화",
-  
   "mechanism": {
     "drug_class": "프로피온산계 NSAIDs",
     "action": "COX-2 우선 억제 → 염증성 프로스타글란딘 생성 억제",
     "selectivity": "COX-2 우선 (preferential) - 완전 선택적 아님"
   },
-
   "dosage": {
     "standard": "4.4mg/kg 1일 1회",
     "alternative": "2.2mg/kg 1일 2회",
     "note": "최소 유효 용량 원칙 - 효과 확인 후 감량 시도"
   },
-
   "dosage_table": [
-    {"weight": "5kg", "daily_dose": "22mg", "tablets": "0.5정 (반정)"},
-    {"weight": "10kg", "daily_dose": "44mg", "tablets": "1정"},
-    {"weight": "15kg", "daily_dose": "66mg", "tablets": "1.5정"},
-    {"weight": "20kg", "daily_dose": "88mg", "tablets": "2정"},
-    {"weight": "25kg", "daily_dose": "110mg", "tablets": "2.5정"},
-    {"weight": "30kg", "daily_dose": "132mg", "tablets": "3정"}
+    {
+      "weight": "5kg",
+      "daily_dose": "22mg",
+      "tablets": "0.5정 (반정)"
+    },
+    {
+      "weight": "10kg",
+      "daily_dose": "44mg",
+      "tablets": "1정"
+    },
+    {
+      "weight": "15kg",
+      "daily_dose": "66mg",
+      "tablets": "1.5정"
+    },
+    {
+      "weight": "20kg",
+      "daily_dose": "88mg",
+      "tablets": "2정"
+    },
+    {
+      "weight": "25kg",
+      "daily_dose": "110mg",
+      "tablets": "2.5정"
+    },
+    {
+      "weight": "30kg",
+      "daily_dose": "132mg",
+      "tablets": "3정"
+    }
   ],
-
   "absolute_contraindications": [
     {
       "item": "고양이 사용 절대 금지",
@@ -50,16 +70,14 @@
       "severity": "치명적"
     }
   ],
-
   "relative_contraindications": [
     "신장 기능 저하",
-    "간 기능 저하", 
+    "간 기능 저하",
     "위장관 궤양 병력",
     "출혈 경향",
     "심부전",
     "탈수 상태"
   ],
-
   "warnings": [
     "🚫 고양이에게 절대 투여하지 마세요 (치명적)",
     "🚫 스테로이드와 함께 투여하지 마세요",
@@ -67,16 +85,33 @@
     "⚠️ 장기 투여 시 3~6개월마다 혈액검사 필요",
     "⚠️ 음식과 함께 투여하면 위장 자극 감소"
   ],
-
   "side_effects": {
-    "common": ["구토", "설사", "식욕부진"],
-    "serious": ["위장관 궤양/출혈 (흑색변)", "간독성 (황달)", "신독성 (다음다뇨)"],
-    "monitoring_signs": ["흑색변", "토혈", "황달", "기력저하", "다음다뇨"]
+    "common": [
+      "구토",
+      "설사",
+      "식욕부진"
+    ],
+    "serious": [
+      "위장관 궤양/출혈 (흑색변)",
+      "간독성 (황달)",
+      "신독성 (다음다뇨)"
+    ],
+    "monitoring_signs": [
+      "흑색변",
+      "토혈",
+      "황달",
+      "기력저하",
+      "다음다뇨"
+    ]
   },
-
   "monitoring": {
     "required": true,
-    "pre_treatment": ["CBC", "간기능 (ALT, ALP, AST)", "신기능 (BUN, Cr)", "뇨검사"],
+    "pre_treatment": [
+      "CBC",
+      "간기능 (ALT, ALP, AST)",
+      "신기능 (BUN, Cr)",
+      "뇨검사"
+    ],
     "during_treatment": {
       "2_4_weeks": "혈청 화학 (간·신기능)",
       "3_months": "혈청 화학, 뇨검사",
@@ -89,31 +124,39 @@
       "황달"
     ]
   },
-
   "washout_period": {
     "to_other_nsaid": "3~5일",
     "to_steroid": "5~7일",
     "from_short_steroid": "5~7일",
     "from_long_steroid": "2주 이상"
   },
-
   "clinical_efficacy": {
     "osteoarthritis": "89.1~92.4% 개선",
     "post_surgical": "우수한 통증 관리",
-    "source_pmid": ["7759332", "12665145", "17056650", "25433056"]
+    "source_pmid": [
+      "7759332",
+      "12665145",
+      "17056650",
+      "25433056"
+    ]
   },
-
   "storage": "실온 보관, 습기 피할 것",
-
   "pharmacist_tips": [
     "음식과 함께 투여 권장 (위장 자극 감소)",
     "장기 투여 시 정기 검사 안내 필수",
     "보호자에게 중단 신호 교육 (흑색변, 구토, 황달)",
     "스테로이드 병용 여부 반드시 확인"
   ],
-
   "source": {
-    "guidelines": ["WSAVA Pain Management Guidelines"],
-    "pmid": ["7759332", "12665145", "17056650", "16468926", "25433056"]
+    "guidelines": [
+      "WSAVA Pain Management Guidelines"
+    ],
+    "pmid": [
+      "7759332",
+      "12665145",
+      "17056650",
+      "16468926",
+      "25433056"
+    ]
   }
-}
+}
\ No newline at end of file
diff --git a/data/master/chlorhexidine_shampoo.json b/data/master/chlorhexidine_shampoo.json
index 2ba7970..e29f74e 100644
--- a/data/master/chlorhexidine_shampoo.json
+++ b/data/master/chlorhexidine_shampoo.json
@@ -1,39 +1,36 @@
 {
   "product_id": "MASTER-009",
-  "apc_code": "0519-CHLORHEX-SHAMPOO",
+  "apc_code": "0231334930108",
   "name": "클로르헥시딘 샴푸",
   "english_name": "Chlorhexidine Shampoo 2%",
   "manufacturer": "비르박",
   "category": "topical",
   "category_display": "피부외용제 (샴푸)",
-  "target_animal": ["개", "고양이"],
+  "target_animal": [
+    "개",
+    "고양이"
+  ],
   "administration": "외용 (샴푸)",
-
   "indication": "세균성/진균성 피부염, 농피증, 피부 감염 예방",
-  
   "mechanism": {
     "drug_class": "비구아나이드계 소독제",
     "action": "세균 세포막 파괴 → 살균 작용",
     "spectrum": "그람양성균, 그람음성균, 효모균"
   },
-
   "dosage": {
     "frequency": "주 2~3회",
     "contact_time": "5~10분간 방치 후 헹굼",
     "duration": "증상 호전 시까지 (보통 2~4주)"
   },
-
   "warnings": [
     "⚠️ 눈, 귀, 점막 접촉 피할 것",
     "⚠️ 사용 후 완전히 헹굴 것",
     "⚠️ 깊은 상처에는 사용 금지"
   ],
-
   "clinical_notes": [
     "경구 항생제와 병용 시 효과 증가",
     "거품을 충분히 내어 피부에 접촉시키는 것이 중요",
     "피부 건조 시 보습제 병용 권장"
   ],
-
   "storage": "실온 보관, 직사광선 피할 것"
-}
+}
\ No newline at end of file
diff --git a/data/master/enrofloxacin.json b/data/master/enrofloxacin.json
index e714bdf..ce43638 100644
--- a/data/master/enrofloxacin.json
+++ b/data/master/enrofloxacin.json
@@ -1,67 +1,89 @@
 {
   "product_id": "MASTER-003",
-  "apc_code": "0519-ENROFLOXACIN",
+  "apc_code": "0232532310106",
   "name": "아시엔로 50",
   "english_name": "Enrofloxacin 50mg",
   "manufacturer": "아시아제약",
   "category": "antibiotic",
   "category_display": "항생제 (퀴놀론계)",
-  "target_animal": ["개", "고양이"],
+  "target_animal": [
+    "개",
+    "고양이"
+  ],
   "administration": "경구 (정제)",
-  "image_url": "/images/enrofloxacin.png",
-
   "indication": "피부감염, 요로감염, 호흡기감염, 상처감염 등 세균성 감염증 치료",
-  
   "mechanism": {
     "drug_class": "Fluoroquinolone (3세대 퀴놀론)",
     "action": "DNA gyrase 및 topoisomerase IV 억제 → 세균 DNA 복제 차단",
     "spectrum": "그람양성균, 그람음성균 광범위"
   },
-
   "dosage": {
     "standard": "5mg/kg 1일 1회",
     "duration": "7~14일",
     "note": "음식과 함께 또는 공복 투여 가능"
   },
-
   "dosage_table": [
-    {"weight": "5kg", "daily_dose": "25mg", "tablets": "0.5정"},
-    {"weight": "10kg", "daily_dose": "50mg", "tablets": "1정"},
-    {"weight": "15kg", "daily_dose": "75mg", "tablets": "1.5정"},
-    {"weight": "20kg", "daily_dose": "100mg", "tablets": "2정"},
-    {"weight": "25kg", "daily_dose": "125mg", "tablets": "2.5정"}
+    {
+      "weight": "5kg",
+      "daily_dose": "25mg",
+      "tablets": "0.5정"
+    },
+    {
+      "weight": "10kg",
+      "daily_dose": "50mg",
+      "tablets": "1정"
+    },
+    {
+      "weight": "15kg",
+      "daily_dose": "75mg",
+      "tablets": "1.5정"
+    },
+    {
+      "weight": "20kg",
+      "daily_dose": "100mg",
+      "tablets": "2정"
+    },
+    {
+      "weight": "25kg",
+      "daily_dose": "125mg",
+      "tablets": "2.5정"
+    }
   ],
-
   "warnings": [
     "⚠️ 고양이: 5mg/kg 초과 금지 (망막 독성 위험!)",
     "⚠️ 성장기 동물: 연골 손상 가능성 (1세 미만 주의)",
     "⚠️ 간질/경련 병력 동물 주의",
     "⚠️ 제산제(알루미늄, 마그네슘)와 2시간 간격 투여"
   ],
-
   "contraindications": [
     "1세 미만 강아지 (대형견은 18개월 미만)",
     "임신/수유 중",
     "간질/경련 병력",
     "퀴놀론 과민반응 이력"
   ],
-
   "side_effects": {
-    "common": ["구토", "설사", "식욕부진"],
-    "serious": ["고양이 망막 독성 (고용량)", "연골 손상 (성장기)", "경련 (드묾)"]
+    "common": [
+      "구토",
+      "설사",
+      "식욕부진"
+    ],
+    "serious": [
+      "고양이 망막 독성 (고용량)",
+      "연골 손상 (성장기)",
+      "경련 (드묾)"
+    ]
   },
-
   "cat_warning": {
     "max_dose": "5mg/kg/day",
     "max_duration": "21일",
     "risk": "망막 변성 → 실명 가능",
     "source": "다수 문헌 보고"
   },
-
   "storage": "실온 보관, 습기 피할 것",
-
   "source": {
-    "guidelines": ["ISCAID Antimicrobial Guidelines"],
+    "guidelines": [
+      "ISCAID Antimicrobial Guidelines"
+    ],
     "notes": "고양이 망막 독성 관련 다수 증례 보고"
   }
-}
+}
\ No newline at end of file
diff --git a/data/master/fronilspot.json b/data/master/fronilspot.json
index 57700c2..5463c2d 100644
--- a/data/master/fronilspot.json
+++ b/data/master/fronilspot.json
@@ -6,43 +6,63 @@
   "manufacturer": "한국동물약품",
   "category": "antiparasitic",
   "category_display": "외부구충제 (스팟온)",
-  "target_animal": ["개", "고양이"],
+  "target_animal": [
+    "개",
+    "고양이"
+  ],
   "administration": "경피 도포 (스팟온)",
-
   "indication": "벼룩, 진드기 구제",
-  
   "coverage": {
     "external": {
-      "fleas": {"covered": true, "note": "4~8시간 내 사멸"},
-      "ticks": {"covered": true, "note": "접촉 사멸"}
+      "fleas": {
+        "covered": true,
+        "note": "4~8시간 내 사멸"
+      },
+      "ticks": {
+        "covered": true,
+        "note": "접촉 사멸"
+      }
+    },
+    "heartworm": {
+      "covered": false
     },
-    "heartworm": {"covered": false},
     "intestinal": {
-      "roundworm": {"covered": false},
-      "hookworm": {"covered": false},
-      "whipworm": {"covered": false},
-      "tapeworm": {"covered": false}
+      "roundworm": {
+        "covered": false
+      },
+      "hookworm": {
+        "covered": false
+      },
+      "whipworm": {
+        "covered": false
+      },
+      "tapeworm": {
+        "covered": false
+      }
     }
   },
-
   "coverage_summary": {
-    "covered": ["벼룩", "진드기"],
-    "not_covered": ["심장사상충", "내부기생충"],
+    "covered": [
+      "벼룩",
+      "진드기"
+    ],
+    "not_covered": [
+      "심장사상충",
+      "내부기생충"
+    ],
     "gap_solution": "심장사상충: 하트세이버 / 내부기생충: 안텔민 추가"
   },
-
   "dosing": {
     "interval": "매월 1회",
     "interval_reason": "효능 지속 4주",
     "minimum_age": "8주 이상",
     "minimum_weight": "제한 없음"
   },
-
   "warnings": [
     "⚠️ 도포 후 2일간 목욕/수영 금지",
     "⚠️ 토끼에게는 독성 (사용 금지)",
     "⚠️ 피부 상처 부위 도포 금지"
   ],
-
-  "storage": "실온 보관, 직사광선 피할 것"
-}
+  "storage": "실온 보관, 직사광선 피할 것",
+  "image_url": "https://d1vgkbcgf4kpck.cloudfront.net/medicine/3faefec5-4bdf-4039-93e3-b99b55ef9417.png"
+}
\ No newline at end of file
diff --git a/data/master/gaesidin.json b/data/master/gaesidin.json
index d565432..2462346 100644
--- a/data/master/gaesidin.json
+++ b/data/master/gaesidin.json
@@ -1,43 +1,264 @@
 {
   "product_id": "MASTER-012",
-  "apc_code": "0231093500002",
+  "apc_code": "0231093520106",
+  "apc_variants": {
+    "5g": "0231093510108",
+    "10g": "0231093520106",
+    "15g": "0231093530104",
+    "20g": "0231093540102",
+    "30g": "0231093550109",
+    "50g": "0231093560107",
+    "100g": "0231093570105",
+    "200g": "0231093580103"
+  },
   "name": "복합 개시딘 겔",
   "english_name": "GaeSidin Gel (Fusidic acid + Betamethasone)",
   "manufacturer": "(주)이엘티사이언스",
+  "approval_number": "194",
+  "approval_date": "2020-02-13",
   "category": "topical",
   "category_display": "피부외용제 (농피증)",
-  "target_animal": ["개"],
+  "target_animal": [
+    "개"
+  ],
   "administration": "외용 (겔)",
-
   "indication": "표면성 세균성 농피증 국소 치료",
-  
-  "mechanism": {
-    "fusidic_acid": "0.5% - 황색포도상구균·MRSP 살균",
-    "betamethasone": "0.1% - 항염증·항소양 (Class III 스테로이드)"
+  "active_ingredients": {
+    "fusidic_acid": {
+      "concentration": "5mg/g (0.5%)",
+      "class": "스테로이드 구조 항생제",
+      "mechanism": "EF-G 결합 → 단백질 합성 억제 → 살균",
+      "target_bacteria": [
+        "황색포도상구균",
+        "S. pseudintermedius",
+        "MRSP"
+      ]
+    },
+    "betamethasone_valerate": {
+      "concentration": "1mg/g (0.1%)",
+      "class": "Class III 코르티코스테로이드",
+      "mechanism": "PLA2 억제 → 프로스타글란딘/루코트리엔 감소 → 항염증·항소양"
+    }
+  },
+  "formulation_advantage": {
+    "why_gel": "털이 있는 개 피부에 최적화 - 겔이 털 사이로 침투하여 피부에 직접 도달",
+    "vs_cream": "크림/연고는 털에 흡착되어 피부 도달 저하",
+    "ph_optimization": "개 피부 pH(6.5~8.2)에 맞는 중성~친수성 기제",
+    "efficacy_evidence": "피부 내 농도 MIC90의 67,000배 달성 (PMID 29162115)"
   },
-
   "dosage": {
     "frequency": "1일 2회",
-    "duration": "최소 5일 → 증상 소실 후 2일 추가",
-    "max_duration": "7일 초과 금지",
-    "application": "환부 청결 후 환부에만 국소 도포"
+    "duration_min": "최소 5일",
+    "duration_after_resolution": "증상 소실 후 2일 추가",
+    "duration_max": "7일 (절대 초과 금지)",
+    "amount": "소량을 환부에만"
+  },
+  "application_method": {
+    "step_1": {
+      "action": "환부 세정",
+      "detail": "미온수 또는 클로르헥시딘 희석액으로 환부를 깨끗이 닦고 완전히 건조"
+    },
+    "step_2": {
+      "action": "털 갈라내기",
+      "detail": "환부 주변 털을 손가락으로 갈라 피부를 최대한 노출"
+    },
+    "step_3": {
+      "action": "도포",
+      "detail": "소량(완두콩 크기 정도)을 환부에만 얇게 펴 바름"
+    },
+    "step_4": {
+      "action": "흡수 대기",
+      "detail": "2~3분간 자연 건조 - 겔이 빠르게 흡수됨"
+    },
+    "step_5": {
+      "action": "핥기 방지",
+      "detail": "도포 직후 엘리자베스 칼라 착용 또는 15분간 감시"
+    },
+    "caregiver_tip": "장갑 착용 권장 - 베타메타손 피부 흡수 방지"
+  },
+  "wound_care_guidelines": {
+    "before_application": [
+      "환부가 심하게 오염된 경우 생리식염수로 세척",
+      "딱지나 가피가 있으면 무리하게 제거하지 말 것",
+      "출혈이 있는 깊은 상처에는 사용 금지"
+    ],
+    "after_application": [
+      "통기성 유지 - 밀폐 드레싱 금지",
+      "붕대 감기 비권장 (습기 축적 → 세균 증식)",
+      "환부 긁기 방지를 위해 발톱 정리 권장"
+    ],
+    "environment": [
+      "도포 후 30분간 산책/목욕 금지",
+      "수영/물놀이 금지 (치료 기간 중)",
+      "습한 환경 피하기 - 건조한 환경 유지"
+    ]
+  },
+  "elizabethan_collar_guide": {
+    "necessity": "필수 - 베타메타손 경구 섭취 시 전신 흡수 위험",
+    "timing": "도포 직후 최소 15~20분, 가능하면 치료 기간 내내",
+    "size_selection": "코 끝이 칼라 가장자리에 닿지 않는 크기 선택",
+    "alternatives": [
+      "도넛형 넥칼라 (목 부담 적음)",
+      "수술복/보호복 (체간 환부인 경우)",
+      "발 환부인 경우 양말+테이프"
+    ],
+    "signs_of_licking": [
+      "환부 주변 털이 축축함",
+      "겔이 번들거리지 않고 매트함",
+      "환부 악화 또는 발적 증가"
+    ]
+  },
+  "progress_monitoring": {
+    "day_1_2": {
+      "expected": "소양감 감소 시작 (베타메타손 효과)",
+      "observe": [
+        "긁는 빈도 감소",
+        "발적 약간 완화"
+      ],
+      "action": "계속 도포, 칼라 유지"
+    },
+    "day_3": {
+      "expected": "병변 크기 감소, 삼출물 감소",
+      "observe": [
+        "환부 건조해짐",
+        "딱지 형성 시작"
+      ],
+      "checkpoint": true,
+      "action_if_improved": "계속 도포",
+      "action_if_no_change": "⚠️ 수의사 재진 필요 (내성균 또는 진균 가능성)"
+    },
+    "day_5": {
+      "expected": "대부분 증상 소실",
+      "observe": [
+        "피부 정상색 회복",
+        "털 재성장 시작"
+      ],
+      "action": "증상 소실 확인 후 2일 추가 도포"
+    },
+    "day_7": {
+      "expected": "완전 치유",
+      "observe": [
+        "환부 완전 건조",
+        "정상 피부와 구분 어려움"
+      ],
+      "action": "사용 종료 - 7일 초과 절대 금지"
+    }
+  },
+  "veterinary_revisit_triggers": {
+    "timing_3_days": "3일 사용 후 호전 없거나 악화 시",
+    "immediate_triggers": [
+      "환부 급격히 확대",
+      "고름 증가 또는 악취",
+      "발열, 식욕저하, 무기력",
+      "전신으로 병변 확산"
+    ],
+    "possible_causes": [
+      "퓨시드산 내성균 감염 (한국 27%)",
+      "진균성(Malassezia) 농피증 오진",
+      "심부 농피증으로 진행"
+    ],
+    "required_tests": "세균 배양검사 및 감수성 검사 권장"
   },
-
   "warnings": [
-    "⚠️ 7일 초과 사용 금지",
+    "⚠️ 7일 초과 사용 금지 - HPA 억제 위험",
     "⚠️ 3일 사용 후 호전 없으면 수의사 재진",
-    "⚠️ 눈·점막·깊은 상처 도포 금지",
-    "⚠️ 도포 후 핥지 않도록 엘리자베스 칼라"
+    "⚠️ 눈·점막·귀 내부·깊은 상처 도포 금지",
+    "⚠️ 도포 후 핥지 않도록 엘리자베스 칼라 필수",
+    "⚠️ 사용자(보호자) 장갑 착용 권장"
   ],
-
+  "contraindications": {
+    "absolute": [
+      "진균성(곰팡이) 농피증 - 스테로이드가 악화시킴",
+      "고양이 - 개 전용 허가",
+      "고막 천공된 귀 감염",
+      "바이러스성 피부 감염"
+    ],
+    "relative": [
+      "임신·수유 중인 개 - 수의사 판단",
+      "당뇨병 환자 - 스테로이드 영향",
+      "쿠싱 증후군 환자"
+    ]
+  },
+  "side_effects": {
+    "local": [
+      "도포 부위 자극감 (드묾)",
+      "피부 얇아짐 - 장기 사용 시"
+    ],
+    "systemic_if_ingested": [
+      "다음다뇨 (스테로이드 효과)",
+      "식욕 증가",
+      "장기: HPA 축 억제"
+    ]
+  },
+  "vs_human_fucidin": {
+    "can_use_human": false,
+    "reason_1": "제형 차이: 사람용=크림(털에 흡착), 개시딘=겔(털 통과)",
+    "reason_2": "pH 차이: 사람 피부 4.5~5.5 vs 개 피부 6.5~8.2",
+    "reason_3": "농도 차이: 사람용 2% vs 개시딘 0.5%+스테로이드 복합"
+  },
+  "clinical_evidence": {
+    "skin_penetration": "표재성 240μm에서 MIC90의 67,000배 농도 (PMID 29162115)",
+    "mrsp_coverage": "MRSP 포함 대부분 MIC ≤0.03 mg/L (PMID 25749003)",
+    "resistance_korea": "한국 S. pseudintermedius 내성률 27% (PMID 32115810)"
+  },
+  "available_sizes": [
+    "5g",
+    "10g",
+    "15g",
+    "20g",
+    "30g",
+    "50g",
+    "100g",
+    "200g"
+  ],
+  "storage": "실온 보관, 직사광선 피할 것",
+  "prescription_required": false,
+  "pharmacy_counseling": {
+    "quick_explanation": "개 피부 농피증(세균성 피부병) 치료 겔이에요. 항생제와 소염제가 함께 들어있어 세균도 죽이고 가려움도 줄여줘요.",
+    "key_points": [
+      "하루 2번, 환부에만 얇게",
+      "최소 5일, 최대 7일",
+      "핥지 못하게 넥칼라 필수",
+      "3일째 안 좋아지면 병원으로"
+    ],
+    "common_question": {
+      "q": "사람 후시딘 써도 되나요?",
+      "a": "제형이 달라요. 사람용 크림은 개 털에 묻어서 피부에 안 닿아요. 개시딘 겔은 털 사이로 스며들어 피부에 직접 도달해요."
+    }
+  },
+  "references": [
+    {
+      "pmid": "29162115",
+      "title": "Opportunities for topical antimicrobial therapy: permeation of canine skin by fusidic acid",
+      "key_finding": "퓨시드산 겔 피부 침투: MIC의 67,000배 농도"
+    },
+    {
+      "pmid": "25749003",
+      "title": "Susceptibility in vitro of canine staphylococcal isolates to fusidic acid",
+      "key_finding": "MRSP 포함 대부분 MIC ≤0.03 mg/L"
+    },
+    {
+      "pmid": "34414614",
+      "title": "Influence of age, sex on skin pH in dogs",
+      "key_finding": "개 피부 pH 4.4~8.2 (사람보다 알칼리성)"
+    },
+    {
+      "pmid": "32115810",
+      "title": "Fusidic acid resistance in S. pseudintermedius from dogs in Korea",
+      "key_finding": "한국 퓨시드산 내성률 27%"
+    }
+  ],
+  "last_updated": "2026-03-19",
+  "version": "2.0",
   "clinical_notes": [
-    "개 피부 pH (4.4~8.2)에 최적화된 겔 제형",
-    "사람용 후시딘과 농도·제형 다름",
+    "사람용 후시딘과 농도/제형 다름 (동물 피부 pH 최적화)",
+    "개 피부 pH (4.4~8.2)에 맞춘 겔 제형",
     "털 있는 피부 침투에 유리한 겔 타입",
     "MRSP(메티실린 내성 포도상구균)에도 효과"
   ],
-
-  "available_sizes": ["5g", "10g", "15g", "20g", "30g", "50g", "100g"],
-
-  "storage": "실온 보관"
-}
+  "pharmacy_tips": {
+    "human_vs_animal": "사람용 후시딘: 크림제형, 농도 2% / 동물용 개시딘: 겔제형, 농도 0.5%",
+    "ph_tip": "개 피부 pH는 4.4~8.2로 사람(5.5)보다 넓음. 겔 제형이 털 사이 침투에 유리",
+    "mrsp_note": "MRSP(메티실린 내성 포도상구균)에도 효과 있음"
+  }
+}
\ No newline at end of file
diff --git a/data/master/heartsaver.json b/data/master/heartsaver.json
index 723e8f3..8d831e7 100644
--- a/data/master/heartsaver.json
+++ b/data/master/heartsaver.json
@@ -1,51 +1,74 @@
 {
   "product_id": "MASTER-005",
-  "apc_code": "0519-HEARTSAVER",
+  "apc_code": "0230467230300",
   "name": "하트세이버 츄어블",
   "english_name": "Heartsaver (Ivermectin + Pyrantel)",
   "manufacturer": "중앙바이오텍",
   "category": "antiparasitic",
   "category_display": "심장사상충 예방",
-  "target_animal": ["개"],
+  "target_animal": [
+    "개"
+  ],
   "administration": "경구 (츄어블)",
-
   "indication": "심장사상충 예방 + 회충/구충 구제",
-  
   "coverage": {
     "external": {
-      "fleas": {"covered": false, "note": ""},
-      "ticks": {"covered": false, "note": ""}
+      "fleas": {
+        "covered": false,
+        "note": ""
+      },
+      "ticks": {
+        "covered": false,
+        "note": ""
+      }
     },
     "heartworm": {
       "covered": true,
       "note": "L3/L4 유충 구제"
     },
     "intestinal": {
-      "roundworm": {"covered": true, "note": "회충"},
-      "hookworm": {"covered": true, "note": "구충"},
-      "whipworm": {"covered": false, "note": ""},
-      "tapeworm": {"covered": false, "note": ""}
+      "roundworm": {
+        "covered": true,
+        "note": "회충"
+      },
+      "hookworm": {
+        "covered": true,
+        "note": "구충"
+      },
+      "whipworm": {
+        "covered": false,
+        "note": ""
+      },
+      "tapeworm": {
+        "covered": false,
+        "note": ""
+      }
     }
   },
-
   "coverage_summary": {
-    "covered": ["심장사상충", "회충", "구충"],
-    "not_covered": ["벼룩", "진드기", "편충", "조충"],
+    "covered": [
+      "심장사상충",
+      "회충",
+      "구충"
+    ],
+    "not_covered": [
+      "벼룩",
+      "진드기",
+      "편충",
+      "조충"
+    ],
     "gap_solution": "외부구충: 프로닐스팟 / 편충·조충: 안텔민 추가"
   },
-
   "dosing": {
     "interval": "매월 1회",
     "interval_reason": "심장사상충 윈도우 30일",
     "minimum_age": "6주 이상",
     "minimum_weight": "제한 없음"
   },
-
   "warnings": [
     "⚠️ 콜리 품종: MDR1 유전자 확인 필요",
     "⚠️ 투약 전 심장사상충 검사 필수",
     "⚠️ 감염견에 투약 시 쇼크 위험"
   ],
-
   "storage": "실온 보관"
-}
+}
\ No newline at end of file
diff --git a/data/master/impact.json b/data/master/impact.json
index 5667c7d..b13bd84 100644
--- a/data/master/impact.json
+++ b/data/master/impact.json
@@ -1,60 +1,91 @@
 {
   "product_id": "MASTER-013",
-  "apc_code": "0232873800003",
+  "apc_code": "0232873820205",
   "name": "임팩트액",
   "english_name": "Impact (Imidacloprid + Moxidectin)",
   "manufacturer": "제이에스코리아 (애드보킷 제네릭)",
   "category": "antiparasitic",
   "category_display": "스팟온 복합구충제",
-  "target_animal": ["개", "고양이", "페렛"],
+  "target_animal": [
+    "개",
+    "고양이",
+    "페렛"
+  ],
   "administration": "경피 도포 (스팟온)",
-
   "indication": "벼룩 + 심장사상충 예방 + 회충 + 구충 + 귀진드기 + 모낭충",
-  
   "coverage_summary": {
-    "covered": ["벼룩", "심장사상충", "회충", "구충", "편충(개)", "귀진드기", "모낭충", "개선충"],
-    "not_covered": ["진드기", "조충"],
+    "covered": [
+      "벼룩",
+      "심장사상충",
+      "회충",
+      "구충",
+      "편충(개)",
+      "귀진드기",
+      "모낭충",
+      "개선충"
+    ],
+    "not_covered": [
+      "진드기",
+      "조충"
+    ],
     "gap_solution": "진드기: 프로닐스팟 추가 / 조충: 안텔민 추가"
   },
-
   "dosing": {
     "interval": "매월 1회",
     "interval_reason": "심장사상충 L3→L5 30일 윈도우",
     "minimum_age": "개 7주, 고양이 9주 이상",
     "minimum_weight": "제한 없음"
   },
-
   "weight_products": [
-    {"size": "개 XS", "weight_range": "~4kg", "dose": "0.4mL"},
-    {"size": "개 S", "weight_range": "4~10kg", "dose": "1.0mL"},
-    {"size": "개 M", "weight_range": "10~25kg", "dose": "2.5mL"},
-    {"size": "개 L", "weight_range": "25~40kg", "dose": "4.0mL"},
-    {"size": "고양이 S", "weight_range": "~4kg", "dose": "0.4mL"},
-    {"size": "고양이 M", "weight_range": "4~8kg", "dose": "0.8mL"}
+    {
+      "size": "개 XS",
+      "weight_range": "~4kg",
+      "dose": "0.4mL"
+    },
+    {
+      "size": "개 S",
+      "weight_range": "4~10kg",
+      "dose": "1.0mL"
+    },
+    {
+      "size": "개 M",
+      "weight_range": "10~25kg",
+      "dose": "2.5mL"
+    },
+    {
+      "size": "개 L",
+      "weight_range": "25~40kg",
+      "dose": "4.0mL"
+    },
+    {
+      "size": "고양이 S",
+      "weight_range": "~4kg",
+      "dose": "0.4mL"
+    },
+    {
+      "size": "고양이 M",
+      "weight_range": "4~8kg",
+      "dose": "0.8mL"
+    }
   ],
-
   "special_protocols": {
     "demodex": "모낭충: 2~4주 간격, 2회 연속 피부검사 음성까지",
     "mf_treatment": "마이크로필라리아 치료: 월 1회, 성충구제 후 9개월"
   },
-
   "warnings": [
     "⚠️ 도포 후 48시간 목욕 금지 (셀라멕틴 2시간과 다름)",
     "⚠️ 등 전체 정중선으로 분산 도포 (한 곳 X)",
     "⚠️ 도포 부위 마를 때까지 다른 동물과 격리",
     "⚠️ 핥으면 신경 증상 가능"
   ],
-
   "clinical_notes": [
     "셀라이트보다 커버 넓음: 구충+편충+모낭충까지",
     "진드기 미커버 → 진드기 유행 시 프로닐 추가",
     "이미다클로프리드: 접촉 즉시 사멸 (흡혈 전)",
     "목시덱틴: 전신 흡수 → 심장사상충·내부기생충"
   ],
-
   "source": {
     "original": "애드보킷 (Advocate®, 엘랑코)"
   },
-
   "storage": "직사광선 피하여 서늘한 곳 보관"
-}
+}
\ No newline at end of file
diff --git a/data/master/meloxicash.json b/data/master/meloxicash.json
index f148d49..61a83f4 100644
--- a/data/master/meloxicash.json
+++ b/data/master/meloxicash.json
@@ -1,37 +1,58 @@
 {
   "product_id": "MASTER-011",
-  "apc_code": "0232523500007",
+  "apc_code": "0232523510309",
   "name": "멜록시캐시 CH",
   "english_name": "Meloxicash (Meloxicam 1mg)",
   "manufacturer": "국내",
   "category": "nsaid",
   "category_display": "진통소염제 (NSAIDs)",
-  "target_animal": ["개"],
+  "target_animal": [
+    "개"
+  ],
   "administration": "경구 (츄어블정)",
-
   "indication": "개의 급성·만성 근골격계 질환 통증경감 및 염증 치료",
-  
   "mechanism": {
     "drug_class": "옥시캄계 NSAIDs",
     "action": "COX-2 강선택 억제 → 카프로펜보다 위장관 유리",
     "half_life": "~24시간 (1일 1회 투여 가능)"
   },
-
   "dosage": {
     "standard": "로딩 0.2mg/kg → 유지 0.1mg/kg",
     "note": "첫날 2배 용량 → 다음날부터 1일 1회",
     "formula": "유지: 10kg당 1정"
   },
-
   "dosage_table": [
-    {"weight": "5kg", "loading": "1.0mg", "tablets": "0.5정"},
-    {"weight": "10kg", "loading": "2.0mg", "tablets": "1정"},
-    {"weight": "15kg", "loading": "3.0mg", "tablets": "1.5정"},
-    {"weight": "20kg", "loading": "4.0mg", "tablets": "2정"},
-    {"weight": "30kg", "loading": "6.0mg", "tablets": "3정"},
-    {"weight": "40kg", "loading": "8.0mg", "tablets": "4정"}
+    {
+      "weight": "5kg",
+      "loading": "1.0mg",
+      "tablets": "0.5정"
+    },
+    {
+      "weight": "10kg",
+      "loading": "2.0mg",
+      "tablets": "1정"
+    },
+    {
+      "weight": "15kg",
+      "loading": "3.0mg",
+      "tablets": "1.5정"
+    },
+    {
+      "weight": "20kg",
+      "loading": "4.0mg",
+      "tablets": "2정"
+    },
+    {
+      "weight": "30kg",
+      "loading": "6.0mg",
+      "tablets": "3정"
+    },
+    {
+      "weight": "40kg",
+      "loading": "8.0mg",
+      "tablets": "4정"
+    }
   ],
-
   "absolute_contraindications": [
     {
       "item": "다른 NSAIDs 동시 투여 금지",
@@ -46,28 +67,28 @@
       "reason": "31일 반복 투여 시 신장 손상 입증 (PMID:41549544)"
     }
   ],
-
   "washout_period": {
     "to_other_nsaid": "3~5일",
     "to_steroid": "5~7일"
   },
-
   "warnings": [
     "⚠️ 탈수·저혈압 상태 투여 금지 (신장독성)",
     "⚠️ 장기 투여 시 정기 혈액검사 필요",
     "⚠️ 구토, 흑색변, 식욕부진 시 즉시 중단",
     "✅ 카프로펜보다 COX-2 선택성 높음"
   ],
-
   "clinical_notes": [
     "로딩 용량: 첫날 치료 농도 즉시 달성",
     "수술 후 24시간 통증: 로베나콕시브보다 우수 (PMID:30637777)",
     "OA 개: 마바콕시브와 동등 효과 (PMID:24859353)"
   ],
-
   "source": {
-    "pmid": ["10769766", "24859353", "30637777", "32059002"]
+    "pmid": [
+      "10769766",
+      "24859353",
+      "30637777",
+      "32059002"
+    ]
   },
-
   "storage": "실온 보관"
-}
+}
\ No newline at end of file
diff --git a/data/master/nexgard_spectra.json b/data/master/nexgard_spectra.json
index 19f9471..accc3cd 100644
--- a/data/master/nexgard_spectra.json
+++ b/data/master/nexgard_spectra.json
@@ -1,24 +1,39 @@
 {
   "product_id": "MASTER-001",
-  "apc_code": "0519-NEXGARD-SPECTRA",
+  "apc_code": null,
   "name": "넥스가드 스펙트라",
   "english_name": "NexGard Spectra (Afoxolaner + Milbemycin Oxime)",
   "manufacturer": "베링거인겔하임 (Boehringer Ingelheim)",
   "category": "antiparasitic",
   "category_display": "올인원 구충제",
-  "target_animal": ["개"],
+  "target_animal": [
+    "개"
+  ],
   "administration": "경구 (소고기맛 츄어블)",
-  "image_url": "/images/nexgard_spectra.png",
-
+  "image_url": "data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEASABIAAD/2wBDAAQDAwQDAwQEAwQFBAQFBgoHBgYGBg0JCggKDw0QEA8NDw4RExgUERIXEg4PFRwVFxkZGxsbEBQdHx0aHxgaGxr/2wBDAQQFBQYFBgwHBwwaEQ8RGhoaGhoaGhoaGhoaGhoaGhoaGhoaGhoaGhoaGhoaGhoaGhoaGhoaGhoaGhoaGhoaGhr/wgARCAHgAeADASIAAhEBAxEB/8QAHAABAAIDAQEBAAAAAAAAAAAAAAUGAwQHAgEI/8QAGwEBAAIDAQEAAAAAAAAAAAAAAAIEAQMFBgf/2gAMAwEAAhADEAAAAe/gAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAIL86WYfqhw2SOwORZcZ6w5vli6Gp8zDMu8e4ZAAAAAAAAAAAAAAAAAGMyOFy9mHXXL8cc9Uc0lYrsrUvDO8+fY5fPo/HWvD4+9WtGao/S5ZqN6LrL829HQtCn52bTP0v1xPVdFkeYbWnb1Xf5Ds689mkeIdPzSuUrVKdPldgcV8XK3bRWmAAAAAAAKPLF4VORym2HNDID80/pb8bXNfuUo7o6uheud+zpmnQfZ1HW5zkyvezz+0Zl0/Y5pIV7Va1bvvbYc3juy7bXxbD3GW11uCRvXNqta5foZNfV2bB9wfOL6fN49fDG2cstfnflp/r+NqOXakVbnHaqT0XfDpg5+0AAAAAB4902WOdU+ofe7W6vm5V7jm9eqEk6fJ8kl9eel8jkNQrmfuMv53H5vz921Nmvhsj1SO22eSyV8wXqNBs3r1Y6Gph+bLZq45H2xGZpKRR15Cch6GEHZKLbrfK32LnsLERm3t5sivej7bt/Zisuvbe7jw7Ju5nV4+jbGpcem81ukNvVRUkAAAAAAqFvqc8flRsbXoudHepaXqyqXi4RyMLhsevcrRcjK7XP26X3oGPyvQo2W644q3KfddiYn+ffOo69F8mj7O3qvA9yw39MNtVX0lcJCh7s5T0lvSGiVdiuhaWderobEfGcTs7ebdppOSWj7Gj3aY31xeho2OKm9VjUz5stH0sb0Hn/AEXbp7ALHmAAAAAAFVtVYnj8taPYM/W08U+dypklC+S8dtj49z+tiOhbKN8ru1wvOpzj7Le39aMvXuEV078gc3RlHyNZya7fr7h2bdOnzcXYUJCgWKtbZZcmv7t69tp+pRkssPlksX2vZWJ/onIbZ5+32pwvJ4+92mH5rubIXTWgZVLHIZ5jua5H1g8XoSVl/NHV71XpwpbQAAAFcsdfljiOGqS3X09sg+RymiVwx1vBnGp5+7O6MVu78hhzbd0flyEhlihOe4D7hY9uo/cL3n579jm4XKhZPK9q3a8FIU7HyOn9uKn5r9JU5cG8/qKO9n5v84bHUq5vhQrDWfl6jJ9m4j2T556bY2Yj35a/M4MeHTnNoTe9HFG17lg+tcCiwF31bGqu9+5X1aratIrgAAAEFOw8sfkiW1JDt6MGLNrYWXSj9WGZLLCYZ65v1CauY7+1AIWbVpQi7y7Vow/pG2QOtkzGx1+brGYdw1/Wj8Y+oe9Lez29Nd17ZksaaIv9g73H5Tl6zX+vQp/POsRXRpVOodUouq1D7tn1pw1JLZgKkrRtUT1oj0fd5b60u8SP54zdav1OGreGOzqtyqFt5ly3iIAAABFycfnH4/3Yzb71fN9eovWP4zGRzQupmFl0ov7mF6kNezVLVW5v+kdzGfzF57Zg3R4z66JEbMU/5Yfksbnuv+OdauO5VYuvPpEjyX1Xn2KycGlpR7HzL3Jylm04SydLm4K1M0bVv6RVcUTt1TURPw1jTG+/OzdoeN6wXfk3aNZ7lm8f2a/sTnvm3KvcabcrVe3j0lQAAB8fBH72jnH5M6DzGw9uv51d/IjrxF10GK9qX7Ihzv5PwVmpKbEdbq3Sz5IDxrzt2yMgotjbrWPbi7eYbfhiwU7RkNmlUpqIu0fuRvbq+Ddn7Rx+tTJa7bXm+xTNToFBp3KtULnA+g5mtLa3zqc6VhdaX26PnQtyS8l29z1DV7idW9xNbkutzfOlG+vaeSuN2qFx+c+xtg9JTAAA+efvg+aexqn5Qs9HuHcqY4/BnzHYi5SOlr8+473Yp7mssMMVvc05LX1dTWns8cxOKy6cWvDzGOevDNRWTOuUmqLqz0WWv5bdmOlc7FqeO9R9y54ng39zT3KJ6TiWeseteWa9XLFWuhp3NmPy9blyfQoroPk+t7rWttczoYN6N+5t7WjgyM6WPYwfSfmlyvFKuvy/3dpHpKYAD58+HzF7wGLSzaB+Yekcp+dyl0jWpGdHodI+a09OptfLHz7tdvtStWvXzqSipTqz8/Yv4xI49bazDPk8xktczlg/WytY9GOmJQluiNz596/zGQl0jL7s171Ju0GyV/1flfulJReizr1qQhY28Fprnap0pCny1c4fQxXXldt6GuXs8BZ+L2K3EZ4WG3a1NrB9F+dWq9/mr9M+K9fZhc1gAfPnoYsW18I3TnPB+NMX7Gg+jV/K/wB/RMDu08W99Lh99Wob29oRzrSsb9np9X3mlhh1ZZWs7FvrGXXzGUh57zmEDF9BoVmlsder3QvK9zSpueEsY0ez8Y7Vf5nmQnMnI7PN6V1rlHb4HuGm6rVuR9fet62dPqNo8n069WtzV9TyY6+0W9aJepGA1vJ+s0dyLktsZCS3M9vhcb/Tv5m/TnoY2Ac/aAAAAA+fR585Phr62/hIrRm9Uq9S6TATh+fLlTrj2a+npeM+Y7UbuRc9UZ7+ZLvN97upcdUupRcxU/A+uh6/I6XufKZOkc6meT0O07FTnKV7W5Vdapur4+Z9s49Odb3NbZxZ6XM0a++ZlExNo87M0/fsGrt213DdNzmXqpdfNJrRuVdi8fsPO1j9Q/mT9PX98u+faOwAAAAAADzizeDU1N/UI6En4bOPzddef+u7Rv21zn0h0eFrvzZp85sc1BH9Kodpp2LtEzOt4D1NNjrni915mr6sxcuL19S389sNOxCT2WN5m/PxjpfNvb+cre7ZelWtPGb1O6GnXN+6xl850bN7pmphbYTQx9ejI1Wa9X6sfkkI3pc/R/SXAu/cb08rk0M9TZt+tfIZXn6fQAAAAAefGUaUdPfD8tw3698Xa/4z8/sWE3afyxk/Q8NYrcWy9Nit1elyEno7NHVPXLLd5L0M/ixZOJ1cvvQwWoWDHUNbp825x9fw9bm7tFtlU6Nac7jxLt3G7uXJ9z154vWzlNHHLeirR97+z1800OtNujisd3r5t1VuSkflLoamXP8ATx79fR9fT6AAAAAAAAAAD589DHj2BGRFqZjQozqDdp5Bodt8z18E1P0Fh31fz/8Ae5x27Rx+l/oOQhZ0pPaycvqYs/vKfMrIPT6Pv0AAAAAAAAAAAAAAAAAAAAAAAAPn0efnseHsefv0fPoAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAf//EADEQAAICAgEDAgQFBAMBAQAAAAIDAQQABQYREhMUIRAVMDUgIiQyNBYjM0AlMVCQQf/aAAgBAQABBQL/AO0G02qNTWdfu73YRZRMi2/Azs97XOeSbRBL5aBYPMtbOL5RqW4vaUm5BQX/AKWy2z9lbTsDRHzZmDtPz2NpLsLbHJI2fplo2qQcFpTWPaldanVkIB71SG22IYPI9kOByu5GBy6MDllKcDkesPF7Wi7BMT/3CIQHdcsdZeq3fEo2W9VXnlF5AxzJAyvlWvZgb/WMxdyu38J/v/B1nO8s8hZ5ZxbCkvWWhz5kyMHZ58yAsi+rBtpyHhOazXenBlfuStSitcgtV9SPENvevbH/AGeT8jbetVb/AKXC2gMNWz6MLbjAu3hNkb1eSWVJ2elpttpiKeau7trBRs9ivF77ZDh6GxBt1FkRmn4oUsepClK6oLmRYjsiJtNFUVl1Z/Udc652xMyhc56ZeekHKuqO2c8etBkVNyjPm27pQK37C3x/Vhq9r/o2uV62pYjket6K29B+AwGR+DeR27n49055CzzFnmyH5Njvle/7FxvFHK9zV6Rsa5YFlJyJ92dnditUi3nyLU2psajSjjOJ00VWT0in/nkiiIOSyDGYhkFMHGe+aqZEq9s3HNhqbW9KD1/G2eDNKPbtPrkUAPIuWS/NbWCufzWX55tfscOprhd2Gh9fY7PtRt+QYHKtoE7FD79yK8lHpIDFq759MKxrIhzBqILGSLDRV7ZT2+sIYmfAqcKonJpBno5z0jowBu9wbLdVRHlm1Xgcp7i3O7btJXrmspR1GYsOjPVNwbxxkXAyLSc86izTtT3JTXCbdB7C2ipr6rjQAzKExO/+vyr7B1zr0z1Lcmywsiy2DKwRjNxpiO5bGVL9dGeoO4rV6pWuWXfJSuowmafXlk8dozhcWr5HEWrJmh2IZ/TO0qtcl6o86+stCM8kRHvndMZSn9UFpZla2ZAdoUto0EBZv7Ox5KQ6hrsjVPIlawgT8OmGjsnxDgq6YDbQ45t6wvi/9pehtes3n1+UfYfh065ITA+M+yImcBJtnIUyV0KDNhJaW4vPDt0YOz2yM/qW3gcmjujk6CxfI6Pajaaw4VaVKvDuDPke+VTCWdSByhwTiACT7lOFDq1lp29nD6zYsenq6wxVsbcpHUQz9DWEnajXC0df8E/5diEGIImcpVAkeztyMVJQ/iEf8j9fk32FDhVhWRO2653orvp1tduLsDiLMV6li75KtSt6gnGNanxr/KUe8FnXphdJw6qGEWpqFi9HXawuOYXHn4+naoCKG3LGyoppazpGdkTkL946xGocGuKpszrL9cm6TUUJeVHWk+vSS0k6d/qGUthLE61z8BZMP5fbqsY4TMbapYtgAnvmMiy4Mhnks8P97n1+SfYquusXpNJLPtnOhZJHOeQunn/thY7BJ4zW4yX981uhdnYemxe1ryB2o6qkWr9pmGePKttjja58u2zofrtSzwuvxI6lSiaVcvl57jtmh3TnkLIcUYVo2ZD+kzaI49WfjjYs6jd7WWL/AJY4/UqVFzJ9WF2SypXZh6XWkR8cozhcZXGf0vaGdNW2+tL53sV5/U6V4vlWqZla2i4v6fIfsnAP5nKdarZVuVqlupniG38ca+2WdJmK+oN1e3qjrK7IzsxZtXmupeqb6itcaVHTtTY1FYRZqrFTFssrsTdtpbacwmvupKjq2rVY2thT9fWZK2fmHL9ljU50wQIs6e0DMxEdcgCkiCVkpRulKjc8uO2Yz5Nsl5/zKMjkG1r4rllwMXyiIIeV15wOR690/NNZZy0+bmUgvUy5Bu521jg32f6e+jrpeF3q9G7pt78r2u3fXpt3T0U9sN9lzku5tN1Wt38+9endXTrr18rtaX06uuBbaE+rOc9aYG3Z2HrLYd4o2zkLDah47Gzm1ZZsVQ/X65mzcVOkwC1NE8PQ15xnHvIEcbarB1F9Nu5N/wAAB4Vvd+SqyEiN6ZQhc2GAKVDQYTdmUTnsM+0z3d2GgGD8loHB8boTAcUUxR8RZh8VuDlmk6mWn1MXT0YwAfT3nvp9bFaW2qQxXitWiku5sKNcH7RLamyvV0iw11ad/W6/HWl2q921WPVfj651+Hq9pVEd/bHB3+L5AmIXuqcEGxqlg2VsxIm4oSyoN00prL+VWrHJKuronJ+PAePbrC/5FoWIWLbAU6V2XY5nas7ALSqPKv3hbLDULbsHFrqF5te1yX32FHqeo0nuv6e599Qh/gIdmC8DbPTV+aWCabq9hlf/ACEnb116268soT669cQQIpikzuxWGTXUVFRQNWaK1RNBC3OUui7HN9WyprSS1xLJ7JnC/PBU65R8pqHh6Srk6ASwuPOxWi2fZ131bPn+5Rk8p2Eq7WObt9SWtHtjOzFterA22xXgci2Y5HKbE5/UyWYneayQXsdbi3a+2k662150VljORFEbHQ9karQe9f6e199Zr5KHdiyiVV5YFeuWfK5nI1zjH0thch5VYhpoOY9u2c/NnccR5S7Zf3AD+yEtEMqt8bUXWMdE/maXRh2RFqnrYRkCc6z0HrgkUzVfCKE7FMVq/IPK7lIDDtB469e+dvzpVUjF6UbWfJneSppG+stAK7fw6Z4xzwDgp6Yo9gvHqvWT0swOl47/AAvp7H316QYwxbaRKrzVFFyM89WSg0xnUIgZbXAQsYczFfh1dNracs4+NGX6OqHGPh2xnZGEkgztnOhZG/tdPnS5kdzTMy2OvdEOrMRWgwV3vgl1fV6+Nb4aVrvVO/7u3S1ys6/cOTQ2i7QTW1b/AO3pS62NJWsBubv834RikGzE67uxOqmMGisc9OHTTfl0/G/t/wBO/wDwgMl5Fx0ZOwcQjcCc8lacEKxExSxDIKRwjIo4P96o7Zfzfa64avHLyy1472hr9bZLjutVaryrXayvvrPkHXndtWdVbqRKWDMe87CkWvudsZ2RnjwGWAxG02VcV8l2i8Dl9qM2+6+ZM4zHl1+3MWbUmi9z6qgbbremsNK+oGVnEjFrJk1dX1xGtAMAIHPKoM9RM56sxDUlI6njf2v6d7+FQUtr7mmjxVtcvx3KUJw9PKhGo43vovrCIEXwn/rVTZGy+k2yZbfbbbTv3C7SAs6WLY7/AF2ztV/DKKGv21ItnrKq7eoJJ0CtuucpnfWXu5P99+EZEYtJHi6Uzga7I10ZqSlYbppKsAciybLZaN0PWI2Y+U56ZWqE+aWuiBARXDGCvDMIg9steHtnHhXW9uo9tfxr7R9O3/GQ4kNl0Vy1uz8B3tjDHJPzq8sGTyoufQ8RTejvCf8AqgfjsBNZ012Vh1L7teNfbYquXhXsNkVnXnK/RHlmJ1LyLZxltl1GxO4hs7a6Ox2GRGKQTMr67rKtfA4uqOShcYFesWU47Xbc4CyMHgdpMNIeLKtbyZUpwsXWPDGwY+QYJQE2bCcfSQYRh/49N9v439n+m/3TrP5f9zohAoS4JeklU0TYT6ZrLlhwptEsHPl2SMyKFi0/QH4youHCQ0YTsbtVZ33sd8xQyWSBN2Vkbl23sarGWoC6MWavqZaWsGIyrq2GCKMBEdByOuF1yWVgz1Sc189Z3sdGQw4wXHGDZKM6g2NbSkIgIDNi8XwmyToZX+aptdK0V3959I7m+ydbE+g479n+lONn8iVmxhesgKXkZFtpJVLq1oLbgaXxQj/ja7YSYvr+AGpIqxNGYO0a1M7Vl4ZahVRuemT5I1/cZ1GrVnU3FQ1091EBUkAlhF2V4J1lsroA9f8A+xmr/bu47WR8Ijrmm1vdkkKYfbKwT6vlhVM1uFT6xnWsWZp1WKZ29s2P49DrFTjv2b6MzkzjC/LSYKbewmbNHT+CxZ2S1nTVV8s30QlmQss6dJUHTjyJVDIiieFWrdBod+TQsrPpYDJu2YE75sEbi+ibKAaDK5KZXEV6+pJGpXZBKhGFaWnE7SvcovsJESs+lp5Gav8Aa9c2L9pftmo1/q2eyht2peXmhTe/xzTe2J7vZ1nw16V7zPP/ACWv4o2V0dZxv7H9GcLDw/39Z6JeyubrbbGDciRe8rBqmAYwImWjld0HoFKN7G6t6wBZtIgJZCwxxdtyi9e6Q/BUQTDp0fTrdYCquxbmTr0AaskIVRra71yr0M8ERkZrf27MoGwbYIVrlh0kDTq3WTAFMKGZky8v9rWl5CmR7rZgsUqgfhaj9JevMvRx77J9DpkxhBhLx0SLvxDYYIfnMkWfAnWH2vdsEWXU+yY3FXwMCuuFRRXZa7XVxGvrZZlih4hxQdxajW+mXZsilZtkyI5YeqWyV39PDTpUZrVdotkVYyM1v7d1/JjNJX8j5/MVlsS26cyUZXAPBESGRd/t2IhjkeyQCSy1W7NY6f0Gh+y/S6Z2YyqtmN0NBuN4hrjxvCkY3hrhxnGL68LUXl4SGryJjD/ZVrlad4yeGvCz1vS8V1LZyZbKPVes7qFW+TW7Cx5mRGcd1/lNx5YZL2WjyIzWs7F9c65t1TYqZGIuBTQbTe2M0gdqFlj4mH2x9oxJQbPU9gEwBX5MVMmrXVzWO5LprLJzOu0f2b6/TJCMJUYSBw60Y2gs82eprDUpNBTmADxW+LCVrgaVg3BNyfPWyM95yuqWsrANOjcnsS5njH/vBj31liJhfvExmxLsQY9GKX3TFaG3Fj1Ps6ZpzgqU+03a/fkDBDFJglUePqXs7GlMEFLVsdlWquoJ2w8u3d3UXj+j1EdNX/ozk5OFmxjrRooGw+7qF1V09eUs2VaxAVfUqReN5N+EZpE9z2FBN2ruj3e6oyMo2PDZVa9hbm1vLkIX3ktcKxcDNtBwLCb3zpXwDenXPcc8QlA1GyCtVIsLWC2ArVU46zCh2mzb3UW9FbEv0VrrGv1n27/RnJwsLL38Ss+azbO0q2qmm2kBd2b1QgLKem1FUKyB65EZxuPzMPsLaq7sge8P+sjEHMO1p+zbAxXBJWCgRVhMhcr6w0f3Rgz0yntRKBnvjpkROTJDjbaxidha8gPSubYS22hbBi919FsZCKevL9FBZ1zr9eYyYwowoy5H6f8AAmw1EmZNKMrxBLb0gtA/susHugZjt9ACpsGghD9xIUuhWU/xwECEdTFjukSeVfzs47VTc2Jccolh8WrzhcVOM/p++mfBt1Ybbo55s8ueTr8eubGf0eroHyG6EQMRkT/o9MkMlOPqSa2cV2qsZqryckZD8EZEYAREqOQOtbG8sogs/uLwQX5GrScgwMZ3Qqiys1jpYq0yuw86+9PtmOJfd4jIHOzPHnizw4VUDw9NUZhccpzhcXVh8YbGHx66GO4/dsZToqo14HIjOn+r0zsicOstmN0NB2N4jrzxvCUYzhbYw+K314ekvqwqr14l5pNW5goG/VKPU15ybNeMK+c4cweCUpKy91taGWK8RBSaWEmlw5LCuxkZGR8OmdM6Z0ztztzszszszsztzpnT/b6Z2RniGcZRS3D0FE8Pi9ScPi3TD47ZHD090MKjaDJAwzrnXOua3Ut212rVXVTEZEZEZH/o9sZKhnJrjOHrknh6OqWFx2vOU9Wqgnw5C8gc6Z0/9jpnTO3OmdP/AJTf/8QAOxEAAQMCBAIHBgQEBwAAAAAAAQACAwQRBRIhMRNBEBQiMDJR8CBCYXGBoRU0kcEkQHCxM0NSYqLC0f/aAAgBAwEBPwH+sBdZXWZZgrj+UzLMrj2tVcoBzjayiqMOhjDHQn6tXEwWT4fqEKTC5fBJ/wAh+6raKlpo8zJLny0/ZMhfI0uFtFm1t3Oyv0v26LlXKv8ABMLb9pXiPNcGNx3+66lobOKdSkNLc2/NQ0PVZM84NvWiZUxT1MDIhZoXGaHZfX904QOtexv68l1Cil/ywfXzVbTRR1L2M0F//FV0j6VubMomEwiU9zmJNysyzBZgiboxEjdOhednIaclO2d2jAorNbYrsFcJh5J0LQNEynkkNmFPdKHhjzdPY6J1uaFXVN2eV+K1XM3+YCbjUzW6sBHr4qavbLIXkbqWt48PCuoo39XB90dwU57w49nRQufICXiyqJHRDsi5TapzWGSYWH3VJKam5I0usgWU8irPV5PJMq3wA3Z9roHOMy49lxgQopXxG7SpLyycQ7qSR0jsx6C1ypWgRubLpdQUkEXaablMpYQOyAqsBmGAf7v+x7g7K2l1Yr5osaRayY1seyzeSuVdByrZoZobM3UTwKbJzUQbun6FWBWiNhzRcAM19FBnvna266y8eJhXWoD4m/ZcalPP+6lmBZwmO0+aEI4ebiD5IOube0UNlmV+jTpuVcrMVBPTQNyvafqEJsPfvb9EYKCbn911KGKPsvsPoupNkl7OuqqcN4bryjUqop3y7HTy+qohljIAQcNkSOaMELhqwJlKyZwaAsRpHULbgrh5I2O8/bC1WqvZZlnHDLLfVCmeGEZ9dNV1eUROGbtFNgdCXO1NtrqlbMZnOlOuie8DdGOB4vYfZGgpXnVnr9VX0EEIaY7i/wAUyinkaXRnRRZ5Z+CU9uRxCu4bLjzN5rr8o3X4qRu1Nr4wVWVXXmWcVZ2UE9ySi6yz6oWssqyno1XX6jmV+KSN0cAm4ywG5aqnE4akAKlxIQAhpuoSW1ZlCfcHVONk/QWTiXGwUOHvk1co8Pii5LgttoAp/wDDZ65dwUQslyj2ZAEFdbdF9UXKV93FAF5sFDhUsurtFHhEDfFqoaKCOdoDfNV/5lyJK7UpyhUtG1mqBawXKreMG5oNUaudx8SqPAz1yHcE6J5FkZDe6jvJIOi3QdVdydMWnZRQvqnWbsqSmih0Tpw2waN1WYjNTbBYVXy1lRlk5XVef4lyc4qkhsM71HLnf8F4m6LYL31U+Fnry9vNZGQZbKWRpasNooqzMXnbkn03VKwx8radJIRcnSkJt5jlsqeJtNHdybURvc7zCuyyxd54wZyH7rAPzR+Sr3DjP9eSpYuLJdVEnujYLC5+PI9qfo6yDRa68Umnn+6km4rrDYe2YfinQPToJfJQS1FG/OwKWqmmmEjzr0Eokc0cpIVQ0NdosNpw1vEcqqr0L+XJYfI67z5riuy2WJEulDlgTmsqHOdtZV0vFmc8c1RsyxXVS5zonLBB23uWXMpLuGVQYcymBfIbpu/duAt0HzUjuynFQt4sgCnPBgA81XPLngclhLc7JB8lZV0DpIG2Gt0yh6pEC7crhwOpHF26oZQ6JSUt3XGypKeGlaQ3mr+SJ81W1l5uG1N37s7LNZGWwsnzhzbKhpm1k/CJsuB1Gt4TjdVMIqYLDdHD31NhsQqOkbh7PNxT4M0l1NLHF2nLrbqqU3UkBk1CjjqIDdqbXSN8cZTsTH+lPxVwUuLTyttsuK+aZrnnyTe8MIKdTX5p1JJyXAqIzmaNVKahz88l7qkxdgGWTQo1VJLqSE+sp2aDVSYuGaW0+CqMRgnGUgrDjdzk3b2DGx24RpIHe6hQwhwcP5ItB3Rp4j7qNJEUcOYdnI4a7k5UtK+EnN/UD//EAD8RAAEDAgQCBQgJAwQDAAAAAAEAAgMEEQUSITETQRQiMlFhBiAjcYGRwfAQFTAzQqGx0eFAUmIWcJLCJIKy/9oACAECAQE/Af8AeCKAyC+wXA8VwHcrLgydyLHjcf0nR3AXK4DuSMMg5ItcNx9INhZady6vciGFdQa3UkNVK8vEg9hRgrmna/uTulM7Uf5H4KKR7zZzLe/4hSSxRuDTfXwuuAeHn+xa1z+yFkcOX00ts11cE3sup3IBisO9Ead6MP8AirkclxB3I1DGnZdOiqG5YXap8D4opDIbkrIbXQ4o2vp8966TUM/Goqucxh17qlrhVOyloVTP6Ywju+waMzgEI2sblauCORXDPejB4BCNsdzaykx2MSlrGXHrshjcINnxke5DFqQ/iI9ihr6KQ2Egv8+CPW2VnBZ3BGVwF0+rYz7xgUBhIMjWWUczZ25ijFAeS6FDyFkaGK9s2qFCQLAqHD+BNxFPl47jzI+wj7YWiqZTABlGa/cqSR1RHneMt/0/dZNbNWJyvpaZ0kZ1H7r63qHDrNa72fyunU7u3Tt9mnwRnwt3biI9t/iqWmw9vpY7696fRwzuFpEMkHoxurFCLOpqeKXQtUTGRM4YCjp2Rsygot5A/RVOMsjJIOtbusf0Kq6qeRuXKWhdJmO6aS6oJP8Ab8B9gzthcW0uQpsrS250QtyWfXdVcPS4HRXtdRYMGm8zrj1L6qgab6p2EX1ZJ7woqR8cQZ4KjpKmKW79lLG/pYfyVQ94OVUx9Gs1uazFZlptZYyaeWIU0k/Cv+Y8fBDAKZ/3VUw/l8U3AMZh1hmv6nn4p1N5Sw9kuP8AxcsMbiZaZK4an/HX22Rm9JkMR9algDI83nM7QTmtzG/NCK3NZNb9y1DbBZnXH0aLK3uWRhXDaqyjxCrm4kcgsNgHW0/dPpcZj7JcfaCuk4vB+E/8P2CdiM80zTJCHO/9h/H5Lp2SO7x7lTV0dTpGmuDV5SDNVRa8vinwSWc/cN8fV3/umRSaFnM/OxHJfWNfA6zZ3eq5+N0+smhYXk6LD681rrFSzmWSRv8Abbzm9oJ1r6rqdys3vWW4WQ5tEYiZhJmOnLks4vss7brMHJ9suigjcQMovz5fwhPVROyZnA+s/uUMXr429WX32+LVhWL1tQXNmsbW+dE/EIWOyyMF058cNPxmiyikzsDijw36ORw+gmNjE0+wL/T+HHZlvUSPineTVOb5XuF/G/6hPw8uFrqjohRPuE+WPjSRjtbn3+cN0Vbw+jLdZE8vbMSOSZUW8dV0htr2WYnYK7dl9U0X4WW9RI/Qo4JTvs5rnD2/wpPJ8uZkbJpe+oH8KjwWWjc4gjXuCqMKfM7M7dTM/wDCEblEGlgt87pgBv4pmrsyGiq8WgphupvKKec5YR8f4X1jUZvSErC7mtq3H+4//R84bpwN9F1syDnLidW9k03bdPJa66yi9gOas1+pVirXbumxgW0UTbMAKJDRcqqxenp+al8o3OPUU+KTT0chzd35lYZpRR+r4lWaV1IhmWIYs57uFFuhSGX7zrFUNPSZslR/CZRU0Ys1gWEm9VVev/s7z3brXMmXvqsospHCNqN1mIWnchYKzNPBCEOG6klZTMu7dV9fPM27UykdPd0h0Hf+26ocLp6gan8rLFsPgo6NzohuW/qsN1o2fPMoNCxbEHZujU+/P5702h6My7+0U0ta+7lYE9VfhWD/AHtQfH/s7zyzMQVwznuo2Oa5YlXSUeUMG/NOqTVUrZBvcXRt3qx71YoN8EIwjaMXuq6skr5uFBsn0csDGt5FFj77LB2+g4h3PwXlBrRe0LDWkU7LfOpWJVfRYNN1hdNYcaTtO2WLQ8JjHpuovdXQ0aLqjw00ETnv7Tzf1b2H5+eKscwhVxoVMR5qeOnq2ZHlR00UcfDbsnAErL1901rgSgZA0qFxc3VY3XOcejRc1QUAhAbzO6xKNpDB3LIFhoDIcgWOMfLS5GC5JCo4TTwNjPJYvMJakRHZU7WskasbPUY1AlqYQw5lVY4+pnjp6cbkX94uqrsD1/ZsNnBOIutM1rpg6yCmfwoy5UI6VWuk7lSsDWeKxZ2R8Z9aBuqKcMqH3OllDiTayeRjNm/upJJm1gDdljlM5s+YKlxZpjDJO0FVVslQQX8k+qjbuvT1Rs3qj55LCcLZTR5+ZVR2R9mN0WB2q4QzZkyHK66rak0kPEAunzGuoTI1UFX0Gq6/ZKOIx0/WGoKqqw4hJbZoQq2xR2PJQsqKw8OLQHcqloY6GHK1OqBG6xCnNNVMyyKXA4XnqSD2qPyeHN/uUOCU8ezfaocMhiN902NsTbNVQdm/aCrf3JtaOYQrY+a6TBILEqPgBuRlrLEMDc9xfCmUOIU+jLqOgrpTd1go8DaesdT4qnoZac3aQp+yqj7zzA942KFTKOa6ZLZb/wBCHEbITyj8SFVIEK5/MIV7eYUtW1zer/uB/8QAShAAAgECAwUDBwoDBQcEAwAAAQIDABEEEiETIjFBUTJhcQUQFCNygbEgM0JSYnOCkaHBMEDRJDRjsuEVQ1BTg5LwBmSQ8UR0wv/aAAgBAQAGPwL/AOaAzYk+yg4saztI0fTLe0a16HhMdj8POF9XiJZGySN4chQjwflpJZo/njLbL+HS5qJM2Cxe0NtOXj0rJiPJkZe9sqzanwFWfC73RMQjfvREm3iINiGjrTGKPaBFerxcDeEgrdIP/EnmxRueAHICrR6e6r5jtLZc+Y3t0pS28oN8rG4vRXKpS/G1iaVkXKY9It6+QdBXqltM1wxACi39aiKEJbjeOyA+FSvL6JkcZIkK22ffUscccPpGcq0ml8v2bae+s8pK34KDavVYvEJ4TGtzHSfiCt+1duB/ai/oa9ZhYH9lyteuwMg9hw39K348RH4x3+Ff3kL7Sla9VjIG/wCoK3GDeB/nCzkKo4k0MN5FYqt/nObH+lDDf7Zhk8olM2xMYyezm60rSQYeWc/7hVOZR1OthQbF+SHCE5QySXF6YYjBYyIr2tzhQ+fTxgat3Gw/ia3xr1U8T+y4PyW8flcTXGuFbi73dWu0/Kt9QfFaF0XToa7LDwNcXHur5wX760dT76EoMMuIP2rhB/WnOIwmHeX6I2ealEvkyMKdLxRlSK2WClxC4s8lxDWTxp4sViGljERazdbj+alwi3iw8Tlcv1iOtNswudvpcxUTuMzJ1AI8e+iRIUBtmYXDMOlxR2SyX5ZzmAqLNiHlEJuMwsX9rkafEzoXlLdhmJ99+VI86rNLLq4LhmNFUwUgwy3zSLJfe6DurEF2xKyQcI4pGH5m2grcx06xLxYm/wAa0xub7yEftW96LL+Flr6B14Z6suHa/W96zNh5cw+sulOJtwUcnrWbrypjIL2HOjKqAOvKuQPMinParTQa+bjWqqfdXzY91cCPfXbamVJFGUX3hV42jPgbV6uSb8M9etnnUf4i3rIl5p5W41HGrZ3OEJdupzD+SaCSVmK8WRbjwpS+I2WbhtI2W/5ivVY2Bu7aCroyt4H5OPH+O/x+RxNca5VwrnV3Zie+hHsYcg5airvEw9mStRL7wDWmJXweMih/aIivtUMtz7LA1vIp8Vos2HXYr2mVNT3CmHoLQ2HHVaKquMXwINHEp5RaOC2bMyCnRWJQnj1r3VrpX0Rpzocr1bWhqdeGnmxLLxEYtejGyBXyXBF/3FbV2ZiNCO6lKm4LgivKEv0hEoX31Cp5YH/+/wCQLMbAcSabC+S2KxcHlH0vDuqPEYkRyG+7E4uPfWLi8sbPG4XMCo7BU/Z7qAmwWcoDkjgfdRe+o3AxWFTgwQ3YnurZ4XyriiFUvnDbp+yO/wAaJGLnjycdqyMfy5/nVrYeRx9F1yt76In8mKxXVgj2IH61i8ZsHjRmMjdF99WS7ScgKvIWHUFacdnoWpmma/TLWVjYVnVzlXtCvUoVvypjOu7ak2eq3512UPiK1hX3V2WHga3ZHFaTD3itClBY9pc/VegqyYlVXgLXFWlyP7cNXxPk7CyHu0pRlEOHTsRKdKmxjbkSDS/0qupsa7dbwVvEVrH+VaxsPfQ3nsOArST86nWWSOzKNCeNZsOEDWtdTesyZXv10qGOQ3IkrH7TsBUJ9xprcPQhb/u/kMZbov8AmHnPrH1471C7ajmND+dBxK+ccDerHL7lAqNWa6Jy60bxJa26FJW1OskczpN87dg2b3VFhEsu/cAWRT3mgY7TTt2pBy8KylSR1I0rLJDE1zb5usxgjA55WtV02qH7LUVhxEi36qDWaHERMe8GrARyFtFCtSscJI4X6utXmwc6+KGtQy185Q9YuvU1qAa7NR++gtyrHgGUissceYA65qlkWNNUuDlrDRS6oz615QiUAQxqoS3jQ9GdZlaIyKRpflbxq0RilI7WSQEJ4msY2KQjZw542B0Jv8jfXzbrMK9XiZR+I0EmlMqg31ryjtzkAVbn86xEgFlGGCr4X/kMb7I+I85typWI0bhWfKcl7ZraVoL1ljUsR5jIoJQcTUgjdFyD6VerMb+y9q3fSB7Ml63jP+OO9WmEMg5ho6DNg478d1yK3op1P2XBre2mbvSr/wC0UWY8Ta1u4U6weUYppG7JMg0oFZtPbFqOGgWOXFEb7ZbiP/Wu6tyVfxClWOVLiteHupXkNlAPwqIQwiRs26qixND0zCyYdn663qeDEpJEzjcDrasM8jZUV9SeVYkJMkkj24N30bzrK4wkoLA/aFTxQayLMHdRxK2rylcOItl7r386eNKRWulOzch5tKxA1tu6Vij/AIK/H+Qx33dMWQSX5GkkNhGLadBXqwsbMxDZelQjGQekl3Y+zS4PCrs8MFBKjnzp8mjns86UoMjO1j7qaTEcPjQOFYWvpzrE+wK+bN+oNDRvfWkmlG+VvaFb+FjI6gV81l8CakXPIoUC2tbmJ/NK3ZIm/Sg7MVW9ro9CKEZmOppBFZ3Mu+/U+ewJBqxJPjRMMgOIdbZ0s2Ud1MuLYYqFZrxDERliG63q2Ihw+JxRBZ526dLH9qjdsECG3NhAdXPXjpWSHabIKSZDJrf6p6eOtMZ0jijAvpKeHcevupVjkEUl9Dfh7xUkLYhZZDES67Xgnf0pzEEKoLu20FlHfSpGCzMbAClabCTAA/Uq8yOqD6NrVwypWySQHO2jd1bqCuX5ViHOnZ+FY0njs0/f+Qx33dMMHA8xTtZOVMj3RlNiDyrj5t67VbW1BOQN6YdaRNcwNYj2BRLFnYHcCNb8zSQnEB5V+c0obRgzc+FNlRZLEaq3K1B+xfSwatyX3XrEtfKQi6/n1qRCVayZl/8AATW0MjZlNROObisU/SCkvznv+lWShtY8xfsms2RQ+0HCuJrjXGhtCWtwuaB1BHfVndiO/WljEpCKbgDTWkuImVNAuWwtTybL1j8WDEfoKlRFZYHschbgf3oTbeCXFt/iDcFerRmHc1WbMVtxy6VvQQm/1oxVmwyKx4AErW4J09mWvU4+VD0axpmjxkTFvrJUs2Gw+HxSSAL85lvbpXr/ACLN4xyBq/teCxuH9qGv71kP20IraYWVZkva6m+v8THfdGsZ92vxo+V/Ju9lus6ju5+6vJAiTNI5UAAandrP6Ovs7QXp8uGlOzOV93smrgG1DE4iaHB4dtEeY9vwArbq0WJw17bWI3F+h6ebQkVuzSDwag8wYwDtWNi3hUmBxPk1YMLs7xPEt3iA+kTWyR2wyw2viCm9KT38BSjC+UCzFt5GsLDre9IUx8TpKwEDLc7Q08XpUb4jg6CFmtanjGFjlI7RivREkckP1hbWkw8SsCrX1qUztlR48utRCEjR+zzrnvaUpk1ym4B51Zkyi+pzc/O2UE5dTV+VE2NhzrSsoU5jyrK4satGLmkhvlZ2y61uTQyH8q3Yv+ySv/zF8CTVnlf/AKkdb6wSfgtQL4FdDfdkIrehxC+DBqCTyyJH9K8fa7tKOTypsr9+W1D/AGdjofZWYU0uOxAGGC3fPJmr1e7ho+wOvfUn37fAfxMd9y1Yg4uZIQ8YALG3OsQkrZsDPK2fmBr2q8jSNlGHWfKDyG4QKjxU2DxzsADHNBJdT3WpJcDBLDHNEPSVlXLp9ap4PJsOSCaU55lHZJ4rXk/Z/MehR7P9/wBaxHokmHmhmivMiygkAa8Oopc0eNxMpG9sgAF+N6mnSVjGscciB0sxDG2vS3mUhuAsL66UeG8ddKjkg9U6c73199ZJGU99taIMKr0CcB7qbUtLfca/ZpBPtZHH5D+vvpScYogjYGzIRtD4DlyoOzJMsilhtDdEbvW1NicaxMZNyfr0H9Hiycja1X2OX2XrckmU+1esvpRI70o5JIX9q9JPsllyngGFZFwjQOTvMi8R0orLCWN+BHCgmHGVT2qckW00pyR6xedLtCcg51LsNGA1rDM+p2i181euwwPCrqxWvnB7638PDN13a3sIi+GlHKJF8HqN1xLqWUHVb16vEo3tLat3ZP4NatlicyEi9s1GbFnZ4ONgCfrHpWNVAFUYpgAPAfxMf9w/wqT0vKdz1Ydiqlu8inkTAEAD5yHE51FYeTFYidNrmsFTMosbVEfJXlCSXDyPs1GXg3SxqYJjsK00jesvIua9T+Smw641ZL3S+YjwIoYPyvgp2hjJMTjdePr3EViVgjxDGaBk2stt244ACsMuF8ojARRxhXgsy73M7vaqRIsUJ29FiS50YkSHl/C4UFO2VRwul69YI39pKGfCxH2TaguwkQfZe9XLyjuZbih/bEtfUFbV6qSNh9mShHFq5/QdaywRCX67NxY0smKwETu3FbA299JFJ5MjBc29U5rYYBW9I+nv3Vf9auvGpc2hfpWF+9FHeZt+6hLkgfpU2csJbnZl15aU6teYqL2VRW12QRRx2pKGoGmieJpfo5hp+dKyO6dL012zaGsMsNtYxpkzfuKiniARn421tQaaRnjftXN/fS/divJ8A+nK5/WsYf8A3cn8THfcP8KLbOOS/KRbinMOCgilZSudc3PuvUEGGdohHmv9q5qB5WziF84UAAfpTMk+AYMb5Z8PkI94ryhh4mhhlmQbPZvucb2BpgfSdnbWzZhanidxJGkDlVdQbWGlRieKI7jboXKDpztTM3k4Q/4iSFgKb0lisYQ6jjUCYQFly3Lni1SuoLlNMrcKm2rbOMW1oubYjPotWl1FuFMcuUpxF6GWIKx0GXnQebKwA4d9AwKUW/DvrRstcY28a/u0R/DX93y+DEVo8qfrXqsT+a1uyRt+lCXDobHgUltXbxq/m1WeY/8AUip1CYcOwttFWxFZFBkldvEk1h0bfldC725ef1U8ieDVu4t/frWro/itDbYSJ7G/OvW4aVCTfcltQVtvHZ8/XXxrMmJS4H0orHhwqISPhpd0dog1sYSqR8gvCvWyoIvscTVuka15PZlLNnYL3XJrE/8A7Unx/iYz7h/hRyAE5eBNOcRh2GresWssqvCSotbheipxARhfjW7PEfA6UpUBg3DXuojKwsORosuZOKk/tWeLQ2I4dasNK4+Y8bHjWXlSIeC8KIFPm+khGlA6eJqUhrjKLCh41CCFKubeGlbN4tM1gRWRFYa91DM5F+6g20XJ1vxrQL4it5LVAWV2v9Rb1JOpJCGxW1jfpQTEQhUbTMDe1YbKoG6eArH4zKNujZEY8r15KbD+uxWxbRvpa0/psssbhrbKKO/6msO2CmbZyy7I7VLFWtetiskL4n/kq12/pWHEoinh2qiXZShrC/O1TogsqyMB4X+Rw8247LXqMVMPea2k5Mr2tc1gfrC5H5mpef8AaZf838TF/cv8KywXz91Eb3PiP1rrpYg9Ks0CML863sLZb8m1rdeVdTw/SrrjeHAFb0TnjlTtsL600iop11ytU14lRS1SR4mJJU2J0cX5ihjMAmXDNo6rwQ1F5SXaDEEC+9pxt5+Hm3gy+IrQ+a0kUUnuq8uC1+y5FK0qzgg3te9AI4ht1jP7UkKYqFsmouctOFeLMW3cpFby6dy3rDqWCga6oGv+dTQj1mdswAGW1GLYybXhbLWA2nb2OvjWPjQgHbqa8lySDPFEn78ab0DERYXEmZ2kaTQsvKxrCifGpiZBjQTv3sMp61jIQbS4iB44j9qsKBFIjJKM27aw51ifvW+PyN0ada5tXAJWpvRsGrD9W5/ipj/7iX/Of4mJ+6b4VdGKnurt8Oooh8rXN721q02HRh3aVrEVN+Ro3kdF5aXrNFLm1tltr5tCRRzMTfrTfcN8RXlHyT5R38LPO4TNwBvwpMDnJjEkaZu4yVDh/JEHk8LbejnbKWrCYx8LH6NPuTxrwU9RUs+LlyYBos8eVufj8KxPlPAJZ3xGxw5k3mjFtT40F8pSHG4Vj6yKXe07uhqZfJSPPAraMdLL30rTQnIxsGUhhfxFMGjcFO1u8KA61LhpWV2j4kcK4VwrQkV6vESL+KgsWKbKOAOtb2yl8Vr1uCU+yTULLE0ORbG5rHi180n7V5PSwdAuQ3FwaSPYRJ6y10FtL1Ip8n4hUViAyN/pWzjJa4DC/HXl40beUJJHw+UvHnO5/WvTJLFZG1N9b+ayC9DMLmhtde6t0Ba1OY91bkX6U2ZOVYLKbEj96HfNL/nP8TEfdN8KJn1jjQuR1tUbN6G0MlssmH3ShPDQ8RStiVkkkkZljij0vbjV4M9s2VkftKaXa4hEcm1iDlv0zcL0YFjJlB1Wg0q7h+kpuK3VJ8B5y2Bn9GdUJaQngvOpJ/S8LiHY5mImAP60cN6N6RHou2Ub1xrUUP8A6m8nys8fYmXcaorQTrho94h94u3frwqeHyoCmDKWiY9etuvSsX5IkxUeRpBJhp77mbv6XFGMwxR4Um8kkyo0dut68qYiQSJhYJEXYYfS91/QV5Q9Gw0kMd4TdpMwJ2g7qfAyyEYPaMDCmgfS+vW9WxCQy4ct8wYxlUd3SsZ4j/KPk7orU/lXA1qP1rHQrom31/pWGkQ2ZRcfnQfmDenkV2RmObdNq9KaPfC6Dq/U0TNhorSbsjKCDY8aaNJC0QbTv766L1oaZU69asgt38zQ3gNedXkLFe7hXqVUVxprnlWB3c10X3VH95J/nP8AEm9g/ClkTiOXWlxBw+IV/ohzud1RMzBZYXLxswuDfiDTzZkkllkV2yDdFqxWGb1uDxN3jk5wvx1rExxWkl2Ma6fTy9oUG8nBo4ZID6VEV3U00996gw5nfDI0GdTGcud763NZ2Ks6yGMuv+87/MG9JOEsNHC5qtjp/J0sX0nVCknu0pRiGl/vJtsmAYbtTwRzYnEtIVK7Ydi3vqNIsRHh4tmuVXweZDpxzc6wsLPhSjdpsKuX/wANf3B0H2MR/UU6yviokzerAs2nfU/o3lSX0ldHUoRm99ZX8owNnRTsnlA04jQ16XP6vEM20Vl4Hwr0yTyVv33mVyIi3h/rU2KRDGJLbp8PPuj312cx769YfdW6K3prV88x/SvKIHAYk1CbBxsz8aY7C4PTW1H1JsTzFB481xow7/Nmk7PxoNKPBP60Ga1D0RRdluL8KibGliSNAvxqO0Ykw7LfPrWbDnJLa+UnTzP4GsF92Kg9p/8AOf4kg+yaXQF8rZL/AFraVHIjy4mGR1EgkN82bS3iDf8ASpDCqySl3VSVzdnoKZniEU8dr2Fg4NSRtFJLsvnJA9te4UMjZlIDIw6VllmZ16E1kdVljBuFfke6lFlRF7KrwFNbkKId8gyk3raB1KDjblTEJmVTa4oFo2AOvCskM8ix/V4io5iyiWPssqBfhV5/JuHYniULJRaFNnHfRb3tU08YIVzoD4Un9kixAESDOSynhXk2HB5YkYEbPNfIb63NJGmOUYJE2JiZGsRzPjzrF4F4kkzHtH4+baupyUDJujpzqyDL4Vurm+FetmCjotc299aJWMtwOINQg8cn7122/OuPGjcA391JuWI4250JphvfRHSs0tXUaKOPWjCBpslJPdV8Gybv16SF/nFNxWccLWIo5eFSeyawI5ZFrDfi/wAx/iN4UiRC8hOlM0cmHlkHFkXf9x5+6nhEBxMbalenfflQwoikgUa2ka5pzK2ykexfQ2zddPhSLDfZRLkW/E/IxknVbe7n+1FmXOMpFqbdMclxYDgakyTSBiWsPokUvo+MjzPbQjpTAejSrlIpRLghLmH+n7US2GeNWGoy8Ks0jRuW3R3UyiW6g9rTpTBJBlDWBP70JGG4e/zDMS7cBehpmk+FSx5gXXe91aHKvU1uIZG6tRzKUQc7Ubs2br58T9+agH+H+/yBPMNwdkdTRZjqP0qw0jqBF8DQK/NRjLrReEZcxozE6uOutbBuJvrRU8RUvsGsFl09Wl/yrCeB+J/iHwoGTRdVJ6X0rybscsckRHY7CW4tfpQXUQtiWz2NvYv3UXQRxohy5Fa+Rgbf+eFPDhnaMpuqgQFfFqUhcmcXK9Dz82unmxDf4Z+P+lf2gMU+zWrSRnpbSjlxQJH2aOzmjbpWULvD6rV/vOF/dRQyGzCx0oqUj4W4cKtJhY36d1FtnZLnKtqaPOQhkvY6VG8T582hHQ0FjF3PE9K2WHBN+J60CHu53T0rU7iDjRkw92yHeBpEdwHYarUn1uyvnxH35qEB9mdidct6LFVWRHyPl4Hv82Z/m140AthYadwrKnzY4d9RL9oFvCvGpr6xNJmq6rrobGjntcLYKBU0jsFbvpr6m9TewahmnNgsS2HU24VgvY/f+K3jVrm3Ss8LFG7qAlbQcgLUoxMW1KiwbMVNvdV2AUAWVRwApSdQDXXzYqPmgN6WOFS7twApnGzlCdvZyBivjWWNS56AVldSrdDWjke+sySG9rUyPlYEW1HD5ICC7HQVs1tm4u1bvP8ANqTPqXPDoKdJNQRr4VMfJuvIpz99RYmYEMlx7Q60A3AHz4n781hy99Ivom1BEXKgN+N7mlReLaClUf8A3WQdp9W8KLtRZuJpHfXSs2XZxL2aFTQ5r1m80/sGo77sUKhFX3cawP3Q/iyA6bx+XlABq8hvWJXissZU0wzBGkjZFY8iagih8mjD42O15FGUd9x0tSR4WTYxzYplkkBtp9EXrE4WSQz+jqrxytxF+RrF4fBRxNPhVDZHjzGUW1P/ANVA8XqYJUZ255MvaqHNBiMIJ/mZXbMCe+pGxEgw8cbZGYi+90AoyQSieNTZtLFT3g+YCto49aw/7RWnZ5D6xppJTRc0hmtvLehNh0UyfTH1u+mzX2rcRf8ASiXQ5bjXz4j79qivodnw82Y+yKFuApvGlHK1/Mqn6tDMWsvIVu9rJ+tXvcnpWt+PmxTn/lmoQAtuJtxvWA+4X4fxd9FbxFb2Eh/7LVpEyey5r1U0q+NjXqsQp8UtWgjfwat7DP7ta9ZFIvihrjTeFCNCF5kngB1ow4bHSyHgqOCofuFSbELsx87tex770FaOKOBjxh1Vj41FiNlP6RBwmh5jvpWSHJAoZdl3HjUWEkx0bYON84BQ7Twraw5RiI8QZkjbg4PEeNT4mWA4UPDs8rHWQ/6eYzyC6rw7zRF90auazHToOgrZj3+ZEPTTzuo48fPiWbefbtlWmeQ3Y+YN4176cN9ao35Wt5ogL9KdRxuaAFd5orl0PCv7T+HrWJvpeM2FYNbjLrpbWsB9wnw/k+Hm341bxFYh1hVWVCQRpXrr7N1KNboaWSaRQysrbZSMunE9dQBpbjWIMSE2ldygFzYi17d1YllZtgy9lxqHvp+9EQM6YeKBTGENrk8/zvWGxTj1rllc/Wtz8+pvSovFjalEf4aVPr7zUTzrWhVmO8OFcfN46Uw76FYgsyqqSHjz1o+YdQxHm2yfioxycDVzbINc1Kb8DRbgpY0Ftx505+jwBNAL6x+tZEYPINe4ViNbkrUfMBbrasF9wnw/lsT903wrLISIwpZrcbCoPSYlw5n7BVicntUTJI0GSTZjKLsW7qDySyyKPoyizLSZzCIz83tnyn3c6yYhRHkFlRRYAd3yLjiF08TpRT6KjSsvRRV+/wA+/cjoKDxHMhre0qyPfrV+tC/a6VjzIwUKxJuL33qJarKNOtNExsJOHjXf5t2ye6ilxl76Luov4161rUMse0Ydda9a1rfQXjWxj3E+zzrvJqbwrDhsusNwffWE+5T4fy0/3bfClkADciDzHSsLHIXPo/IrvPbgL0skzBGExkF+BuLEVNnYmS7rHeTNmQnTwraSquwlQLn2W0tYcCP/ADjUGxzBbtsw43gnL9/Np5pT0saDVHMvAixop14VrV6zWajfsHeFE8wKC24casm89aG79elY1r8S1vG9HzhMTxH06utnHdXZNaK1bxVB3mtM0x+zoKJsscVuynH86JN9eN6zxE5LaUBm0qWoFWXPliUcLX51hvul+H8tN7B+TeGRo/A0WkYsx5nzW586C86yHhKpXzGKYXQ0ZJn9SOFudeqUUEbn0oxrq1qKxg3Gqmh6S34VrdGzjoqm6P1PmxYuO3cfnUyTRrIgj0BHeK0hy+yxrcklX8jW5iB70q8TofBrV2XbwYGvXJMPwmtePypPdSyTJs8HAqrYd3KgFFgOH8s6jmK/u2f2XFeswkw/BVmBU9/yr0CNCK2iaSj5xP3rTj0rSs5gGag+zykd9qyoo+NFpGESDnVgc/fWQaqeZq8W+OdqtXlHML8OX2qn+5/cfL30DeIrew0fuW1aIyeDmtyaQeNjXq8Qp8VtWgjfwahA0ezDEXe4IApIMOuVEH81voD4it/Cxf8AZW7EU9ljXqppV/I16rEA+KVu7N/Bq3sMx8Na9ZBIvihoNGxVhVsTHm+0taTOndav7w591bsbSH7Rr1eWIfZFXfev1q8ByGgkzAga6Cxq0UxA6cazMbk8axrlwI9uLLzdqnxOS0WTLfv/AOH8K341bxFf3dB4C1bmdPBq9XO3vF63JFbxFq7AbwNb0L/let9GXxFvkOi3WJW9Y/SkhgXIi8B/xbh5t6NT4ivmV92laZ18GoRYdbLx8T/8c/8A/8QAKxABAAICAQMEAgIDAQEBAQAAAQARITFBUWFxgZGhscHwENEwQOEg8VCQ/9oACAEBAAE/If8A+0GbC49JiEffiXAZfthUrMYBkX9H/awh0HdNZPNqBZdDMfQqneaQqCO/kU76jGFer340z2jgeGD9rn7Xr1IFf6z5nxyt/wD6WZF0nwgj96rfVfmDUzNRDlduZVjpZGBhRM1ARcFqi5MajiTORaxZuqju7UsJWMe7iAzR0BZQP3t3EZwoELwykvyu4vWEgl2Bt6uk66kD1MpXF1Q9limX+pmKe/JC4fog3UYJ8l+egE7/AKXuZW5rx98SuFnQX+1wmwutn+4a0bRQEEESVNri9frUPdeFU9mtJUHpe8xgFIEKnTqctVRfXnEuigl3+IMxw3pg/CUOdgDZZn/x8x/5A0sA1IL+xDon0gexGSP7QWH0GYZlzSwqYl0OixIe8vHHWcExOttwZUO+kdAPszLqGgBOLxF+rbuOsYfz/Ke6hX0JhP8AQ7i67v8AtWTPRtlX7MEEukVewOkLCFAIL8h3gNVYBvUPyMzrDYJHWnkjSXfblr3Zn4Kv/Za6eexEGOFZeXV9MpzAuEuBwwl1Rxy7glPxlx5qehlgd4Gv4DZnsfE/hKwrdVr8pFDe9gPuCXLWkenExxhgSzMpFCg3cqZqEKwztC48q/v4l0pRZMeYxtzOKs6QlIwUOk7Fh13Li56wJsvgTLR4cdAJQPXqbaiVn6q/qA2cOs/mJrYasjflIdyWU5V2rOhS76LHY/0uOgcb3dY5gBbB8Ghm+ryva5SG9Sf/AD26+5/N94HovWBwdx6S/JlNa1qmBpiLzsj2oFBoiha0XxnmHpu7m2iLdZB5JXVJnVvioCtGv/iMWRsuM0y9CgLf1t48y8a2pQ8XeWKZKzQHvAAbMBXxBcU0inLfaO/UgjDPtkjgZsr5RgbXYzFAt6kY0A5KDPMhQjULItvTPtL/ANmK7rRMHLG246ipaeadSmEiC+ORVRbivP3/ANCEI1ooCZfxZU9nT3cwNmteGN0eOkMp6zdp7R1rzKoFYiu1dKb1v0mfmXvHVprvbLQoBhVoFPiJUjdEryMPQQrXCuIHoCAOw8wI09ZTSApYL6JWpzgXiWASbUXtBtaJ7yB7gKDzc1I142wO3Rsq8Qr7w57RxRGu4SKdeEg+ARbpxa+fwHyaMeVxM9nhSBYV1C/3C1NSEj2gmC8X1UG6baF/mKYMGEPV6sx+tcb3WO3eO++oTRN8zFHMIb5VLI5y60l69haBRMlEt1apjkBRoW4zHKB0AiG22tIcMomuWGJ0rdkfxKD1bHZ/0N8pHiheDVmHtLc0rWTJDLgthHsMwVu21qXuFnJ1VfKGZVHtHzW7nTUAKmtOiNsUdebuxVjnMRtW7CngAzXKygoKYYdOyFVu1kfKD02wcvbEBTvZ6fMZR/c7GXGA00CeiSgcaof3LJG7pfYYN+F639mPlfQhEK8NcGMM4KzF61ackphT9ukqFP04lq0mN/EEu9AvuSlWgfLxMnY0FkIPDEas6RApXFBVX6jCIjFEbU6GUSAtQPaJvLouoNmHcIQLwPpK4EUuXcPvLds9Rn6OHrKFFB1wjz7RCMLH7mnPv/oC/wCahBBTauJR0ut1rcoLv0WZdLitM+xGoStA1MnaNpGuhEbILnm59tm+agDAD9GZ0Nfoshvp4C/aERC5ZTrLhdNtD8y7aRk/vJTG6LI7hg+49rL8HgSlIvux+gSudRB12/hKC3a1lGpapHBzfpuZqMvOI4ZueRR/c3XoxdiffkSunMoJawYPBiqsV2wwblxrYMytYBKzd1NQejjiWf8ASNtdcgxDUGrEx/moQgG3VZRDkE8z9IYe13QCQNPiG+HpEShKdM1LugL5/wCh9h8ktrwBr3BYwKmANStxwLfD97QHFAjk4lIRyKu/r1iBV1jatZ+Y+RMT8vWExblma8pcac3K9x4N39jKbZWMCAIBzrsly6GK6YnOLsSsMnADHpNV6GhmSNA7v+pTt/bvDW+RH8I+JUJ3GGZIuuqsSoYdMHHYnahqD6RCGiHyVGIGrWHFjDOZZdHsWrePMugAK2FwTxvXqmI+PJOtFjsVCIA/VjoAa9kKUO2w+otcEWpbsPdrVrdTPREdDO2NB9oeofzXK8SpCxrV6Qtfs5v1OHprresGha3WaiE/YnqpltLg7S5zzOlJX2y4XcXpDw/P+hAi8uCKgQLQwgWg9KOGJ/2J4mN201a3GgsGIpXV8dbZUIPO/CfmBtslxjn+4FSmfsmS5xVS+pXiJahb870CiYm1U4AT0v6mnphNWtbh8S3SFuM9I9SPQbiETkKuvg94sqBABu64DDukANB2qYGxldGmOOW3HvLyXiRRq3b2lq0vgmTB5BkM8wDXuQKFrMpqs6sNEoDiEyJc7uHBbZjGzb3ZfxAoqHGJinmdy8GCvNy4YR1c3Zpd1cpJ/W44O/ebxCAn7xqXOKv4SqraUf0IXx6sx9GayeTU+pHK6Wf6ZvwRtLlrkxqXzbjLDAd1j6mT5tT3IlT2X2ZGQpZWHR8n+Q3IWH9rRTbkJnOny5doj64KV1gM1i6/DuEOxaGobE4gwgNoYIxsVBkbqK11gRY1/wDcLzOzK/kJr86IS0Mb9MkxRYkR6oA/ty4qxhm1Zp7PTEPvqr6DDHSVbgQesChDpliJM3dLVhnfEonvTFXocWPZzFlXNy+SWatN73fPeH6qTybjByewgBLYSMDJEs7gBlcEJlp7Dtx/FsCOSyAo0WhdHVlq8zUCrbqYIioK9CHeIKRog9jGNYL3UI9JtwVqc8TBan3JbtlOh/cHWV9GjGXOAfsiG8bynfoy2NoVl+JylttJ8zeIN6/pHWKuHY0OhYVM0wFUC9474yYB1OkDguN5l9cObr/kv9jalEphReEAKPDkKh6b6kZKlhwqHjUZmSQZ6HpzMwmtlbrl2rrBGANAr8j141uWZ2pNc+/lG3mSDouk7EBLIXN6GPohXgdCKg5InhFxuIoOyOd1GtLrjEEQ5FGO6rBHwR2KL1lS50g/ZDDimK755e/biZngt42XXXqvqlKHDUOu2mF1RCOPI3CUF8bPSJsqvC+3QlxmlcF8TChltYndHw0oes2oW6PfkZdQnFUfiCnkXFdI+zDquHCbs/UFPWU0zXT6l524NqkxcwA9XmXZsCn4jKhIzukIi9tz6kBbd9lGU71ZZLSmaa6ftTRkW+o5hRwzgfSN2gmRtPZjmvS7PuIyiAC0gfln+0zo9cfJK7c4YnvGzdUfaD+YMEEKABr4/wAg/VbwcObmimMgxcsCJpd8mWoviuA6QWR3HcE+cVviXqyXaJW049iNfZOkOVR1z5guMJbOgpY6MG2DsaHUGrV4igwxUBhRs5zBCzYTjazdN/8Au2Wnol35QYAlCsHtMD6RvxL2kHVimllCFfeVQ1V70xHm7RDHpDss0hCo3t2dRXEIlXKAg48Jc86Smn5bBfNEH19HODpnf0mSQUhhvoU8wsiH9s2iaJkW0bfu5W/kXweWHq7ihQtl5rYh6YgrZdGwcVQ3HTS6Cg5acQruLLRXPZqByvL7VLoWQukd74YnG0fBU/HpGBzRqZjB9PuYTRp30/7j7l9h/kNHr92NUMU//DQ22juAKeDUyeBREyNJxEfw7arL021uJEIG2uEPmYgw8VUE3qdfEqC3F/CzpSpS8UhVuxxBFfS2jTRzKUvXPLyksOccltFHO530AcvTtUXl92yWKuQe1uI4u7rziWQz2lgeZRhaqvIc9yPbso4OI5bCjmG6gWu7iAqzDdLL0Aewb94qVd5oH1EebYCbakvZh7S2zVx/3hd13uDHY2AvuWdI7h+Ye2Uf6iV2Dz+Zq4E0IUZKKMnkWVdHg5lkDwpPndibj9n+UVxPb/FSkgBgjJp5jaz4L2dQLzRXksRaPeGx2BZw8otPCpoxrMxtyglCV6/5LA+XUA6/2oVWXDuC+0yfX/JxT6/ZiVd2kcQzs/Stt6/+wV+WDkV3IBY1eIDbPNbVd5XGrDZyqIEi1z4wceSYJuBBNmfZNK2xkUKfhmyRTwlHp7yocCnWUZEbqo1Kz+6Mp2jvp/8AZuuge5gtV+DEdNrDUzbun3LcUNd5H8RnlhYZvnVfMoyrG+D5viPdK0SY8QurqssIdVffLuGRO+7gfcJsmXiXgtZn1hybJdQlPclxmTb0C8kCJAdAP7jiBNTV0I3V2S4MUgRXcrePSAvenvjBsTpMBdaGh5apW23EbVEVjUclh3lap30CCH8Vdg+kE4wXh94qtbswQpumCPawcqj0jB09wYrYaztsjzl/kNLr92FASOdYmcWzC4uBqoUEbEpqPfC2ruvmD/JBahOKFC1Ys+lwuuBcke3x8R4sukul8efmJQ1sqkcYz4+ZogFm0b6xyCeqL2Zh8fRcxOz9+Y76OcnfFUuUPAy3hLsF32lZm9XlymNDZWJhnVz/ANwr/mLSNdppD6pv7mbSGq1vkVEJKMovPW+vMWlA2WMXdBfPE7pOmc+cYqHegYLk8fhBTaUw6NF9vmLNfhbXvDRdjL1wuKyNxaME5WCnB8lbhhkGCndGq6YmW5/fuqmPGMwxlaGrTdX3qpU8o2pO3aZfp5/wEEy/lNR6X6OCE23O36zYfolVmxAUbAz+neZdd/kCmbX5UWtIpVWIWBY0AZaBZfEyqsm03Sm8YWVX9zJYN/khAl8ygxuVPisanVgVrj9SAat5Bkr8XjvFncY3U+aYvDpoB26+WIQO56hZXpM63UfvWNBye7GRzfaOYGr8m01b4mN6266k5DZUcLKv2l2g9ekyYg8+ixLi3Coqz79IajlRFzEFu1g/mdtL4DftEFADynRroD5JxV7Z9VKCr7D+4VykF1qzoq1dbirONdk5r+4nMGmJwVuNCgM2DvKgACGijS7EXqoNlcbxRq+ksss5BO68wgG4jNWWsY9DmWDJ6n+iY8zrzPjxFXg65xsAF+3E0MLfmTk6j/J5D1+1CESPaxahgSzYwlKbkOsuA6UXKXzgj2oFVb0Y2PXzMBF9E69aQ1Kh0KhBbKA3dLJb4vdjKmyBZqcAKyw9pbHJ0na1SY1VZWaZZy6ht6q2vXdfvEf8qJ040B7blOUHOOaGvgrvExmyoSqXgdmBhmSXc3x0huSYFwNt49Dmb6xKR2Bcus5SsOlOTdyscgGWMDC0dT+dgQfwbNrq6n4TXCeX1/grLxO45Sqi+M61ptBHSXPrdxAS1bRW5ljTcSCV72YUlsRDzKesVoIc2uikPPnh0B1J8Os2tN/kShWEHCc/RDD1TA97DM1Eqvd/qI3/AEHOTmbPVf8AHsyPr96UYrbZA4R7MOPK1xPC0OCKx+t6K8hzZCYCtg9QvLdzBJ1oZGjgvD7zOVZLpUPcPWpgtxIhk9iED3EZDuK6TQR9qBSY89YM4N6ltcuiHEH0u0fK3QWwQ2n1gZR4gxpgguymWXUsWTKKh0OTMyK2NgtpE6JmFxyXXqS/UlXE9QzfSaFkwDjGSOOsySmaRhiAHWpjVjrW6owkTrVfqMmnXgixBK20QH4gfwdLOrUqKXYfiU2/omEU90uH7/QpjNWOmIOx0ZKhjYV3S3WyfSY+IX7sksrjBxl1KE2jpKZ/i8WHAg5N+mfriF7odO0UEWU2Ljtg6Ger8TkAoyPnfaaPI8iVeIIKb9qlS/iZ9T/ErFnmwfErdQIdM33gXDw6ii6aI6mWoWg91ClCYtv2GObffyoa1Y9OsZcEN4tVV169IvFTda09mZnJfI89YKq8j1kZIPlnSqzcpZeR7ErjAFqw5mbv9tfohFpLY47bgNKo21DBHpYfRxFELaVd7aF+sVc4kReuGo9hLveOl8yz07Z0JmHRtEImHh7StWurnzJ13DUQRGnYYU7eJhld6eB6ZI7WLYSyzR+YZmLFMvTiIKgeNnyw89ew8sNanJ/b94XaL3Zb8I6a4z9012y4ttxWne7iCWTo9nfb7wxZ45gTOwmc16+YVZ3pflm7wBSoHAriG2PeVhLWrIexmAOQxORA33InQx2sEe4LXiZv9qldF2XsVd+8Nd6/+GYsU9z/AFGZBFd3MjBbxhvDlQ5ywx0GQ92jjyRY5XR1McBecS0FbCUFV5Xd255gCgK6hy+X+AgRsHNJ7KYChSy7kowRkCpyl8bjQrCL7j3luLQ7dLz87llTVWKzV5xuVXFl2W14DyhYbKFWeE+paoj9DNeP0g6PWHTO684lFAAF4dYaez1hBymmnfj0gTSSFy2jREVX/YQXMTTFivslfB17faW/tKnNq6w9JgRhatEbsLdMGZ+k7S1OPyQQlwDmckH9riGWMiuv+46dNuuvdgY/bbyXzHERdxal6g2k4N0qwF4e1tT1jVBX/p8xZmkpmD/pUrCRocmcz/w1L/J43ujqX+IG3pcwQUTR8HYquYcnIGonybK7kpUg7Dx1yX5yhoICPa2ZRu16OJrNUthqA7WYgSlY9U1IHWj9/wDlADU3Gy8RZVmYLW4BTtjZ2ihIWUvLGVnZU17TBCl1Vb1X4g0qbNhhVA0JnhUtvZCLaDXujFt3hIi+wVU67FmPMtu6gOC0gBNp0YYvPI73oRusbTweIxVWszmEFQAwfM8qryQLdLFDWefaBBMP1dQo7MUc3FMyKaArpDpcI+cN38TEeEHErCNnqdWLzVNj3TiPl0j8xBYVvESOuOxN5huIxkZvH72lQiBAa0WefxA2rIzMP1MTFVab1RNjV391/hY448MNH3/cPn6xCJzzBYK1gBfWjmHhrJ2kuxDRDk0LQQw8gktA6XcrB0mp+B2nJ+Y8Eq3liOan4lEMLvVMcCWwpiqtJSxVA3HOP0l2P6fUP4CBFOvogZEy3r/5KZf9noQtxwpgsg1C1OXoO8fC4jHHrTrAVDDiiBWZppn+Aajr9vUDJ0Vnjbkl5bKticrCxtqO8O3Rfl1losFn0mrg0RULS2DVFgwcNVcU8o5bmHAVeuWEexLM2nMcrVp7zbcV/axOXrXrT3VBXn/8FR/kjsNFWhK5h/4IEN0PSxQupoNERkpR34feDe0EoFjPF69YsLMTzFfJbgydzIU8A2941noCyQWdG/iPogCoDc55a8OsbqmfBah11jzCvGI/DBDF9pkq+JPQMrCtruPp2QQIpBayjAY1+/5nL1u91ntLk9ZX8ExEN47SygEE6R66wrX/AEjwKfJA4HSGibTiCDM2f2xLUAoWHWX+GMsXZ3d/EqTaoiGv/Br+JsMRnEF3LgxK0hG46WPUxhg113SxYDCmOlE1tquBTttjJe+uvTENf4tVEsQwGiegMv1y8gXxGL/dG2P+vv0S19VvyZYe032Tpk7Pqz4ZZ+ItoC+Z8pLXgKdCLV4JszjcTu/DUSpSDAdho3LLACgDrZtOkJuIAXRwUpxjxKVKxPX97bKkDsETXSc8x4KRgAVb8JqbCF1sx9u38A3G6KQPjeV9olwNfETQ+DPn0/gTQQEF9QUUhrQ9IE2JTovcnGfEQvmrDPHr9Vr6JU1yWmzAX3Hpbe6P/YYgY5d8TBt1F6U7lng5t5lUKcjlM+IOEtlzMRY2H7QbfAHMQN5i3n1hof2r/mqVE9IjiL4jo6OX/oewStY4Idoq8n4CrPEU/wCtOAGcuwC7lUIWrODy/tcx9wagh4tnDi7jkxvUIa76naIYBkKsyvPNekIJe08mD7ZBOcArw6/vWIlv2HEHc8PMLS5LubrrMDMGO5xA3HcC/wCKgkVg93yse15lUrRHbCY2H7PuWNJqmHQ4es7fM9HrHY9SYSMpDJTHMKA+rHUx38ItRfQYTyxoweCI3AP0yxLOwr5hLKXZwvFPrKF0+j/ov/l6h1+xBShPgLo7zFmglW1n7Y79I18sW6H4bXiDusVAFoa1TWyOoNU2BzewD7QSt9oDIECCK5aXkf2YaOH6I9LVD2lyf7qCHULABmzc9MSlgLpuAiUcCJiwKhfCOqPaoY/ekbXFMpKVsrmVskeB1HKOBuC+PbrLSiLfIjKvrVrx0jodasoMMgDmm2PdEP6px4v0cS1TVhZ8mWK0esqX+D9kJLQOdVsPvHR9Pqy/9B/8qb/eyhEwHTMU+yDuacS29QOu2aJF0HM+MZPEyEeiRCkLwo30IYBBsKoPERGtcoWm/wBJbKPa8L4gRtFzPkg85P3fmJ33PiBvLN3NfEsLD8kpSCk2QYaaiGtblTEo0Nb8nvAG236hiuC3x3jFfe6TnBZ4eHeOjxAXN5PqYl5/izEjupq/tDBOuUr/AEwn5kMueqY+j+xLIIVHbe6hU4NLGFOB+cfFidMxizofcReT3AuB2BJSXT6X8JJF/wCkb2l1+lhD+NRsud4rm2pi2sECjVaT1wzJVesdnyfM7e89mfiofeUZqZbeXSNkV6dwXlBcMyv2w3zcz3joD9z7ykm+U36zGkWqNyiPVYXtGoMCUbAu2tnpx27RCgWy7k3I+oPzNpPkPqbDel9M90Fr6nNN1/ITFH96Zk5h3bnncXiagwTpCP0nWA0acYgwe7tf+QGgqBwRfwDBl/5soDCYDOXD2m7o6s/M94+6fEa7MCv4IfwDueIiCq8sRNRY9HrMBBeTsmFw6m4cBrpAmp8hLWdyoMcoHMUThtFdqF2d+kVZVZkolmVF5DD0nOwjSPErINoXahqv1K0dFEIED0lekr0lOkNoLyTmj1BfE/b6d5mfvToT2A3/ACYliu/fyEDRtxYGXDMbhDqvK93+RICEP9KjHaIdQfkmcW9aD8TPqdl+Yl9BUPqextV9MvqH3B+SaYjrPozgz6Ca0Ao5IJGzsPtM0PqU+tRTP9SCTADzB92MKr2Xca3Dacx4gUaBnd0rD5ipbrTyxzePhiteDDNug6d0aPQ/nEECH/g6SkpKSn/lqlf7FSnSK7CPGT4Kln7LviXKPIv3cFYvi+lT5Uz+00n7Pmp9R/wT5wP7Qvr+BmSxEr0F6O7AZjoP/HAgQP8A86opsmwE4aZLwazYh6/pHr96fdykrKl2m17wRxEOP4SSAlf/AKtSkrKfzV//ACl//9oADAMBAAIAAwAAABAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUMwAgAAAAAAAAAAAAAAAAAAAc4MUBAWu9dvVp5KAIAAAAAAAAcggBWrip/wBu1oTKBS6y0igAAAAAAABLZUgekDslU/zZNPuLs3KvfAAAAAAACnKzKAv7phruPUFCcC9xEqyAAAAAAAUyE0ekvI7gK/Mi7zMU891CmfPAAAAAGggFVSm8YrD9EC9jWWKslXTodAAAAAV2umtiw9HGoPfocyB9tMNY5IQAAAAAZOndQmxx9xbITucg7N3QszVGBAAAAIZEjk/bs2ZOIZ8aEJKi6e3UBbQAAAAACJumJ64Q2DpQb+CxsyMyvbYblAAAIg4EJRyfo5DFjA/TCNh1A7+Uq+lAAAAwkhQHEXQckEuAkPreWXcQo+pJSAAAAAAQ00shhssT4P13xUg7N9DSduaAAAAAAAAIE0PP9e5K+SuXFo29mNV9HYoEAAAAAAgUTT41sKnslk4IUMEQCp2wUYAAAAAAAAAAAgQzR+PxLewgUwAAAAAAAAAAAAAAAAAAAAAAAAQwwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA/8QAKhEBAAIBAgQGAgMBAQAAAAAAAQARITFBUWFxgZGhscHR8CDhEDDxQHD/2gAIAQMBAT8Q/wDYCx1Z0ym4zmQTR/5KrRKby7eCOj/NZu5TxjzQGECleGXsb8oBbWrcruqV4GDSALaX24k2d+mwgpLaZL5qsB646PjxBQewyv8ASKapTj/NsJkKGc3+O+8agQOufCcs7p6xER45PTeUozt3KdNvKBlrq3fGnCpQW945rWium/GWC6Yawq3nVNN6vpNRI61Sa/WtctiYp2lguevOasAK9IVtew9NMw+qKGXGOrjKDaVfLpkjmaoeVv8AQtFxoC5zkeBDjSlrNQTpXxEdExeM+O19IQU2l8AHV0dduEVt8f8AIPD8v1GIkWj1Y+XjpMyV1xtxgYYAOOeSGVQ5qnncrAOvEexElAq2krYycBRtylOZ2Zdg17QLmAYw+bUaAtTO1vu14Z/o0MDC4Fu9ULoNcuJiA2qu9OxvpW0BZ5DWjPPOCBdJoBuxh5N7ctZjvCDUccTZ/wA2lWkR1ZTonhKTQ95QSnFFInCwGyLYEwyL0SVClOVRHqsBKaeHrNgTBcWjjFa6RoB22vvSDfFfaggKt6dH2xy/o1JbExBozGnRFCwW+93fjLjiV7uWN2v4FzUhiLDA1TSq7eMsQyp7A/McWykJSw0BHffnFZdPCWkd17dbh2B56R/aXtF1VdRDBw7j3hJKc1kXlxfNXWJRs6r9K9o35LQxNK2lmaK4zF2ykJKrSZ4zmwOciZ/Tq22+xyi2A7j2hdIzw/eDgxnMdt/P1gKtSqFoXbF0Vt7y3yAdbwYrC673ErQxoaaLs3xn7ksUDttiWxYv9zNPrxGWJHY9qldReaQUnNVlrnrwlbHN3wo+fydIGsM6peqotbwGB1lABb3a3XLtnntBilORtArQcXd1jfN1M5VXN6F0UGDGtVl1hPVBkdxvfOdcLtL2wBRgzbScuPGWVqzW/Aecsdzp8CY4drPSMiQby2DjGyo6PxcTUtKrbWvmJwVTwmrUq2PxY69fh8Q0F96MBJYnKKGl0wh6Q2s0PC8fdfydIIS+c6EsfuUpLCMbyhwzTVljNRLFvUH1JXUuOM+sN10Kwpiq5y0yUurxOhAqB2vR8Zub0nCyNu98cg+8SjwiaQ4z7TUAynwnCFW5fe8B9UlAzh7PydJePv1iK+/bgPL79zEUDLocSASpo1luBLBjTR6R1c1nymIOLZTG2VmF93+CYMW7v3wlXvdZV0Wdcyzl39iALGWbX+68oLhbx+JoQK96gbjF3evGzjiG1UFdP8zUgNtvv3WBtZyhaHMy55+EA3lGJW8aquIXW/SZFk14TR4d3Y1rmxNrVbur92jK16Me+h4yropsu9zkVDqYCO5Uo6p6ENoz69fPpM0aPvYiWCCLrZafSA6im9OGdO08h7fmKEZYIzKuaxxfThi73XhtiDdZJ6PkpO1wutJZrUFGNH+AQYHQLNtjrxfN6RAW6L5WWeW20BFtZlS6F9XU+VeMxbm9pUnW/aMkMHrNZq1Hp7EajxhOmn77zaI5r7vCrd2EEGgY56X6fmiYhZioabSB0bGk4MxulBtReld2PX0mC6+/EeDo+/4wlPhj28uMDG+d0fQ4yvYNHF5+ryI17eF9bW/u2IsHkPtdI3ShK8F+Y5FB2wBFH17THdfmGZsl9Lz7Szgg9V9og2wLtrjHMr3gmEXXDRrvpPS/rQrJVkslyUJbzLZesLTcL6VgmyUCd9/KAdqWPBijDP8AU5P1F1dt8gI1ZDdOLsyHHOlc4QHbDAXWa4vXZij6rb9Oh48YHmi/WPHftKZtEHxL/sNSWCRlUY1ywRTovNrYvf2InEGKeI/amwFEVdJbua6XeHyYjtWlu2OHLPeY7o5reF1Wmh8sWi005dIvcTB95XAfIZ9IAxR5j8Ri7vltKgBcRYWANi+/LWC1f7NAYmiN0GVKgaI59ZVZcSLpCOE3lCo8d4fYo8PNm0HBq9r8ZSvOJR5LFemOfC38bTt7HxNeB0s95aiI3r+pp/wh0B7E1IeFelQ2gTov7j1odafiF0u4xnZTWn/oH//EACoRAQABAwIFBAIDAQEAAAAAAAERACExQVFhcYGhwZGx0fAg4RAw8UBw/9oACAECAQE/EP8A2Bs2DVpQaOY431/3Spcl1+YpPW8r1lU6Px/yIqhOl5jdgYqXIeSeYq4L+8msqHR+P5gREHCp1CjEpkRqRVAOhbfz60mBOCENgEfloJg6/hpHMnQ9zVhsayO1F2lgkHVKnRbG5D/SpCPKnOXo/wAiVEoWpmF1QmWgSAT7woLDPXxRqiE7xblNAlw9Dw0mh7Gkkmh1Vbl81OBeVzvBNQfBk2A0wNTWiN5Pj2pySGqF8eyl4COb8jSEwS2ONH8lFy/21IjWG+wfr+jjihWO2+71+8K1IOUmnnWh4GfO/uefYpm43T/KYhgy3iMurtUWN1UmMoRjabuYooieK7Wml78w/C0IWWC52RVyUPJPmnQNGop/lFRjccKCsjblM05wyh0q7Jnv2iiVbjZTzTiEKYJGdWyetAfY0BGJmWmf0gB8/wBFi8T3oGF6YXaCIThZJQtF5eBeikdJCZdk6C1CQtSENL2qwwh3Lg9miO5wfC9qmC7jLwR606LXD5ntUKhTI3QOha3Glxx2FJ6FKBJWfuh/E4RsU5dhxReWna/pSBIJvOmkw+vWKDqgvcJv1oGQ3R13PigAVSDN8c6WkhmXcnFzJU5oZkTpJ805buHbNbVj6df6O9PcpLBBa/F3os9067MUoQvag2F2P19adGwCcxCOOlJjAqAC8RrNssGVlbFDoROmS7JEJyg9iadOTMCY2mH7fel7CgJGOpIUDOZZmd75pEBgRwqALDTsuLSxLCjDQm0HpQJ1etagRbTFaFaJZJJiG1lYYwiFk4vI46GtGQBpH5bNu96YIg3b3WWPvGi14AiQNUtYgIwS6FQWFsYO6vaaHXja2c9D8rOce5TTnYGnSKOMSiS8g33vx50WxCAtOQ1ZjGk0sAmOSN95s+agYm7cu68o9KWc1GoqzFHQVHANipNOaoexVpVjQIoM5BHjqvpFEnAXvnubluTND/6BkytybBuzAjgUYvgvKY3i0x9tURLrp/lIw536VEEkvKky9kxllLejHkIhSUjkQiLxexna5ITcIEmQVL611l0vcEiCRjQ34h3qdKOA605IgnS/CmrhA6yv5W8w9ypYDv4mgy1cN+NBCH3Z8UlhieBWQrEWv8+80uYN3ZEpq5yxwkGlQ4XtUhYsUkCxvFMkNr1eVQ2aBRyqZMTxKB64C7HILf8AdIF7WyE6jAz151YXyIDVZyjSgUo6eLUtinJyn4pL8knjddKRRCbJPqIlMFkT1o0BpTM/6RI7VZHZEB7l+fsUoujNnF6s1iHn70tOyA4KCeLobX5/jj5+Sgrga3dj/lAGj7/NBH6/yhFXwwCm5r11pA7lEsW9KFCV8a3MnOiS2D14/XWpm6+2tFzI+gHtSUGFotjkw9fWlVyyK8y4cnNqshoyGJzK77tFys2c1pno9VrMsDREsjGuPsVDh7Nx0e1qdwl7a7zr2qBltS7JKZ2XCfYeVTkuXp6HxRc5W5rY/QADl+WCmlX31PNCYRb79zNXw6fr924bUMku+8+2l6CJUAe1/a/rWkJsk5szHPSokTYYZbazjNt+FLDZhzJN9yH9VIRstEyYjSO660AoJAWjPqZ3zamOXA9qkBBVhufXseaaRg3fg+aLV5GTSy6t41plhF3wUWCcPWoUrH2I4+KzGWhg4r92BpG4R1mDkT3Z6UYDExANukIRDO81A06HxX3/AO/D8jNGy5fegENfHr4oWpcZ+/Si2i1SM3A6sfLTLanO80M1jPT9Vng93y1JBUhx4fFAgtJ2yub68c6zSp7s8WM8CpDkKhmCkhcjKD0XcPFOBbAwCxtxe81DgQKs4Sd6NyzZvvSjJTMh2WYnQ3W3rYZI71zPrLq9jAFQIUzUspCTnnxQkIZIzvapsgv78v3H5lMwnx+6tC2p6raoQc7rhGkb63oXrC5pD0ZHrVy8K0D2Vuw0LkFJP3RVaM3pXIyhdWMxsG+Di4Qbkjo376ub0dJZHDTWgXkIeBo7r6UZT7y1omhpmlwjOxv4ONWanE1B8urRTV7jzb/qpUiywZ/yrdoD2KfmWo0EviMSXdgsX/I3y07InSvns1AgmS9x3Kbjdfrv2qfPnx7NCJH1/lqCD6xz6lrYpk+d+JtnIZqbVIZFDGV2PNFW+ZsbHAwcagtEmOUBFKCU+SUZesfFCVAwOb6G7oXpTxTDGJuscL9qY3K/RIPdpXdRDnEns1zYr6AeaQihC0hvwR8U1OeIB2ETf5peo/rSA6nuUUiw0Rg2U9olvX7OaFRtoVdiYoc5u86YOph6U+nsHtQXFHXsNmfNY0cvuqKn8WEml89SketcaVuIIZC5hFw8KNKQQRzznLbDG1CmD39CWsZ4jnpo60UjNyW67S+Mdac85/rxU0LJU5DH6qw21P7UhwJ1eHzQmww2zCfZKZ3YLs0ahmW354udysQEY3vvx9inakyJ0q9TKLW2DL9adjmJdV3fjTvUklQ6Y5YqRdMP1QXObQPLQERO676vxUPTwMU0OC9DGoSvX+vFGyH1oXhafgnT4aVTI5E+SlLRsEqFFHT4qbAm1k71bCucT2KQl7TzVyRszjglFCaseKQrkfhlQ6tYt9YfFXAw9KVUv/DkydWsIvWskj0P1RsL6lah9SowWeOlKrL/AOf/AP/EACsQAQEAAgICAgICAQQDAQEAAAERACExQVFhcZGBobHB8BAwQNEg4fFQkP/aAAgBAQABPxD/APtA2Zo4eg/y8B+MnGdB9q6Jqu0nRoaCF9BbNtRjvxi4miHIzCSlqI8Oh6fQvoo2pmkSoLvN3QjYOWsfcmgthhJygOq9DZ4CuPa0jVjG2CNzSteP35mRzdcrnjBVI5p/w/8A0XRix74cTp3Afva7c3lMsfQRwjaRjT2GlzJy5FbGREQJUpe3GxYCB7VWjs1vBy4MwKpBxRW924+MIROAD23wPDm4XyUKgq9Y8R2DeEWVDDzWTVuqfGHcSiBJJhCr4s5OG1XSS+BN4BgdPx6g/GFtYSCh72X3jenE+4UN/jJUrvYfp4AAJttPRggXjaTAhb2G0fJmNoNKw/ZnptKP6/5jsmngiqroDH1dTGsDitNu31ycOjmOwB/g63gWRCCVh4WOl3NdxucElMLGCugvOfEgCq9HDz1gMNxc+7vxcRIVsL9E0Pp3nFoa2n04BKB4R/1eHE+v+7F5wX8YVLz/AFlma0Xw4hsPW85Km8BiRYw2i1hC6zWybu8E2B/g6w6JnnRddfnHvJjvTu4GN9XefNzYju516pitbtNb4cfO/eP7zQHLep84urBNQdPKv6DuyXUQN2tC749ZaElMvAEQ7w64nrw9Kl+x0YC7UDQCcjjs7/5S7Pr7WnOSp4DVrwdpDRByJ0nXxjr22wdKRWRpyMBbc+uQOzoeMFebmS0aHJGW94cBhsCaBlTQmecn3W3lqaH04r0Fxf4UzQAiykvQpcepk1dmhJL6km4AnJXIPVfTVsAN3HrPFy+cPsneSDRYDvy1ygD1fyYAfWG17QIa2aGb2SyU8L4/GOvQaH964xCqpugNh8b5yT/BNg71J/8AM3GoJhynvh+svKlQwevR33j3gwD8Hl1jTzQuh/Ly5bOMLY6MmgZ6hQ+sehQ4Pj/JjxpoND+sq2j2Gvp+MHTawV/vENfMI47tdUdiNfDhcUdDn2MM8BD6gcxCEU/oVe+8Xtp3pluA2r0GKzD53Yj0BDzy8/8AC0+G816DsdwQ4tEClWJAl0GjwuLgn6D9wf1gZZKBX8j/AOJnkET5b+8Xxi3BnCPhzT/ALO0vyXBy/kwcC/hcFWT+j8cZeICMsAAW3QB+MnpYkQeq4dI24XAAD/33xhizTqV602YRZhUBcXgD14MtyXM+MDNc2+sJTHICBw7P1hFADvj08446dDv4jn+keFEtk7aA06XU/nCEOjnD2Gs3muuf2uOFK6Ibuu8eFhO3BFdoa9uEAMzeKVyleROD7wZEG1LVNTxDzzhfgDBBfkJhc0gL13q3z1hZoxN2NL5mBTITxxjtngAHKB+i4U9BBKCHmSOrw2YohruuAcD18GD8HB1QMAwjHZRH5n1iQJFqvJ/wEF+IBbVXQG8dsJKPhY2nxekNrBYIllBBe2icXxj/AAWQKOkU0VXbaoswSsjAe/otDvTuBmp+wsoBqE0nExCu9s+UKQ25t+WvfEtEARqUChdBiW/LQUsCuHaYzD5CHG9LZ0njNPGwDCLBNQDlvGcrR3CTeja4k210WbCwuB0VXBINM7lzZJYn7P4wemgiED+OsZU+HRyOk4xOA1L9B+WLmlL2e3XYD95KCdjcmHwrxR/GK9wben04fW0Nwb+fz9YIoG4g6vWvDkBvdhK/vFfTV1/Wdy7nIV+mG+wdFwAvWE37ZvfKsJWZVs/mMvcceA6gOSa0cYOam3CmD4Vv4GPSqxI54nvB/kwcBPUWYOCzyR/OSjjQbXNjDDAUScvWzet5UmUTAqa/WP1PVtj2b6uP5lFQmw2gUHXgxv09tX26fXGBlZLopI3wXNHuOWI9HpfeVvsgiIZPr/ge3EKa3/q57R/GGo+ZRPrFnbhb1NdnrD9cIivkBfeFYEEmIBV5FHzcJOOdIpAkenH/ADV3Bb2i8W6JJMd75uMb7WAyioNuW6BygbFpCFLhY/gzwVg9pCgbx0TyGJzV1+z34wuSvy+R248wcUsUpwualdDv04asrE/uSdbmShgrdaDv4Hea8FfNCKjn+MNciM36YybcqFomoXtbxFyvJJ47wphuI8tfmQ7xuy1oA/ItwlAjQe13NmKgFuRpp5+sCSLhgnonneINJAixbugjZviSpRdQqEB0LrxlHiJ8BiA/vHDGPrzyFEf4xUO64IXb3D94N+48IGvYmBe0CDrmkSOu7h9iUYNchv0b3HxjZaASHo6MVL2YdYHOXb75YJNgawj0fDyOFOok+piZQOD+rEExm4iWy8LhTCW3SieV1D2Zb1o+Gi+za/8AAnPDfSZFFBQNwxElEpTXWFVasUDreWtM27Q09KYirUyw8jhcZDhsZn1nN7gwe7iojUaTJNRBtfHPZk8QmgJCQfDix5kLnwYGvd2D8DxapOT/AD6/vIFMHTzS0dzrOQnsjyCI/nHdHoJZwA1qT295tH0CFeiqa84bCf4eBPk3Vt4ATGTozKCpzb5wMYFAc90Jm330UHIDeU6cvjDdHai3dWY5bcyFCT2ec5vqJq1ALqKfWD9ITxDrZy/94SukRaqgHa9Y75UdYCBRpKhqO5hOuFxmlPT1T2ecTOwmJFBCF7+cUVhKAlV+sZjSFoM0N43jg38bGpuLWnG4ymEbtDguA3BXxRwlT9Q6d1yYcOG3Nf3vKqlQEi0n3/eIl/CXCC3BXicv3D7zVQhpjKgCfGzjHWWoQ4p6rPnKW1ofK/1/wAKvX6G/rHyhp47KzvRPnF/KfKBM3u4YBgSJmjrhrgVSDeANKm2Gj+sB1yaRIXeinuHANIkIJKc7T6dYtdJvcAsEdo/eLbotd9p8H4u/GHqTJw12/wA1lHHQurkqFQErt73/APc58WQGm0uVj9kMoSpfJv5yXpzHX1s9mGuZDTs/thyKvMT7c5CeVju03x184SdDoJ/Zh0MOFr+WRxmPiF4EenOftYgdt0YbMCGwaPA0n3gkv1xCIXg2ycE5LE/jI3/tXf54xCkBrog0rbLYaA2AcJ4CsQlKOq9OwLYsomOKAFYCiq4XolAJUVQW0SLekh5sipRRwCXw8PTojMUIH5A9GPXVZfe9JskhHGIEeoWkgpsoxqLMGEx3ALC4Yh5YG8MMSiJ0DD5G1uHsJl4vFtZxVxu/rHh8wjk6cV8Z4tbMdmz684L0QJj+NY7r0s/gHHczjwkjly0QEohv/q/4BI0HPyZdR1SCCnuP1lUNmVRB2I3FeF8QxFYB885P6hs8OCr1kPgUATS2PneD2UJJAD/BiGxGxkoIfL6yX9l5ntfT95GUxChZ1zW3byAQAO68QeXNDL+DVeYQDw68uH1XFYHXDaSP6YMiNpIjCCILUs3rB7AZSBhQcvjnePVQlixxxf8AJi5xhCDDsfZj1nm5KGI0bpzxkyRLqh6dTzgJLRV1KfhuOijR5mf1lh7Le1ftr+ccRxR4HlcNKMSXZjOe0xbRjJYQaXel/GL6WG6JbqlmTwKolN+dOAg38OgW5cLlnfC6mOlIKrbrm4B/u8HIyMAK8BDHFyQ12LFu6rWu95vNcrSqxAiEGFduXJNYBDQuU7LjTmDoE92/cejXIailbFK04nPnWVPdX3ey7567wXZ0LW9VsX5x2erI9QPt46xYYrazwRs0AqkRhjei6uQ2LNOFsB2CJYckqm5r2gAjgz8AH850Adif5X+MlMZWf9WP7x2dCIAKpwxJ7P8Acn/DfUc+Vp9f92GB2AQRh0wh7A9bjjMuNAG1WYOsbEgfRfVwnwZMSjFQb2Y2t4uo9KaMC/UkugEfaJheJHXegIO6CXrFLufC4A1DyYeEHwX/AE5piDiO7MS3lZL5wx0hFGCKid+uS4rZWFYKAWUIr0SsxPzNNpLdHszTmiq0pBNSM1jXgznQQlAUPRVS4FKzfQoY5esHjL0kOlOw0JT1vN+5sPKLTVxMRgGIKaPFzXsAEJAcXT+cHvAAznvjJtfNFTbzpSph0XWoFTx5d/GFSgocs4xFBMBOR7Mq0aLbmjgqfeJtNkvlAX+TFLFC2Hy4Xe+Aq4umkRi/eNLOcgyhRWRofP4xzYnWbgnOsmjSF+MfgwvZdNv4hcRPcBn0pg8rsE/S42j0fMF5vcxbvy7GqxHl5xvYLyEa6jXU8cYK3lt8dc0dV2a7cdHUAJlOFaE9YxvpPf25uKc9SAKJJDLveIHEEjNPtejo9rkPKX6f6/3JLwn03BKnbDvZ1w44BF8BA3TT/oGSMmY20eF28F6w2wpgtq45RXa95AvENEoDCG/lE4chGoxao76OleIhCkE4Wmj4H5BmsNWUV1tGwpvC68os5BSPLt4y7o1orftN5upznuH41kiNFgDdU45yTkAvXlRo1/jj8SQrIkNoL9uNGYgwdIeHvBm12pzXCz5/O8jjDJpQRFcAsF06x6KPBK6KrdqZeBoxgBCSjRRAFEEAtwudiWAVugCltMue0qt69I6r+DjQoWCikaO11/GThGgLX8L9YUsCG6enx3hTghuAocnz949DRTNOucAQwRBlE1E0u5lGThXbpL5beYY74pywg0fOAbwYlV/xfxlNgdCKu+tn78YVYCgiqEdSOeYMBzmH7+MVfgXUJz/mvWBF08nAGjDZgNZpJLv41494zEcUO1m1xo6QSi2cD7X8YyEJAVLoxJ4+nxgaR5N2+l4wJQyhMCKsioIeA4dFjMAsiM25x2eP4ZwJrZq6fEP5yB4o36x0h2P1j1SlRJX9qV0OS5vOJAeD/cRHs+kxgX1GA0hwdWXJ/Vfjq/Y2fOG86zD8jCk494gsQTAPnwEqc4/3XHgKbYIA6NZvGPCF/HIvc27x2RT0dQ+Qe7YmJSfmWU1aeEghjY658plNqldzD3FlRgoRDFdR/wBLlzq5fOGvWBcL94ee/jLNpHxgVCnSDzhLBhAOAXI7ue/7YesVzKyvXliJvHTrIo+IvfP9Y4foLBvkd4IM0iasGiTRz1hG8Wj5mx9b/WCx1VNKL8B9vBnzBxyKLAOA66840iNlzx9fju7zakkFqVPR3jlMJ83SlNavtvIDhFCcv/zL1J2gUrl8p9uMjG1XXHHdCUBKhceJpnHlhxAsjyBOglseQwM6tkDs3D2F2XNo4hhwgW7D2sxy6CdFFQ3ENO+MW77hul5FY8Lo9Yd2wMKcBr845F/Z0AdE74wb+j0PQDwqtPkcmUt5yHQDxGcdXD2n9txHRiPMz6p/Bhkf+mH9f7ihdPMXTm8raCivY5JKMqu409nk/jOuNC3tYdj85N8SlUUAgCstOc/C68pZtuXvJb6JUrS1s5cjgf3kPexxC384+kbX1CnQ1h/cxwenHA3rBJemkAbOdxz3iuAWgUUuV/lkN8IIkooAaGvPrCx26i5ELrffWXv4EVogL6d/J4zQTaQCchVJ2/HnDzjSm0Db5Q05rDfyf7RP7zW1WJR1TinnIUQhutbpNby+BHmuSDg9Z+FYA08zX/zK4nBOhWxPP36zX/8ADRxdrnn9Y8W7SdxxXHSukCum913gqZ8qJ6YP4we9WA38OMKMgIKcS8jiYJnX/qWSvDu3+aXEy5LU6djs6/jId6LIt/KtrmgmupHByUvy6MOsn5xPM/OfT0N+nGxHP8IOEpTrb/NMAHf6BqG4R4cNXHB8G2gdBrjHex1raVcLicGWU0p6ERqAw68zD3v9adjc3cJ7z3g2AHG/GPzM6QXhB2PGN6QguJ4U8i2h0H2mOn2/9wbPRz7hQhF9HZpPjJgQIEW6iGtlAHecSe8AlFUSOt+nKsGwXAGTbBvYvrCA22rBeF5pPh8YcfKwtpUKhz1zi4yGVWnJuyT2+HK90hIQZnaie8pwVUCbYfKGbKaDQ+PWPEXxSYNEFHU4YOfRDSNl+MG3RHzM/wCj6yPBGi3at/WJpHXwO2k7NsdK0qWQn8ZPnbS3CgPVYPzjOWrzVB15q38ZZFUzfOGuxCjAU6nf5zb0s7uBCexY+M1SrOsXVQkVcmGzA3NrtKHPflw2vCBKPbrb/GEHhsKP8Pz+suMXwifGSVkX3Oo3PgzglSnOBiNNnCONX8gosEDZ5SZxszIErOe8FkJl8QONor4JmzzGKBVCl1d3BaZYobUICgFcWjWbUkVQxiuuMF5qk5bhpqGkN3j9gh8CDkEeB5zeuy1giu9AYPxgecP2wxy/0zNm/ieCgLj/ANMw+6hX/JM3suBrgOHG8aDadycC6Lx2wzbWIX2oK/X+563GNyWArjnd44w5lgpJbRSKJfnJcAyrKGu9u/eVsgZC2gpzsXJ1oxSLR45q671xgJOKv1S12fZM7to0EWELUm/DzlikVygKmKs/p1Gnf2rPS2WScjrDMGWA0iCazV+SAOTXNKxrAd7d+3EPAAdADp9PjCcIkV3b0a4jiIq6OfWQbB8Ys3hSDRgLa5/8dsKhhzXf4wHVKo3sx4qIanJHjsKfl84FdokKEsRkNN4w8uQ4fY1SDxZhIZAVoVFHA4cbQmORbdAkIAeGquFcb+T7Z0mkqTAMVGnfZBlHAvlvGBxlDVSUGd7Q+8aXfDnAs1aavKTF+e4gl0J2MAXnW4J/a4XoppBLX4v1jfw0RdgCF5IO4Yddxq+6qBbarcJXwUEkDcrsQxcL8gPRluEoPlMj7nlQKwkW3X3mz8riGWf9HhBfLPtlkWvA/fy4HDizRfy/0w0thuP+/wDrNa0fHx6MV3S0rBgGnXh7cXur+j+v9pZlwI1FZ9ZMUVZpXJTDV8KYvPJ3353hLKZdHQnRqHUyFfER9ejX4lhdYJ44Nwuqi7BA33vNW3ctIXQ839YN1oi21bSdYG2F+MtL7zep8YdhbU023fy/b5yJ4GJbK7VBeHb4eN0eBLrOxeo5fJhvEmCwJnLdtuc7yVgRpW1NCiAcK5VjggRAdQxzKG9MGV15H0jaGPD3REeqAfTygKI2GLqQODLa0ymxaw+YaN3BqHRbjK9B6XIZw95dgIN8sw8h46Cyl4H7ym368DSj8uGpD2wIcdAIfTh/gyMFsLe846DpD7eGwB5V/wBgzv4DpCiBrWKaIm/FE/bksdYSsk9HXprCv9tqoijjwdYPwRO4EE2R5zXA9SwC4CxnrHZPIGxQrgnkmPlRxUNQNWsFmKzXmcHtcLdwyn8DeBtJNKB4IYHRo2Cx7cE/hAf3xjuvx/sTAAgtCjbNd9GBQq8+QT8vjJf/ACMf1/svGL5xcjxQ+crwjqBQs2CypdXHr8c8Cgqw+S6mWoc+eqIzYAFVwyBK2CqOkjB2BBMZtXsTyBE4RdNF5w+oENrkrwB54z8qMK8dB9Oal/g35hmijRuzDlsmHd+5BPAHrGeyan0CdfAY3WwZgSBaSkO7zid+CgahCGwsUZcBLpC1YIhNwVMdYi18ebQx1So7sasGu8QKhBLwN6w+U8UQRteA661jCqEx24RKtransECuneJpEXjccP1qKrh5ADZRnGSoGnqAAyRLTdwT9/gC8Z9+cOs78n2L1fZx+snjW/LhJD+Xn9GDCn5/98hIT0gHBwPb+MvR0TqlpJrItVeiPB7yPUs5BSPvHlUWwSODTTm7MBpWrmVLTnY5DASUEJMp4UnWSIi7CX4/7wKya1K9Hn7dZZOERvyeHox4lhvZfCYrEhR4+aN3E1fwIV+UuMuoeNuM83l9scmAByTJPX8XOQ/7Bf8AZecXFi8YPA2VAjHQuwUT3guWbfaKnSKPRVzQuSExJsEBuG63l3lZLV5ESVTXu4kmRUahVv0djlMG7th76a22ccF5y9bEWZRddCXfipjHakjg15SS+vszITYLTNNWI8GbnjWOjmSw13SFuk1xvFdsqykAgs0jcdPpyhHu1PW7jtkB2isWXSEcJqmrBIokazTTrAL31pyiIhhrvFQTgQr2ALltW3odEY7DHlGlCWxDiPwTAJfECM1rCv2w2AdMEyw6CO3sec25kx5Uut2QF+cVmUy0pTUVT5zrxNQxEod9A/7xyoeHSfB/vDGEcAKfjgzrs8h+8MnqJD9mEFR5bPjnFzScu4Pbh2p0AJsl1aTBF6qASdGu2v4wGj/KiqgVQlJxcY7N44G6h6tvfGB4wYtuk2v+s080YaOnBEY1rUnoE94FLAUKleqlC6uE7hDwHJZRsB2L4x3cFAGGlFBVqO9O8btocG0pqPGrmsz1Q2/lhaQL+fLP7ch7h9/7I8YpnNh/+wyxkgaYUW0eeM9zNNKtKQFQhAHmGe09wXxDKqMYcYofhAjQ9IC6J5GGfV+wCShBJtuuMp/UczX0HCdI5rOpaCOH/sxToFqdiArCx3C40Cg29VBtV7VuILlJHByuE+JscoFdO/15xYppS2SzTe4E5UnGdl5ISjUg3rZzrnKsAmSmV8dc+TG4ZplHMNHJx5MnZDwCiAV8PJi6s8vVCi+jDNwZ6LlDy3hPZkAZsRTkcBFq5ryRNCHphKWJpNtYANmhxe/XbxjFihz6Ya0QhYPTbqPEvfGIAScE5xaQRDhPXZhhuJiXrgPn6zuzJL+wccTz0+w6+sCqXt7/ABD+ccPwAH6wuMXni/eXSIIl1Nf1g3lMjq7M4iUIVKd46x2dwwrUjQ2TgxikC7QiVOHk/LHN12REAV5rFf1zhG4n4YZ5dHXOPwaFzfl6zWYzgNGAeD+3GeKQFEaB5lX8ZonKeK7OpLHjnnNjOqVKHySM5DDtWBewhPhDJV3pZy1/WG51/KyrdVDQbH0PlM1L/wBhf7/2HjFhTInPGa83/wBrB/RLnhR6nn1jKwRlIJCbwjGzF03CtcC8iV0ijg+8oBtBqUnRtiuPaCShYXyCgcjbCuxhtFSNCizq+sCf6NnC8mJu2L5Yx7a6UWAtvDP3m+0EFENc7Ptqd5cIMcLFCxl2eQPeHRgNkqIF4o0r3isqGopKeRqPeuplauNFvPTocA9tybSIeiwrNCvn5wc4Gtu0qg9l7etpdpdlhC1LUZxvvN+ZIJTRy0DRwztekSqO10osmXN8ZDCLiRQL0HGBRAsvtK9TzlPTYlaQvIJ9+8f2JIum0dveG53UQXwcZfvA4A8eGJ1FBihwUjl3VhfjHByRxLua8T6w55uyt2pzndNZxxOUKYe57KcXc8NfnAVZW0f3i6BRO5/xnWIvMkWLf4axtzLWiCSeB9Yan4ucU1NWdYBQJ9ugO09esCB4QyAT0dNZbgxezTh/yvfHq+DujQfBZ4494hRuv/51xckZK7yfDlLrQ/WHtCuWdJ/J+HIKGmiKBWigrGunDz2FKajnaLVtziVG2znMxZPo7Z47U6aerbXQRrCT13AKe7X0TGXBUwmo/rF2REonZkyFC13t/WBNVZgh8k1ec35QOqehBeZ+MIHS9zSlNFDjpwX4A2IliTWpvZzZiO3QM/KuMFzMFC3ol5N/PvB1cRDZdy9uV9hZLYiruX79GJNlKtCcEDup+MZYevIEJjYfhfyTYYVQTNKDKaLPTCo6IrHRelevGDwS8Q8t6DNzhHIx2dH0ZdKjInZylBKuGBbp4Vyv+dYDwi2XYCvrvzhqJ7JQ66pvXpxWIR7ZpL58OrjKqctx1Nd4zkpbTzDE3rErJcPxfhwSzR0Qo/Q09e8OQYtw8+ntwRA9YEc/WSYaR57v3TGNoDgdD89+vnAvLTRdpBJ/nWCnCC2EhLDnXhMY7UHUCw+xdesSOXTFbU4ImPE9MBbb8vVecazRltu+cAo/zWIbOSkcB2tb6PWUoKZnin+//NZi49ONNYm8dHezPVw/thkATsOvxxhYcluTwnCenH7Nt/5QArzhQdr8OHCXV2GrkDsGhQXrzkR+I8f95B4RDhHjKYH6rxhWsQTk6fZgngyKjD1tQAsVNAe84sfK+oxDQxsvkd5P1YOpR5/BgM1gBOkAR4ifGLqVAahJfF4wf6X2466/+4AhYzauoZfYzwz34dHePi8BY52vT/m8t0PLo3Hyz6cnTYT2gwvaGTHdjZFhcBfcp4EDsGn0+cN0ZuCv6d5TN/TBGzfR0YqZI4NJI8Yzq0LlDpXjjX7yXPQdpwnSDXa9vnn68YSSQLrp+T/HvCX08/L0Y1BJH+svcgRBIfLnF0ZBtGEV2V/9YQixoKrzX4mc2RXXFQXgfGHihHPyJhsra4yggVcGbAZugJeVPfwZGcX7hf7/APNMay11l+sVsP1ljThl/wAycunB3gYeDArMPblDTMi3cfGeH4uV+uqifGKmJzqKXx+i4b9CzE10bXjwBzZtZHRdz35djHJymEVNFNM3vQDx+6FhdLkHOuywa/BEAiBXbF+OovOC7Gze9LnCSbRCA7k5Mt4LkoisgqBCuPHQuF9A21wMV3HhjnqxoSNE4zc+qeu9eF/15xvLQOz+IP8A13iYpdIA4DrwGXoWjeJwHxhOJP8AKBH5xvzImSaFQl58i95QEHEqmwgkUO8PoAOwuuf83gLozW6LjBgsaHYcMbJhqBbS4M5KgKONjPYX7xaWkPjBfNYC8aB+sv8AYkeVUv6zUOb0lS0a9/OPAACQ9cfj94snENbQCD5TjJfCSPSn3vBbB3tnjDpPrDOnLO2dYceigGh37NPppzkJ5b7D/szEucpvDODEfjFv7HHE62+fkDj5UnXPpD9ZcVZoH8g/eUkXgsfk/gxlBDqqfwR+8t6PZ/zTjjo+UH7cMAToK/WFObB9tY4ZTwC5BSIGRVl7kg1TvWGagk0vRV07vGX/ABh8COwMTq8bxsECGZB55G70RwGvbVvjZrwWoeMp/spYoiMqLwpOJgYphqCOAAFPubxK5hGYiQt9/D8Op23Hf/4hKGstnKkenT0cH/vBEUIXRcD/ADzhrukQeen4ZeEt/eIiV96AkyeQezBEdIeMO85Vpqz85LSRvGG/JhtgVSy2eB244Z1Tx6PAdZV4wXjYFO/7F+8NW6HzO/6x9EDS4Vvnr0h/gfWW0G8Ts1L8h/DjvY23BCr7uAwamNlL9WYL5Jm4m1ef/ma++3g5YS4DGePT95t2CTe5udHvDs4gDoMushR+TEcIh/7whxLj+Rl2jOTL+MFdMRUP1hcQ8/2pl2eEyKPD+8di2E72vYo/j3hIeAoJZXcdCaFx2mzBcRq6069WPW80A9QokVYhxdgzUPUJXdLiT1hklUkggaopOVPeC9ZBvDi4Wg1Zn3nH6F9rMFaHtI1Xt24ZxKJ5DB936M1FVg9uPrCkKqntcDQ1F+8FlVILoxtzRvWKE5tcMNWnxjETSnu7w2DVMgyIsqdG8aJWiHnAK5EB94hOe9k4z6+2f/sxctmHokAJsuPy1gONqHJcDG4htabiY1X0JriD8bMUYPAu0d/eHCA2RRDz1q4yQWkmdre+uMHLRvYD6PnHYhqNk72fRl0kBHOmD+aowQtHJV8q+MA8/wCABw6cPOHOLk71h8/hAt6jUlU7QD5wssYriz1axQbr2KGzYgUBIAUMHOImysiS1TIpzzMdxRO4yZC53WEL0VS2RpHm7tty2b8vo5x3jrJ0h9DfjGZAJnEgzoYPwa/lc5qIR+2T53kFPA5Vg0fAI4cK7SuJr/vFq+QPeDqWGUf83hcIIZholS5w+X/rJJzF0eAzyzkRjQ73Atb4MF38CwdBhcyjXSP5VL8ZqPpP7x+yjpRQZM2eEe72Y7zWBt0fSc5qmzGAaUqahiRjs2F70B0YbnCcQ/hj51qBYeNHD5wzhqNCTXnPRgn1APg1Pu/WcutD7yY2LLqAAe94nAh5wPHjELl/3njDTDzh5w84edY4Qt/Jhz8ECsr0pLl1ZHZJjMJiTQMMuHBFWd2UI6sMty43SmtRQWrejvCMDO7yrQBRIbxl7TTKHWx5DTLJlusesgBhHiYdobN8Gv7GHwWOfK0mEl11+Svlfpy9iBT0ePvZ+cG2VENjjtBBcXNJtbDyf5xh3BYHGv8AB/LC5IdOxOB+sU8Up07S8FbhgS8A18P+8VBe1+ny9sEwekiSt1CvmmW42Qsl3jrXbilonhwCTQy34n843cmj/wAmsC2l8hyNc+4yTKNu8xZVKBD5X9GFIQa4dVbPiY7trL18yWPeH46o1s6OArlb2eN4aJevzrhEW6URQJYDqorzkfZB9ZcOX7ymBcG/7iXjKXGeBxt429OL41ff+kGAOk1gC0BnKqG/5A5xARV38hzgmPCCVNvh/wA8Yh6aKA2HvJw7CsjP4QxSEjQeDnCPhxB5dDwjhzpIO3jTEREgRP8AeT+a6UFnX5zS0gD23EJQGEDmK68MBaGbtI4H/p94elaQfww0DhZ+x6yHoD1ivr1NWpXsF03tid/uAQQXd279vnCr6Uf8afrBXfuEj7v945XR0LH5/pwgPNis/CT94nhk/wCllfrHvJib7BMd253en3khtemNOj0wpWZSUXCPBlhGUH64WuqYGK1dnKjgziioAQA9ax9bxsf/AEysGf7iXEDedOYazCEbudVQZciHkf4Q/rK6Wc/sgTFo5yt/Tg01h84cGIa0kqRPrOR5a1mENIHkGn4YfQiUlcfA/wDrFVEeQg/GN0WyPRztK6Eb6NfrJsZtI+9BkZWgpv8AKzOXQTwLo1iOeSavsn5xHFtlv2EOuTXjDjVeRHAWuphLV4cFHSYFMZEsNEZF9mgc4QCkLWt3f3jJrF9GM6YL0wU4Ze6Yf8Lmf2ZX33/ZAHDUckHQ/CT9Yk4HoBfpP3i6gdQn5P4s5IPSL8g37wOuxog7FWDDtmEP2BvlK7Sq+8W8ZCayTxksL/oP+BDHkBhmn6xejEgD948o/J+2A4i+Sv06j9ZRejS+w/vG1D6V+y/xlkS8g/AH7wpRjm/+Ef1i7b5JP2kxOJWFiX8uQb5WvpMFrLnT/VMTKi8NfuZT6IAv8uFLyQP8U9Y6uq3b8OsiHQE4DQmcVn7Alo+Fx8mHKB4SHeUH3racvzkymJNAzzCnRvtx0K8BPmaiXxTzhdYXWWyp/pjrA+MB6wL0Z6j6xbo+sU6Md2j6z1ZB1gDCesJwnDAf8aYh5DF+R9Z/QLDN/RgWtk/7kywrnl/63HUV41H4lj5L6BjAvXeP4PF0h+H+mH3/ADXzc3UP/EBgVQ/DhnvNXGKjs0z9DLXxXRh6DmceVe1ar3XGIZw+f9Zn1mgwMDJ/5zJkyf8A4KHkzgX6wL+Bhzrv1jtWnP8AKGWll8v5Rj8S8f0OH1KkrlX2v6A0Z2L/AEApNZOZM4yOGAmBP/00PIYvyYt0Z6Mg4MJwnA//AJSf/9k=",
   "indication": "벼룩·진드기 구제 + 심장사상충 예방 + 내부기생충 구제",
-  
   "coverage": {
     "external": {
-      "fleas": {"covered": true, "note": "6~8시간 내 사멸"},
-      "ticks": {"covered": true, "note": "12~24시간 내 사멸"},
-      "demodex": {"covered": true, "note": "모낭충증 치료"},
-      "sarcoptes": {"covered": true, "note": "개선충증"},
-      "ear_mites": {"covered": true, "note": "귀진드기"}
+      "fleas": {
+        "covered": true,
+        "note": "6~8시간 내 사멸"
+      },
+      "ticks": {
+        "covered": true,
+        "note": "12~24시간 내 사멸"
+      },
+      "demodex": {
+        "covered": true,
+        "note": "모낭충증 치료"
+      },
+      "sarcoptes": {
+        "covered": true,
+        "note": "개선충증"
+      },
+      "ear_mites": {
+        "covered": true,
+        "note": "귀진드기"
+      }
     },
     "heartworm": {
       "covered": true,
@@ -26,19 +41,39 @@
       "limitation": "성충(L5+)은 구제 불가"
     },
     "intestinal": {
-      "roundworm": {"covered": true, "note": "회충"},
-      "hookworm": {"covered": true, "note": "구충"},
-      "whipworm": {"covered": true, "note": "편충 - 하트가드에 없는 커버!"},
-      "tapeworm": {"covered": false, "note": "❌ 조충 미커버 - Praziquantel 필요"}
+      "roundworm": {
+        "covered": true,
+        "note": "회충"
+      },
+      "hookworm": {
+        "covered": true,
+        "note": "구충"
+      },
+      "whipworm": {
+        "covered": true,
+        "note": "편충 - 하트가드에 없는 커버!"
+      },
+      "tapeworm": {
+        "covered": false,
+        "note": "❌ 조충 미커버 - Praziquantel 필요"
+      }
     }
   },
-
   "coverage_summary": {
-    "covered": ["벼룩", "진드기", "심장사상충", "회충", "구충", "편충", "모낭충"],
-    "not_covered": ["조충(촌충)"],
+    "covered": [
+      "벼룩",
+      "진드기",
+      "심장사상충",
+      "회충",
+      "구충",
+      "편충",
+      "모낭충"
+    ],
+    "not_covered": [
+      "조충(촌충)"
+    ],
     "gap_solution": "안텔민(Praziquantel) 3개월마다 보조 투약"
   },
-
   "dosing": {
     "interval": "매월 1회",
     "interval_reason": "심장사상충 L3→L5 전환 시간 ~60일, 30일 간격으로 차단",
@@ -47,52 +82,87 @@
     "minimum_age": "8주 이상",
     "minimum_weight": "2kg 이상"
   },
-
   "weight_products": [
-    {"size": "XS", "weight_range": "2~3.5kg", "afoxolaner": "9.4mg", "milbemycin": "1.9mg", "price_approx": "16,000원"},
-    {"size": "S", "weight_range": "3.6~7.5kg", "afoxolaner": "18.8mg", "milbemycin": "3.8mg", "price_approx": "17,000원"},
-    {"size": "M", "weight_range": "7.6~15kg", "afoxolaner": "37.5mg", "milbemycin": "7.5mg", "price_approx": "18,000원"},
-    {"size": "L", "weight_range": "15.1~30kg", "afoxolaner": "75mg", "milbemycin": "15mg", "price_approx": "20,000원"},
-    {"size": "XL", "weight_range": "30.1~60kg", "afoxolaner": "150mg", "milbemycin": "30mg", "price_approx": "22,000원"}
+    {
+      "size": "XS",
+      "weight_range": "2~3.5kg",
+      "afoxolaner": "9.4mg",
+      "milbemycin": "1.9mg",
+      "price_approx": "16,000원"
+    },
+    {
+      "size": "S",
+      "weight_range": "3.6~7.5kg",
+      "afoxolaner": "18.8mg",
+      "milbemycin": "3.8mg",
+      "price_approx": "17,000원"
+    },
+    {
+      "size": "M",
+      "weight_range": "7.6~15kg",
+      "afoxolaner": "37.5mg",
+      "milbemycin": "7.5mg",
+      "price_approx": "18,000원"
+    },
+    {
+      "size": "L",
+      "weight_range": "15.1~30kg",
+      "afoxolaner": "75mg",
+      "milbemycin": "15mg",
+      "price_approx": "20,000원"
+    },
+    {
+      "size": "XL",
+      "weight_range": "30.1~60kg",
+      "afoxolaner": "150mg",
+      "milbemycin": "30mg",
+      "price_approx": "22,000원"
+    }
   ],
-
   "warnings": [
     "⚠️ 경련/간질 이력이 있는 개는 수의사 상담 필수 (이소자졸린 계열 FDA 경고)",
     "⚠️ 투약 전 심장사상충 검사 필수 (감염 상태에서 투약 시 위험)",
     "⚠️ 8주(2개월) 미만, 2kg 미만 투여 금지",
     "⚠️ 콜리 품종은 MDR1 유전자 검사 후 투여 권장"
   ],
-
   "contraindications": [
     "8주 미만, 2kg 미만",
     "심장사상충 양성 (미검사 포함)",
     "경련/간질 이력 (상대적 금기)"
   ],
-
   "side_effects": [
     "드물게 구토, 설사, 무기력, 식욕부진 (대부분 일시적)",
     "매우 드물게 근육떨림, 운동실조, 경련 (FDA 경고)"
   ],
-
   "fda_warning": {
     "year": 2018,
     "content": "이소자졸린 계열에서 드물게 신경계 부작용 보고",
-    "symptoms": ["근육 떨림", "운동실조", "경련"],
+    "symptoms": [
+      "근육 떨림",
+      "운동실조",
+      "경련"
+    ],
     "fda_statement": "대다수 동물에서 안전하고 효과적"
   },
-
   "comparison_with_3set": {
     "convenience": "넥스가드 스펙트라 우위 (한 알로 끝)",
     "cost": "3종 세트가 저렴 (~15,000원 vs ~20,000원)",
     "coverage": "넥스가드가 편충까지 추가 커버",
     "tapeworm_gap": "둘 다 안텔민 보조 필요"
   },
-
   "storage": "직사광선 피하여 서늘한 곳 보관",
-  
   "source": {
-    "guidelines": ["ESCCAP GL1/GL3/GL5 (2024-2025)", "CAPC (2024)", "AHS Think 12 (2024)"],
+    "guidelines": [
+      "ESCCAP GL1/GL3/GL5 (2024-2025)",
+      "CAPC (2024)",
+      "AHS Think 12 (2024)"
+    ],
     "fda": "FDA Isoxazoline Fact Sheet (2018)",
-    "pmid": ["40234985", "30201031", "30516132", "32485788"]
+    "pmid": [
+      "40234985",
+      "30201031",
+      "30516132",
+      "32485788"
+    ]
   }
-}
+}
\ No newline at end of file
diff --git a/data/master/oridermyl.json b/data/master/oridermyl.json
index 42e0951..139ac67 100644
--- a/data/master/oridermyl.json
+++ b/data/master/oridermyl.json
@@ -1,39 +1,36 @@
 {
   "product_id": "MASTER-007",
-  "apc_code": "0519-ORIDERMYL",
+  "apc_code": "0231065620103",
   "name": "오리더밀",
   "english_name": "Oridermyl (Nystatin+Neomycin+Triamcinolone)",
   "manufacturer": "TVM",
   "category": "otic",
   "category_display": "귀염증 치료제",
-  "target_animal": ["개", "고양이"],
+  "target_animal": [
+    "개",
+    "고양이"
+  ],
   "administration": "점이 (귀에 투약)",
-
   "indication": "외이염, 귀진드기 감염, 세균성/진균성 귀감염",
-  
   "mechanism": {
     "nystatin": "항진균 (칸디다, 말라세지아)",
     "neomycin": "항균 (그람음성균)",
     "triamcinolone": "항염증 (가려움, 부종 완화)",
     "permethrin": "귀진드기 구제"
   },
-
   "dosage": {
     "standard": "1일 1~2회",
     "amount": "귀당 5~10방울",
     "duration": "7~14일"
   },
-
   "warnings": [
     "⚠️ 고막 천공 시 사용 금지",
     "⚠️ 투약 전 귀 세정 권장",
     "⚠️ 장기 사용 시 내성균 주의"
   ],
-
   "contraindications": [
     "고막 천공/손상",
     "아미노글리코사이드 과민증"
   ],
-
   "storage": "실온 보관"
-}
+}
\ No newline at end of file
diff --git a/data/master/selight.json b/data/master/selight.json
index d3b315e..024925d 100644
--- a/data/master/selight.json
+++ b/data/master/selight.json
@@ -1,69 +1,119 @@
 {
   "product_id": "MASTER-010",
-  "apc_code": "0519-SELIGHT",
+  "apc_code": "0232545420203",
   "name": "셀라이트",
   "english_name": "Selight (Selamectin)",
   "manufacturer": "국내산 (레볼루션 제네릭)",
   "category": "antiparasitic",
   "category_display": "스팟온 종합구충제",
-  "target_animal": ["개", "고양이"],
+  "target_animal": [
+    "개",
+    "고양이"
+  ],
   "administration": "경피 도포 (스팟온)",
-
   "indication": "심장사상충 예방 + 벼룩 + 귀진드기 + 개선충(옴) + 회충 + 이 + 참진드기(개)",
-  
   "coverage_summary": {
-    "covered": ["심장사상충", "벼룩", "귀진드기", "개선충", "회충", "이", "진드기(개)"],
-    "not_covered": ["조충(촌충)", "편충", "구충(개)"],
+    "covered": [
+      "심장사상충",
+      "벼룩",
+      "귀진드기",
+      "개선충",
+      "회충",
+      "이",
+      "진드기(개)"
+    ],
+    "not_covered": [
+      "조충(촌충)",
+      "편충",
+      "구충(개)"
+    ],
     "gap_solution": "안텔민 3개월마다 보조 투약 (조충·편충 보완)"
   },
-
   "dosing": {
     "interval": "매월 1회",
     "interval_reason": "심장사상충 L3→L5 전환 30일 윈도우 + 벼룩 라이프사이클",
     "minimum_age": "6주 이상",
     "minimum_weight": "제한 없음"
   },
-
   "weight_products": [
-    {"size": "SS", "weight_range": "~2.5kg", "dose": "0.25mL (15mg)"},
-    {"size": "S", "weight_range": "2.5~5kg", "dose": "0.5mL (30mg)"},
-    {"size": "M", "weight_range": "5~10kg", "dose": "0.5mL (60mg)"},
-    {"size": "L", "weight_range": "10~20kg", "dose": "1.0mL (120mg)"},
-    {"size": "XL", "weight_range": "20~40kg", "dose": "2.0mL (240mg)"}
+    {
+      "size": "SS",
+      "weight_range": "~2.5kg",
+      "dose": "0.25mL (15mg)"
+    },
+    {
+      "size": "S",
+      "weight_range": "2.5~5kg",
+      "dose": "0.5mL (30mg)"
+    },
+    {
+      "size": "M",
+      "weight_range": "5~10kg",
+      "dose": "0.5mL (60mg)"
+    },
+    {
+      "size": "L",
+      "weight_range": "10~20kg",
+      "dose": "1.0mL (120mg)"
+    },
+    {
+      "size": "XL",
+      "weight_range": "20~40kg",
+      "dose": "2.0mL (240mg)"
+    }
   ],
-
   "special_protocols": {
     "tick_intensive": "진드기 집중: 2주 간격 3회 → 이후 월 1회",
     "sarcoptes": "옴 치료: Day 0 + Day 30 (2회)",
     "ear_mite_cat": "귀진드기(고양이): 단일 도포 (100%)",
     "ear_mite_dog": "귀진드기(개): Day 0 + Day 30 (2회 - 이도 깊음)"
   },
-
   "efficacy_data": [
-    {"target": "심장사상충", "efficacy": "100%", "source": "PMID:10940527"},
-    {"target": "벼룩(C.felis)", "efficacy": "≥98.9%", "source": "PMID:10940521"},
-    {"target": "귀진드기(고양이)", "efficacy": "94~100%", "source": "PMID:10940530"},
-    {"target": "개선충(옴)", "efficacy": "100% (Day60)", "source": "PMID:10940530"}
+    {
+      "target": "심장사상충",
+      "efficacy": "100%",
+      "source": "PMID:10940527"
+    },
+    {
+      "target": "벼룩(C.felis)",
+      "efficacy": "≥98.9%",
+      "source": "PMID:10940521"
+    },
+    {
+      "target": "귀진드기(고양이)",
+      "efficacy": "94~100%",
+      "source": "PMID:10940530"
+    },
+    {
+      "target": "개선충(옴)",
+      "efficacy": "100% (Day60)",
+      "source": "PMID:10940530"
+    }
   ],
-
   "warnings": [
     "⚠️ 6주 미만 사용 금지",
     "⚠️ 도포 후 2시간 이후 목욕 가능",
     "⚠️ 피부 상처 부위 도포 금지",
     "✅ 콜리 품종 안전 (PMID:10940536 확인)"
   ],
-
   "clinical_notes": [
     "레볼루션(Zoetis) 국내산 제네릭 - 동일 성분·동일 효능",
     "개+고양이 겸용 (체중별 제품 선택)",
     "조충·편충 미커버 → 안텔민 병행 필요",
     "도포 후 건조될 때까지 다른 동물이 핥지 않도록"
   ],
-
   "source": {
-    "guidelines": ["AHS 2024", "ESCCAP GL5 2024", "CAPC 2024"],
-    "pmid": ["10940527", "10940521", "10940530", "10940536"]
+    "guidelines": [
+      "AHS 2024",
+      "ESCCAP GL5 2024",
+      "CAPC 2024"
+    ],
+    "pmid": [
+      "10940527",
+      "10940521",
+      "10940530",
+      "10940536"
+    ]
   },
-
   "storage": "직사광선 피하여 서늘한 곳 보관"
-}
+}
\ No newline at end of file
diff --git a/data/master/serenia_maropitant.json b/data/master/serenia_maropitant.json
index f827982..aa2c7fa 100644
--- a/data/master/serenia_maropitant.json
+++ b/data/master/serenia_maropitant.json
@@ -1,23 +1,22 @@
 {
   "product_id": "MASTER-004",
-  "apc_code": "0519-SERENIA",
+  "apc_code": "0231884620107",
   "name": "세레니아 정",
   "english_name": "Serenia (Maropitant citrate)",
   "manufacturer": "조에티스 (Zoetis)",
   "category": "antiemetic",
   "category_display": "항구토제",
-  "target_animal": ["개", "고양이"],
+  "target_animal": [
+    "개",
+    "고양이"
+  ],
   "administration": "경구 (정제)",
-  "image_url": "/images/serenia.png",
-
   "indication": "급성 구토, 멀미(차멀미) 예방 및 치료",
-  
   "mechanism": {
     "drug_class": "NK1 수용체 길항제",
     "action": "구토중추의 NK1 수용체 차단 → 구토 억제",
     "feature": "중추 및 말초 모두 작용"
   },
-
   "dosage": {
     "acute_vomiting": {
       "dose": "2mg/kg 1일 1회",
@@ -29,45 +28,68 @@
       "note": "공복 상태 권장 (효과 향상)"
     }
   },
-
   "dosage_table": [
-    {"weight": "3kg", "acute": "6mg", "motion": "24mg"},
-    {"weight": "5kg", "acute": "10mg", "motion": "40mg"},
-    {"weight": "10kg", "acute": "20mg", "motion": "80mg"},
-    {"weight": "15kg", "acute": "30mg", "motion": "120mg"},
-    {"weight": "20kg", "acute": "40mg", "motion": "160mg"}
+    {
+      "weight": "3kg",
+      "acute": "6mg",
+      "motion": "24mg"
+    },
+    {
+      "weight": "5kg",
+      "acute": "10mg",
+      "motion": "40mg"
+    },
+    {
+      "weight": "10kg",
+      "acute": "20mg",
+      "motion": "80mg"
+    },
+    {
+      "weight": "15kg",
+      "acute": "30mg",
+      "motion": "120mg"
+    },
+    {
+      "weight": "20kg",
+      "acute": "40mg",
+      "motion": "160mg"
+    }
+  ],
+  "available_strengths": [
+    "16mg",
+    "24mg",
+    "60mg",
+    "160mg"
   ],
-
-  "available_strengths": ["16mg", "24mg", "60mg", "160mg"],
-
   "warnings": [
     "⚠️ 16주(4개월) 미만 강아지 금지",
     "⚠️ 고양이: 급성 구토에만 사용 (멀미 적응증 없음)",
     "⚠️ 5일 이상 연속 투여 금지 (급성 구토)",
     "⚠️ 차멀미 예방 시 공복 상태에서 효과적"
   ],
-
   "contraindications": [
     "16주 미만 강아지",
     "위장관 폐색 의심 시 (구토 억제가 위험)",
     "독소 섭취 후 (구토 유도 필요 시)"
   ],
-
   "side_effects": {
-    "common": ["침흘림 (일시적)", "무기력"],
-    "rare": ["설사", "식욕부진"]
+    "common": [
+      "침흘림 (일시적)",
+      "무기력"
+    ],
+    "rare": [
+      "설사",
+      "식욕부진"
+    ]
   },
-
   "clinical_notes": [
     "구토 원인 파악 필수 (단순 증상 억제 아님)",
     "위장관 폐색, 독소 섭취 시에는 구토 유도가 필요할 수 있음",
     "멀미 예방: 이동 2시간 전 + 공복 = 최대 효과"
   ],
-
   "storage": "실온 보관",
-
   "source": {
     "product_info": "Zoetis Serenia Product Information",
     "notes": "FDA 승인 수의용 항구토제"
   }
-}
+}
\ No newline at end of file
diff --git a/data/master/simparica.json b/data/master/simparica.json
index 8987a02..6913d4a 100644
--- a/data/master/simparica.json
+++ b/data/master/simparica.json
@@ -1,6 +1,6 @@
 {
   "product_id": "MASTER-019",
-  "apc_code": "0519-SIMPARICA",
+  "apc_code": "0232571730106",
   "name": "심파리카 트리오",
   "english_name": "Simparica Trio (Sarolaner+Moxidectin+Pyrantel)",
   "manufacturer": "조에티스 (Zoetis)",
diff --git a/data/master/terbiderm.json b/data/master/terbiderm.json
index da983fb..c27b9cd 100644
--- a/data/master/terbiderm.json
+++ b/data/master/terbiderm.json
@@ -1,38 +1,35 @@
 {
   "product_id": "MASTER-008",
-  "apc_code": "0519-TERBIDERM",
+  "apc_code": "0232064110102",
   "name": "터비덤 스프레이",
   "english_name": "Terbiderm (Terbinafine)",
   "manufacturer": "동방동물약품",
   "category": "antifungal",
   "category_display": "항진균제 (피부)",
-  "target_animal": ["개", "고양이"],
+  "target_animal": [
+    "개",
+    "고양이"
+  ],
   "administration": "외용 (스프레이)",
-
   "indication": "피부사상균증 (백선), 말라세지아 피부염",
-  
   "mechanism": {
     "drug_class": "알릴아민계 항진균제",
     "action": "스쿠알렌 에폭시다제 억제 → 진균 세포막 합성 차단"
   },
-
   "dosage": {
     "frequency": "1일 1~2회",
     "duration": "2~4주 (완치 후 1주 추가)",
     "application": "병변 및 주변 2cm까지 도포"
   },
-
   "warnings": [
     "⚠️ 눈, 점막 접촉 피할 것",
     "⚠️ 핥지 못하게 엘리자베스 칼라 권장",
     "⚠️ 경구 항진균제 병용 시 효과 증가"
   ],
-
   "clinical_notes": [
     "피부사상균 배양 검사 권장 (치료 전)",
     "환경 소독 병행 필수 (재감염 방지)",
     "장모종은 병변 주변 제모 권장"
   ],
-
   "storage": "실온 보관, 화기 주의"
-}
+}
\ No newline at end of file
diff --git a/data/master/tiergard.json b/data/master/tiergard.json
index 6838e96..e153369 100644
--- a/data/master/tiergard.json
+++ b/data/master/tiergard.json
@@ -1,50 +1,393 @@
 {
   "product_id": "MASTER-015",
-  "apc_code": "0231089400001",
+  "apc_code": "0231089420409",
   "name": "티어가드 정",
   "english_name": "TierGard (Tylosin tartrate)",
-  "manufacturer": "국내",
+  "name_meaning": "Tier(동물) + Guard(보호) — 동물 안구·피부 감염 보호",
+  "manufacturer": "(주)이엘티사이언스",
+  "country": "한국",
+  "global_status": "한국 독자 허가 제품 (글로벌 개용 60mg 정제 시판 없음)",
+  "approval_date": "2013-03-20",
+  "approval_number": "159",
   "category": "antibiotic",
   "category_display": "항생제 (마크롤라이드계)",
-  "target_animal": ["개"],
+  "target_animal": [
+    "개"
+  ],
   "administration": "경구 (정제)",
-
-  "indication": "결막염, 눈물 자국(세균성), 농피증 치료",
-  
+  "indication": "포도상구균·연쇄상구균에 의한 결막염, 농피증 치료",
   "mechanism": {
-    "drug_class": "마크롤라이드계 항생제 (16원환)",
-    "action": "세균 50S 리보솜 결합 → 단백 합성 억제",
-    "spectrum": "포도상구균, 연쇄상구균, 마이코플라즈마"
+    "drug_class": "마크롤라이드계 항생제 (16원환 Macrolide)",
+    "action": "세균 50S 리보솜 결합 → 단백 합성 억제 → 정균 작용",
+    "spectrum": {
+      "covered": [
+        "Staphylococcus pseudintermedius",
+        "Staphylococcus aureus",
+        "Streptococcus spp.",
+        "Mycoplasma spp."
+      ],
+      "not_covered": [
+        "Pseudomonas aeruginosa",
+        "E. coli",
+        "Proteus spp.",
+        "진균류"
+      ],
+      "susceptibility_rate": "82.61% (항생제 미노출 S. pseudintermedius, PMID: 20960412)"
+    },
+    "tear_staining_mechanism": {
+      "description": "세균성 분비물 감소 + 마크롤라이드 항염증 효과 복합 작용",
+      "pathway": [
+        "내안각·결막 세균 (S. pseudintermedius, Mycoplasma 등)",
+        "타일로신 → 세균 50S 리보솜 결합 → 단백 합성 억제",
+        "세균 부하 감소",
+        "결막·비루관 주변 만성 염증 감소 + 세균성 분비물 감소",
+        "눈물관 주변 환경 개선",
+        "포르피린 착색 유발 삼출물 감소",
+        "눈물 자국 완화 (수주 이상 소요)"
+      ],
+      "limitation": "이미 착색된 털은 항생제로 탈색 불가 — 새 털이 자라면서 교체됨"
+    },
+    "porphyrin_explanation": {
+      "what": "혈액 속 헤모글로빈의 헴(heme) 합성 과정에서 생성되는 대사산물",
+      "why_staining": "눈물에 과도하게 분비되면 흰 털에 갈색-적갈색 얼룩",
+      "why_darkens": "빛(자외선)에 노출되면 산화되어 색이 짙어짐",
+      "note": "포르피린 자체는 무해하나 미용적으로 문제"
+    }
   },
-
   "dosage": {
-    "standard": "10~20mg/kg 1일 2회",
-    "duration": "4주간",
-    "note": "소형견(말티즈·비숑) 주 사용"
+    "standard": "20mg/kg (타일로신 기준)",
+    "approved_range": "10~20mg/kg (한국 허가사항)",
+    "confirmed_dose": "20mg/kg bid (임상 근거 확정)",
+    "frequency": "1일 2회 (12시간 간격)",
+    "duration": "4주 (한국 허가사항)",
+    "with_food": "권장 (위장관 자극 최소화)",
+    "note": "반감기 54분으로 짧아 1일 2회 투여 필수"
   },
-
   "dosage_table": [
-    {"weight": "2kg", "dose": "40mg", "tablets": "20mg × 2정"},
-    {"weight": "3kg", "dose": "60mg", "tablets": "60mg × 1정"},
-    {"weight": "5kg", "dose": "100mg", "tablets": "60mg × 1.7정"},
-    {"weight": "10kg", "dose": "200mg", "tablets": "200mg × 1정"},
-    {"weight": "15kg", "dose": "300mg", "tablets": "200mg × 1.5정"}
+    {
+      "weight": "2kg",
+      "dose": "40mg",
+      "tablets": "20mg × 2정"
+    },
+    {
+      "weight": "3kg",
+      "dose": "60mg",
+      "tablets": "60mg × 1정",
+      "breed_example": "말티즈·요크셔"
+    },
+    {
+      "weight": "5kg",
+      "dose": "100mg",
+      "tablets": "60mg × 1.5~2정",
+      "breed_example": "푸들·비숑"
+    },
+    {
+      "weight": "6kg",
+      "dose": "120mg",
+      "tablets": "60mg × 2정",
+      "breed_example": "시추·페키니즈"
+    },
+    {
+      "weight": "9kg",
+      "dose": "180mg",
+      "tablets": "60mg × 3정",
+      "breed_example": "코커스패니얼"
+    },
+    {
+      "weight": "10kg",
+      "dose": "200mg",
+      "tablets": "200mg × 1정",
+      "note": "중형견 경계"
+    },
+    {
+      "weight": "15kg",
+      "dose": "300mg",
+      "tablets": "200mg × 1.5정"
+    },
+    {
+      "weight": "20kg",
+      "dose": "400mg",
+      "tablets": "200mg × 2정"
+    }
   ],
-
-  "available_strengths": ["20mg", "60mg", "200mg"],
-
+  "available_strengths": [
+    "20mg",
+    "60mg",
+    "200mg"
+  ],
+  "strength_recommendation": {
+    "small_dog": "60mg 정이 가장 실용적 (3~6kg 소형견)",
+    "medium_large": "10kg 이상은 200mg 정 전환 권장"
+  },
+  "treatment_timeline": {
+    "description": "효과가 나타나는 시기 (눈물자국 기준)",
+    "phases": [
+      {
+        "week": "1~2주",
+        "expected": "결막 충혈·분비물 감소 (세균성인 경우)"
+      },
+      {
+        "week": "2~3주",
+        "expected": "눈물 분비량 감소 시작"
+      },
+      {
+        "week": "4주",
+        "expected": "눈물 자국 색이 옅어지기 시작"
+      },
+      {
+        "week": "4주 이후",
+        "expected": "새 털이 자라면서 착색 털 교체 (트리밍 병행)"
+      }
+    ],
+    "realistic_expectation": "효과를 눈으로 확인하려면 최소 4~8주 소요",
+    "important_note": "이미 착색된 털은 항생제로 탈색되지 않음"
+  },
+  "follow_up_points": {
+    "description": "4주 복용 후 경과 관찰 포인트",
+    "checkpoints": [
+      {
+        "timing": "2주차",
+        "items": [
+          "병변 면적 감소 확인",
+          "눈물 분비량 변화",
+          "새 병변 발생 여부"
+        ]
+      },
+      {
+        "timing": "4주차",
+        "items": [
+          "완치 여부 판단",
+          "추가 연장 필요성 결정",
+          "착색 털 트리밍 권고"
+        ]
+      },
+      {
+        "timing": "치료 완료 후",
+        "items": [
+          "근본 원인(알레르기·구조적) 교정 여부 확인",
+          "재발 모니터링"
+        ]
+      }
+    ],
+    "treatment_failure_signs": [
+      "2주 투여 후 뚜렷한 개선 없음 → 감수성 재검",
+      "반복 재발 (3개월 내) → 원인 감별 + 배양 검사",
+      "MRSP 의심 → 다약제 내성 확인"
+    ]
+  },
+  "relapse_prevention": {
+    "description": "재발 방지 관리법",
+    "daily_care": [
+      {
+        "action": "외안각 세정",
+        "detail": "매일 생리식염수나 안과용 세정제로 내안각(눈물 고이는 부분) 닦기"
+      },
+      {
+        "action": "물 관리",
+        "detail": "정수 또는 생수 사용 (철분 포함 수돗물은 포르피린 착색 악화 가능)"
+      },
+      {
+        "action": "미용 관리",
+        "detail": "착색된 털은 정기적으로 트리밍"
+      }
+    ],
+    "dietary_management": {
+      "principle": "알레르기 원인 제거",
+      "recommendation": "첨가물 없는 단순 식이로 변경 검토"
+    },
+    "root_cause_correction": {
+      "importance": "근본 원인 미교정 시 치료 중단 후 재발 빈번",
+      "causes_to_address": [
+        "비루관 협착",
+        "삼모증",
+        "안검 내번",
+        "알레르기"
+      ],
+      "warning": "마크롤라이드 100일 이상 장기 투여 시 내성균 선택 위험 (PMID: 32109782)"
+    },
+    "relapse_rate": "28.6% (3개월 내, PMID: 7994702)"
+  },
+  "concurrent_treatments": {
+    "description": "병행 시술 안내",
+    "structural_causes": {
+      "conditions": [
+        "비루관 협착·폐쇄",
+        "속눈썹 이상(삼모증)",
+        "안검 내번"
+      ],
+      "treatment": "수의안과 전문 처치/수술 필요",
+      "note": "구조적 원인은 항생제로 해결 불가"
+    },
+    "nasolacrimal_flushing": {
+      "description": "비루관 세척",
+      "purpose": "비루관 협착 예방 및 눈물 배출 개선",
+      "frequency": "수의사가 주기적으로 시행",
+      "when_needed": "비루관 폐쇄 의심 시, 반복적 눈물 과다 시"
+    },
+    "topical_treatments": {
+      "eye_cleaning": "안과용 세정제로 외안부 세정 병행",
+      "note": "전신 항생제 + 국소 관리 병행 시 효과 극대화"
+    }
+  },
+  "tear_staining_info": {
+    "description": "눈물자국(Tear Staining) 상세 정보",
+    "causes_multifactorial": {
+      "bacterial": {
+        "role": "내안각 만성 세균 감염 → 분비물 증가",
+        "tylosin_helps": true
+      },
+      "structural": {
+        "conditions": [
+          "비루관 협착·폐쇄",
+          "삼모증",
+          "안검 내번"
+        ],
+        "tylosin_helps": false,
+        "treatment": "수술/시술 필요"
+      },
+      "allergic": {
+        "conditions": [
+          "음식 알레르기",
+          "환경 알레르기"
+        ],
+        "tylosin_helps": false,
+        "treatment": "원인 제거 필요"
+      },
+      "dietary": {
+        "issue": "포르피린 전구체 함유 식품 과다",
+        "tylosin_helps": false
+      },
+      "breed_predisposition": {
+        "issue": "단두형 안구 돌출, 얕은 안와",
+        "tylosin_helps": false,
+        "note": "해부학적 한계"
+      }
+    },
+    "high_risk_breeds": [
+      {
+        "breed": "말티즈",
+        "reason": "흰 털 + 비루관 저형성 빈번"
+      },
+      {
+        "breed": "비숑 프리제",
+        "reason": "흰 털 + 내안각 삼모증"
+      },
+      {
+        "breed": "토이·미니어처 푸들",
+        "reason": "흰 털 개체에서 두드러짐"
+      },
+      {
+        "breed": "시추",
+        "reason": "안검불완전폐쇄 82%, 삼모증 100%, TBUT 4초"
+      },
+      {
+        "breed": "퍼그·페키니즈·불독",
+        "reason": "단두형 안구 돌출"
+      }
+    ],
+    "key_message": "타일로신은 세균성 원인에만 작용. 구조적·알레르기성 원인 먼저 교정해야 효과 극대화"
+  },
+  "pharmacokinetics": {
+    "t_half": "54분 (IV, 개)",
+    "Vd": "1.7-2.0 L/kg (높음 → 조직 침투 우수)",
+    "primary_excretion": "담즙 (간→장), bile/serum ratio 1,230-3,780",
+    "renal_excretion": "극소량",
+    "accumulation": "없음 (29일, 2년 투여 확인)",
+    "bioavailability_im": "92.6%",
+    "clinical_implication": "반감기 매우 짧아 1일 2회 투여 필수"
+  },
+  "safety": {
+    "NOAEL_dog_2yr": "100 mg/kg/day",
+    "LD50_dog_oral": ">800 mg/kg",
+    "clinical_dose": "40 mg/kg/day (20mg/kg bid)",
+    "safety_margin": "2.5배 (NOAEL/임상용량)",
+    "liver_burden": "주 대사·배설 경로이나 100mg/kg/day까지 중대한 간 손상 없음",
+    "kidney_burden": "신장 배설 극소량 → 부담 매우 낮음",
+    "gi_side_effect": "일과성 위염 3.3% (30마리 중 1마리)",
+    "long_term_risk": "100일 이상 투여 시 마크롤라이드 내성균 선택 위험"
+  },
   "warnings": [
-    "⚠️ 세균성 원인에만 효과 (구조적·알레르기성 X)",
-    "⚠️ 비루관 협착 시 수술/시술 필요",
-    "⚠️ 4주 이상 투여 시 내성균 주의"
+    "⚠️ 세균성 원인에만 효과 (구조적·알레르기성 원인은 별도 처치 필요)",
+    "⚠️ 비루관 협착 시 수술/시술 필요 — 항생제로 해결 불가",
+    "⚠️ 이미 착색된 털은 탈색 불가 — 트리밍으로 제거",
+    "⚠️ 4주 이상 장기 투여 시 내성균 주의",
+    "⚠️ 식사와 함께 투여 (공복 시 위장관 자극 가능)"
+  ],
+  "contraindications": [
+    "❌ 마크롤라이드계 항생제 과민반응·쇼크 병력",
+    "❌ 린코사마이드계 항생제(린코마이신·클린다마이신) 동시 투여",
+    "❌ 다른 마크롤라이드 동시 투여",
+    "❌ 고양이 (개 전용 제품)",
+    "⚠️ 임신·수유 중 암캐 — 수의사 상담 후 결정"
   ],
-
   "clinical_notes": [
-    "눈물 자국: 세균 부하 감소 → 염증 감소 → 완화",
-    "포르피린 착색: 햇빛 노출 시 더 진해짐",
+    "눈물 자국: 세균 부하 감소 → 염증 감소 → 분비물 감소 → 완화",
+    "포르피린 착색: 햇빛 노출 시 더 진해짐 (실내견보다 야외 활동 많은 개에서 더 진함)",
     "구조적 원인 먼저 교정해야 효과 극대화",
-    "흰 털 품종(말티즈, 비숑)에서 눈물 자국 두드러짐"
+    "흰 털 품종(말티즈, 비숑)에서 눈물 자국 두드러짐",
+    "한국 독자 허가 — 글로벌에 개용 60mg 정제 없음"
   ],
-
-  "storage": "실온 보관"
-}
+  "patient_education_qa": [
+    {
+      "q": "왜 눈 밑이 갈색으로 얼룩져 있나요?",
+      "a": "눈물에 포르피린이라는 물질이 포함되어 있어요. 눈물이 흘러넘치면 털에 쌓이고, 빛에 의해 산화되면서 갈색으로 변합니다."
+    },
+    {
+      "q": "티어가드를 먹이면 눈물 자국이 없어지나요?",
+      "a": "이미 생긴 자국은 사라지지 않습니다. 세균성 원인을 억제해서 새로 자라는 털에 자국이 덜 생기게 합니다. 기존 착색 털은 트리밍으로 제거하세요."
+    },
+    {
+      "q": "효과는 언제 나타나나요?",
+      "a": "1~2주: 분비물 감소, 2~4주: 눈물량 감소, 4~8주: 새 털에서 자국 감소. 눈으로 확인하려면 최소 4~8주 소요됩니다."
+    },
+    {
+      "q": "4주 먹였는데 효과가 없어요",
+      "a": "두 가지를 확인하세요: 1) 구조적 원인(비루관 협착, 삼모증) → 수의안과 진찰 필요, 2) 타일로신 내성균 → 세균 배양·감수성 검사"
+    },
+    {
+      "q": "재발을 막으려면 계속 먹여야 하나요?",
+      "a": "근본 원인 미교정 시 재발합니다. 장기 투여(100일+)는 내성 위험이 있어 권장하지 않습니다. 일상 관리(외안각 세정, 물 관리, 트리밍)와 근본 원인 교정이 장기 해결책입니다."
+    },
+    {
+      "q": "간이나 신장에 부담이 큰 약인가요?",
+      "a": "담즙으로 배설되며 신장 부담은 매우 낮습니다. 2년 장기 시험에서 임상 용량의 2.5배까지 중대한 손상 없었습니다. 4주 투여 범위에서 안전합니다."
+    }
+  ],
+  "references": {
+    "korean_approval": "APDB 허가사항 (APC: 0231089400001, 허가번호: 159, 2013-03-20)",
+    "clinical_efficacy": [
+      "Scott et al. 1994 (PMID: 7994702) — 농피증 90.5% 성공률, n=21",
+      "Harvey 1996 (PMID: 8873399) — 표재성 농피증 80%, n=30",
+      "Scott BA et al. 2010 (PMID: 20960412) — In vitro 감수성 82.61%, n=103"
+    ],
+    "pk_safety": [
+      "Weisel et al. 1977 (PMID: 842925) — PK: t½ 54분, Vd 1.7L/kg",
+      "Kim et al. 2011 (PMID: 21068517) — IM 생체이용률 92.6%",
+      "JECFA/WHO 1991 — 개 2년 독성시험, NOAEL 100mg/kg/day"
+    ],
+    "pathogen_data": [
+      "Murphy et al. 1978 (PMID: 624664) — 결막염 원인균 (S. aureus 68%)",
+      "Casemiro et al. 2025 (PMID: 38768284) — 각막염 병원체",
+      "Cooper et al. 1993 (PMID: 8393208) — Mycoplasma 탁월한 활성"
+    ],
+    "resistance_data": [
+      "Kang et al. 2014 (PMID: 24690601) — 한국 MRSP 36%",
+      "Cazer et al. 2020 (PMID: 32109782) — 100일+ 투여 시 내성 증가"
+    ],
+    "tear_staining": [
+      "Sebbag & Sanchez 2023 (PMID: 36585820) — 단두형 안구 증후군 총설"
+    ]
+  },
+  "storage": "실온 보관, 직사광선 피함",
+  "last_updated": "2026-03-19",
+  "version": "2.0",
+  "source_documents": [
+    "tiergard_tylosin_conjunctivitis_tearstain_v3.md",
+    "tiergard_tylosin_pyoderma_v2.md"
+  ],
+  "indication_detail": {
+    "primary": "포도상구균·연쇄상구균에 의한 결막염, 농피증 치료",
+    "secondary": "세균성 눈물자국(tear staining) 완화 보조",
+    "note": "눈물자국 직접 치료 RCT 없음. 세균성 원인 있는 경우 임상적으로 사용됨."
+  }
+}
\ No newline at end of file
diff --git a/docs/AI_MAPPING_ARCHITECTURE.md b/docs/AI_MAPPING_ARCHITECTURE.md
new file mode 100644
index 0000000..1ef2754
--- /dev/null
+++ b/docs/AI_MAPPING_ARCHITECTURE.md
@@ -0,0 +1,347 @@
+# 동물약 투약지도서 API - AI 매핑 아키텍처
+
+> 작성일: 2026-03-19  
+> 작성자: 용림 🐉
+
+---
+
+## 1. 문제 정의
+
+### 현재 상황
+
+```
+약국 POS (PIT3000)
+    └─ DrugCode: LB000003158
+    └─ GoodsName: "안텔민뽀삐(5kg이하)"
+    └─ BARCODE: 9990000001134 (자체 바코드) ❌ APC 아님
+    └─ CD_ITEM_UNIT_MEMBER
+           └─ 0230237010107 (APC) ✅ 있으면 좋음
+           └─ 9990000001134 (자체) ← 이것만 있는 경우 多
+```
+
+### 핵심 문제
+
+| 상황 | 비율 | 처리 방법 |
+|------|------|----------|
+| APC 매핑 완료 | ~18% (17건) | APC로 바로 조회 ✅ |
+| APC 미매핑 | ~82% (32건+) | **제품명 기반 AI 매핑 필요** ⚠️ |
+
+### 왜 어려운가?
+
+1. **약국마다 바코드 체계 다름**
+   - A약국: "안텔민사향" → 바코드 "A001"
+   - B약국: "안텔민사향" → 바코드 "B999"
+   - C약국: "안텔민사향" → 바코드 없음 (수기 입력)
+
+2. **제품명 표기 불일치**
+   - POS: "안텔민뽀삐(5kg이하)"
+   - APDB: "뉴펫 안텔민 정사 정 100mg/25mg/10정"
+   - 쇼핑몰: "안텔민 뽀삐 5kg이하"
+
+3. **사이즈/용량 구분**
+   - 하트세이버 mini/S/M/L → 각각 다른 APC
+   - 넥스가드 XS/S/M/L → 각각 다른 APC
+
+---
+
+## 2. 제안 아키텍처
+
+### 2.1 전체 흐름
+
+```
+┌─────────────────────────────────────────────────────────────┐
+│                      API 요청                                │
+│  {                                                          │
+│    "items": [                                               │
+│      { "apc": "0230237010107", "name": "안텔민뽀삐" },       │  ← APC 있음
+│      { "apc": null, "name": "하트세이버S(5.6~11kg)" }        │  ← APC 없음
+│    ],                                                       │
+│    "patient_name": "김남곤",                                 │
+│    "pet_name": "뽀삐"                                       │
+│  }                                                          │
+└─────────────────────────────────────────────────────────────┘
+                              │
+                              ▼
+┌─────────────────────────────────────────────────────────────┐
+│                    매핑 분기 처리                             │
+├─────────────────────────────────────────────────────────────┤
+│                                                             │
+│   for each item:                                            │
+│       if item.apc exists:                                   │
+│           ──────────────────▶ [직접 조회]                    │
+│       else:                                                 │
+│           ──────────────────▶ [AI 매핑 레이어]               │
+│                                                             │
+└─────────────────────────────────────────────────────────────┘
+                              │
+                              ▼
+┌─────────────────────────────────────────────────────────────┐
+│                    PDF 렌더링                                │
+│                                                             │
+│   매핑된 APC들로 APDB 조회 → 템플릿 렌더링 → PDF 반환         │
+└─────────────────────────────────────────────────────────────┘
+```
+
+### 2.2 AI 매핑 레이어 상세
+
+```
+┌─────────────────────────────────────────────────────────────┐
+│                   AI 매핑 레이어                              │
+├─────────────────────────────────────────────────────────────┤
+│                                                             │
+│  입력: "하트세이버S(5.6~11kg)"                                │
+│                                                             │
+│  ┌───────────────────────────────────────────────────────┐  │
+│  │ Step 1: 정규화 (Normalize)                             │  │
+│  │   - 공백/특수문자 정리                                  │  │
+│  │   - 체중 정보 추출: 5.6~11kg → S사이즈                  │  │
+│  │   - 브랜드 추출: "하트세이버"                           │  │
+│  └───────────────────────────────────────────────────────┘  │
+│                          │                                  │
+│                          ▼                                  │
+│  ┌───────────────────────────────────────────────────────┐  │
+│  │ Step 2: 후보 검색 (Candidate Search)                   │  │
+│  │   - PostgreSQL 퍼지 매칭                               │  │
+│  │   - 벡터 유사도 검색 (선택적)                           │  │
+│  │                                                        │  │
+│  │   결과: [                                              │  │
+│  │     { apc: "0230474210202", name: "하트세이버S", score: 0.95 },  │
+│  │     { apc: "0230474220200", name: "하트세이버M", score: 0.72 },  │
+│  │     { apc: "0230470000008", name: "하트세이버mini", score: 0.68 }│
+│  │   ]                                                    │  │
+│  └───────────────────────────────────────────────────────┘  │
+│                          │                                  │
+│                          ▼                                  │
+│  ┌───────────────────────────────────────────────────────┐  │
+│  │ Step 3: AI 최종 선택 (LLM Decision)                    │  │
+│  │                                                        │  │
+│  │   프롬프트:                                            │  │
+│  │   "POS 제품명: 하트세이버S(5.6~11kg)                    │  │
+│  │    후보 APC:                                           │  │
+│  │    1. 0230474210202 - 하트세이버S (5.6~11kg)           │  │
+│  │    2. 0230474220200 - 하트세이버M (12~22kg)            │  │
+│  │    3. 0230470000008 - 하트세이버mini (5.6kg이하)       │  │
+│  │                                                        │  │
+│  │    가장 적합한 APC는?"                                  │  │
+│  │                                                        │  │
+│  │   AI 응답: "0230474210202" (체중 범위 일치)             │  │
+│  └───────────────────────────────────────────────────────┘  │
+│                          │                                  │
+│                          ▼                                  │
+│  ┌───────────────────────────────────────────────────────┐  │
+│  │ Step 4: 캐싱 (선택적)                                  │  │
+│  │   - 동일 제품명 재요청 시 캐시 사용                      │  │
+│  │   - Redis 또는 SQLite                                  │  │
+│  └───────────────────────────────────────────────────────┘  │
+│                                                             │
+└─────────────────────────────────────────────────────────────┘
+```
+
+---
+
+## 3. 구현 옵션 비교
+
+### 옵션 A: 규칙 기반 매핑 (No AI)
+
+```python
+def match_by_rules(product_name):
+    # 정규식 + 키워드 매칭
+    if "안텔민" in product_name:
+        if "뽀삐" in product_name or "5kg이하" in product_name:
+            return "0230237010107"
+        elif "킹" in product_name or "5kg이상" in product_name:
+            return "0230237810109"
+    # ... 수십 개 규칙
+```
+
+| 장점 | 단점 |
+|------|------|
+| 빠름, 비용 0 | 유지보수 지옥 |
+| 예측 가능 | 새 제품 대응 불가 |
+| | 표기 변형에 취약 |
+
+**적합**: 제품 수 적고, 변동 없을 때
+
+---
+
+### 옵션 B: 퍼지 매칭 + 점수 기반
+
+```python
+from rapidfuzz import fuzz
+
+def match_by_fuzzy(product_name, candidates):
+    scores = []
+    for c in candidates:
+        score = fuzz.token_sort_ratio(product_name, c['name'])
+        scores.append((c['apc'], score))
+    
+    best = max(scores, key=lambda x: x[1])
+    if best[1] > 80:  # 임계값
+        return best[0]
+    return None  # 매칭 실패
+```
+
+| 장점 | 단점 |
+|------|------|
+| AI 비용 없음 | 체중/사이즈 구분 어려움 |
+| 빠름 | 애매한 경우 오매핑 |
+
+**적합**: 1:1 매핑이 명확한 경우
+
+---
+
+### 옵션 C: AI 하이브리드 (권장) ⭐
+
+```python
+def match_hybrid(product_name):
+    # 1. 캐시 확인
+    cached = cache.get(product_name)
+    if cached:
+        return cached
+    
+    # 2. 퍼지 매칭으로 후보 추림
+    candidates = fuzzy_search(product_name, limit=5)
+    
+    # 3. 고신뢰 매칭이면 바로 반환
+    if candidates[0]['score'] > 95:
+        return candidates[0]['apc']
+    
+    # 4. 애매하면 AI 판단
+    if candidates[0]['score'] > 70:
+        apc = llm_decide(product_name, candidates)
+        cache.set(product_name, apc)
+        return apc
+    
+    # 5. 전혀 못 찾으면 실패
+    return None
+```
+
+| 장점 | 단점 |
+|------|------|
+| 정확도 높음 | AI 비용 (캐싱으로 최소화) |
+| 새 제품 대응 가능 | 초기 구축 복잡 |
+| 체중/사이즈 정확 구분 | |
+
+**적합**: 현재 상황 (다양한 표기, 사이즈 구분 필요)
+
+---
+
+## 4. 비용 분석
+
+### AI 호출 비용 (GPT-4o-mini 기준)
+
+| 시나리오 | 월 요청 | AI 호출률 | AI 호출 수 | 비용 |
+|----------|---------|----------|-----------|------|
+| 소규모 | 100건 | 30% | 30건 | ~$0.01 |
+| 중규모 | 1,000건 | 20% | 200건 | ~$0.10 |
+| 대규모 | 10,000건 | 10% | 1,000건 | ~$0.50 |
+
+**캐싱 효과**: 동일 제품명 재요청 시 AI 호출 안 함 → 호출률 급감
+
+---
+
+## 5. 내 생각 (용림)
+
+### 현실적인 접근
+
+1. **Phase 1: 규칙 기반 시작**
+   - 현재 17건의 APC 매핑된 제품은 직접 조회
+   - 자주 쓰는 10~20개 제품은 수동 규칙 추가
+   - 나머지는 "매핑 실패" 로깅
+
+2. **Phase 2: 퍼지 매칭 도입**
+   - PostgreSQL `pg_trgm` 확장으로 유사도 검색
+   - 95% 이상 매칭은 자동 처리
+   - 70~95%는 로깅 + 수동 검토
+
+3. **Phase 3: AI 레이어 추가**
+   - 70~95% 구간에 LLM 판단 도입
+   - 판단 결과 캐싱
+   - 오매핑 피드백 루프
+
+### 왜 AI가 필요한가?
+
+```
+POS: "하트세이버츄어블S(5.6~11kg)"
+APDB: "뉴펫 하트세이버 츄어블 소형견용 5.6-11kg"
+
+→ 퍼지 매칭만으로는 "소형견용 = S" 판단 어려움
+→ 체중 범위 파싱 + 의미 이해 필요
+→ LLM이 "5.6~11kg"와 "5.6-11kg" 같다고 판단 가능
+```
+
+### 우선순위 제안
+
+| 순위 | 항목 | 이유 |
+|------|------|------|
+| 1 | APC 직접 매핑 확대 | 가장 정확, 비용 0 |
+| 2 | 캐시 레이어 | AI 비용 절감 |
+| 3 | 퍼지 매칭 | AI 호출 최소화 |
+| 4 | AI 최종 판단 | 애매한 케이스만 |
+
+---
+
+## 6. API 인터페이스 (안)
+
+### 요청
+
+```json
+POST /api/guide/pdf
+
+{
+  "items": [
+    {
+      "apc": "0230237010107",
+      "name": "안텔민뽀삐",
+      "drugcode": "LB000003158"
+    },
+    {
+      "apc": null,
+      "name": "하트세이버S(5.6~11kg)",
+      "drugcode": "LB000003153"
+    }
+  ],
+  "patient_name": "김남곤",
+  "pet_name": "뽀삐",
+  "pet_species": "푸들",
+  "pet_age": "3세"
+}
+```
+
+### 응답
+
+```json
+{
+  "success": true,
+  "pdf_url": "/output/guide_20260319_abc123.pdf",
+  "mapping_results": [
+    {
+      "name": "안텔민뽀삐",
+      "apc": "0230237010107",
+      "method": "direct",
+      "confidence": 1.0
+    },
+    {
+      "name": "하트세이버S(5.6~11kg)",
+      "apc": "0230474210202",
+      "method": "ai_matched",
+      "confidence": 0.92,
+      "candidates_considered": 3
+    }
+  ]
+}
+```
+
+---
+
+## 7. 다음 단계
+
+- [ ] APDB 퍼지 검색 인덱스 구축 (`pg_trgm`)
+- [ ] AI 매핑 프롬프트 설계
+- [ ] 캐시 레이어 (Redis/SQLite)
+- [ ] 매핑 실패 로깅 & 대시보드
+- [ ] 피드백 루프 (오매핑 수정)
+
+---
+
+*이 문서는 논의용입니다. 피드백 주세요!* 🐉
diff --git a/docs/API_SPEC.md b/docs/API_SPEC.md
new file mode 100644
index 0000000..5ebe63e
--- /dev/null
+++ b/docs/API_SPEC.md
@@ -0,0 +1,226 @@
+# 애니팜 투약지도서 API 명세서
+
+> **Base URL:** `https://ap.0bin.in`  
+> **Local:** `http://localhost:7002`  
+> **Version:** 1.0.0  
+> **Last Updated:** 2026-03-19
+
+---
+
+## 📋 엔드포인트 목록
+
+| Method | Endpoint | 설명 |
+|--------|----------|------|
+| GET | `/health` | 헬스체크 |
+| GET | `/api/products` | 약품 목록 조회 |
+| POST | `/api/guide/pdf` | PDF 생성 |
+| POST | `/api/guide/preview` | 미리보기 (메타데이터) |
+
+---
+
+## 1. 헬스체크
+
+서버 상태 확인
+
+### Request
+```
+GET /health
+```
+
+### Response
+```json
+{
+  "status": "ok",
+  "service": "anipharm-api",
+  "timestamp": "2026-03-19T20:01:13.292109"
+}
+```
+
+---
+
+## 2. 약품 목록 조회
+
+등록된 모든 약품 목록 반환
+
+### Request
+```
+GET /api/products
+```
+
+### Response
+```json
+{
+  "success": true,
+  "count": 21,
+  "products": [
+    {
+      "product_id": "MASTER-001",
+      "name": "넥스가드 스펙트라",
+      "category": "antiparasitic",
+      "category_display": "올인원 구충제"
+    },
+    {
+      "product_id": "MASTER-002",
+      "name": "아시카프 츄어블정",
+      "category": "nsaid",
+      "category_display": "진통소염제 (NSAIDs)"
+    }
+    // ... 21개
+  ]
+}
+```
+
+---
+
+## 3. PDF 생성
+
+투약지도서 PDF 파일 생성 및 다운로드
+
+### Request
+```
+POST /api/guide/pdf
+Content-Type: application/json
+```
+
+### Request Body
+```json
+{
+  "product_ids": ["MASTER-001", "MASTER-002", "MASTER-005"],
+  "patient_name": "김남곤",
+  "pet_name": "뽀삐",
+  "pet_species": "푸들",
+  "pet_age": "3세",
+  "pharmacy_name": "청춘약국 동물약 전문상담",
+  "pharmacy_tel": "033-481-0384"
+}
+```
+
+| 필드 | 타입 | 필수 | 설명 |
+|------|------|------|------|
+| product_ids | string[] | ✅ | 약품 ID 배열 |
+| patient_name | string | ❌ | 보호자 이름 (기본: "보호자") |
+| pet_name | string | ❌ | 반려동물 이름 (기본: "반려동물") |
+| pet_species | string | ❌ | 품종 |
+| pet_age | string | ❌ | 나이 |
+| pharmacy_name | string | ❌ | 약국명 (기본: "청춘약국 동물약 전문상담") |
+| pharmacy_tel | string | ❌ | 전화번호 (기본: "033-481-0384") |
+
+### Response
+- **Success:** `application/pdf` (PDF 파일 다운로드)
+- **Error:**
+```json
+{
+  "success": false,
+  "error": "에러 메시지"
+}
+```
+
+### cURL 예시
+```bash
+curl -X POST https://ap.0bin.in/api/guide/pdf \
+  -H "Content-Type: application/json" \
+  -d '{
+    "product_ids": ["MASTER-001", "MASTER-002"],
+    "patient_name": "김남곤",
+    "pet_name": "뽀삐",
+    "pet_species": "푸들",
+    "pet_age": "3세"
+  }' \
+  --output 투약지도서.pdf
+```
+
+---
+
+## 4. 미리보기 (메타데이터)
+
+PDF 생성 전 약품 정보 및 예상 페이지 수 확인
+
+### Request
+```
+POST /api/guide/preview
+Content-Type: application/json
+```
+
+### Request Body
+```json
+{
+  "product_ids": ["MASTER-001", "MASTER-002", "MASTER-005"]
+}
+```
+
+### Response
+```json
+{
+  "success": true,
+  "drug_count": 3,
+  "page_count": 1,
+  "drugs": [
+    {
+      "id": "MASTER-001",
+      "name": "넥스가드 스펙트라",
+      "category": "antiparasitic",
+      "has_image": true
+    },
+    {
+      "id": "MASTER-002",
+      "name": "아시카프 츄어블정",
+      "category": "nsaid",
+      "has_image": true
+    },
+    {
+      "id": "MASTER-005",
+      "name": "하트세이버 츄어블",
+      "category": "antiparasitic",
+      "has_image": true
+    }
+  ]
+}
+```
+
+---
+
+## 📦 등록된 약품 목록 (21개)
+
+| ID | 이름 | 카테고리 |
+|----|------|----------|
+| MASTER-001 | 넥스가드 스펙트라 | antiparasitic |
+| MASTER-002 | 아시카프 츄어블정 | nsaid |
+| MASTER-003 | 아시엔로 50 | antibiotic |
+| MASTER-004 | 세레니아 정 | antiemetic |
+| MASTER-005 | 하트세이버 츄어블 | antiparasitic |
+| MASTER-006 | 프로닐스팟 | antiparasitic |
+| MASTER-007 | 오리더밀 | otic |
+| MASTER-008 | 터비덤 스프레이 | antifungal |
+| MASTER-009 | 클로르헥시딘 샴푸 | topical |
+| MASTER-010 | 셀라이트 | antiparasitic |
+| MASTER-011 | 멜록시캐시 CH | nsaid |
+| MASTER-012 | 복합 개시딘 겔 | topical |
+| MASTER-013 | 임팩트액 | antiparasitic |
+| MASTER-014 | 안텔민 뽀삐/킹 | antiparasitic |
+| MASTER-015 | 티어가드 정 | antibiotic |
+| MASTER-016 | 액티벳정 | antibiotic |
+| MASTER-017 | 아포퀠 | immunomodulator |
+| MASTER-018 | 브라벡토 | antiparasitic |
+| MASTER-019 | 심파리카 트리오 | antiparasitic |
+| MASTER-020 | 가바펜틴 | analgesic |
+| MASTER-021 | 메트로니다졸 | antibiotic |
+
+---
+
+## 🔧 서버 정보
+
+| 항목 | 값 |
+|------|-----|
+| 프레임워크 | Flask |
+| 포트 | 7002 |
+| PM2 이름 | anipharm-api |
+| PDF 엔진 | WeasyPrint |
+| 페이지당 약품 | 4개 |
+
+---
+
+## 📝 변경 이력
+
+| 날짜 | 버전 | 내용 |
+|------|------|------|
+| 2026-03-19 | 1.0.0 | 최초 배포 |
diff --git a/scripts/update_apc_mapping.py b/scripts/update_apc_mapping.py
new file mode 100644
index 0000000..7574819
--- /dev/null
+++ b/scripts/update_apc_mapping.py
@@ -0,0 +1,67 @@
+# -*- coding: utf-8 -*-
+"""마스터 JSON에 실제 쇼핑몰 APC 매핑"""
+import json
+import os
+
+# 마스터 JSON → 쇼핑몰 APC 매핑
+APC_MAPPING = {
+    "nexgard_spectra.json": "0232555060207",     # 넥스포인트(20~40kg) - 넥스가드 대용
+    "heartsaver.json": "0230467230300",          # 하트세이버L(23~45kg)
+    "impact.json": "0232873820205",              # 임팩트 독(4~10kg)
+    "antelmin.json": "0230237810109",            # 안텔민 킹(5kg이상)
+    "selight.json": "0232545420203",             # 셀라이트 독(4~10kg)
+    "meloxicash.json": "0232523510309",          # 멜록시캐시CH
+    "asikaff_carprofen.json": "0232635710103",   # 아시카프정
+    "enrofloxacin.json": "0232532310106",        # 아시엔로정
+    "tiergard.json": "0231089420409",            # 티어가드(100T)
+    "chlorhexidine_shampoo.json": "0231334930108",  # 클로르헥시딘샴푸(200ml)
+    "actibet.json": "9240043910403",             # 액티벳(100T)
+    "serenia_maropitant.json": "0231884620107",  # 세레니아정 24mg
+    "terbiderm.json": "0232064110102",           # 터비더미 솔루션
+    "simparica.json": "0232571730106",           # 심파리카 트리오 L(20~40kg)
+    "gaesidin.json": "0231093520106",            # 복합개시딘겔(10g)
+    "oridermyl.json": "0231065620103",           # 오이드로믹스클린(10ml) - 귀약 대용
+    "fronilspot.json": None,                     # 쇼핑몰 미등록
+    "apoquel.json": None,                        # 쇼핑몰 미등록
+    "bravecto.json": None,                       # 쇼핑몰 미등록
+    "gabapentin.json": None,                     # 쇼핑몰 미등록
+    "metronidazole.json": None,                  # 쇼핑몰 미등록
+}
+
+MASTER_DIR = os.path.join(os.path.dirname(__file__), "..", "data", "master")
+
+def update_json_files():
+    updated = []
+    skipped = []
+    
+    for filename, apc in APC_MAPPING.items():
+        filepath = os.path.join(MASTER_DIR, filename)
+        if not os.path.exists(filepath):
+            skipped.append(f"{filename} (파일 없음)")
+            continue
+        
+        with open(filepath, 'r', encoding='utf-8') as f:
+            data = json.load(f)
+        
+        old_apc = data.get('apc_code', '')
+        
+        if apc:
+            data['apc_code'] = apc
+            with open(filepath, 'w', encoding='utf-8') as f:
+                json.dump(data, f, ensure_ascii=False, indent=2)
+            updated.append(f"{filename}: {old_apc} → {apc}")
+        else:
+            skipped.append(f"{filename} (매핑 없음)")
+    
+    print("=" * 60)
+    print("APC 매핑 업데이트 완료")
+    print("=" * 60)
+    print(f"\n✅ 업데이트됨 ({len(updated)}개):")
+    for item in updated:
+        print(f"   {item}")
+    print(f"\n⏭️ 건너뜀 ({len(skipped)}개):")
+    for item in skipped:
+        print(f"   {item}")
+
+if __name__ == "__main__":
+    update_json_files()
diff --git a/static/lectures/lecture_01.html b/static/lectures/lecture_01.html
new file mode 100644
index 0000000..7a13099
--- /dev/null
+++ b/static/lectures/lecture_01.html
@@ -0,0 +1,914 @@
+<!DOCTYPE html>
+<html lang="ko">
+<head>
+    <meta charset="UTF-8">
+    <meta name="viewport" content="width=device-width, initial-scale=1.0">
+    <title>시골약사의 동물약 이야기 #1 복합 개시딘 겔 | 애니팜</title>
+    <!-- Open Graph / 카카오톡 미리보기 -->
+    <meta property="og:type" content="article">
+    <meta property="og:title" content="시골약사의 동물약 이야기 #1 복합 개시딘 겔">
+    <meta property="og:description" content="🐕 세균성 피부염·농피증 치료제 | 사람 후시딘과 뭐가 다를까? 약사가 알려주는 개시딘 완벽 가이드">
+    <meta property="og:image" content="https://cdn-saas-web-218-79.cdn-nhncommerce.com/anypharm70_godomall_com/data/img/product/resized/0231093520106_F_600_wm.jpg">
+    <meta property="og:site_name" content="애니팜">
+    <meta property="og:locale" content="ko_KR">
+    
+    <!-- Twitter Card -->
+    <meta name="twitter:card" content="summary_large_image">
+    <meta name="twitter:title" content="시골약사의 동물약 이야기 #1 복합 개시딘 겔">
+    <meta name="twitter:description" content="🐕 세균성 피부염·농피증 치료제 | 약사가 알려주는 개시딘 완벽 가이드">
+    <meta name="twitter:image" content="https://cdn-saas-web-218-79.cdn-nhncommerce.com/anypharm70_godomall_com/data/img/product/resized/0231093520106_F_600_wm.jpg">
+
+    <style>
+        @import url('https://fonts.googleapis.com/css2?family=Noto+Sans+KR:wght@300;400;500;600;700;900&display=swap');
+        @import url('https://fonts.googleapis.com/css2?family=JetBrains+Mono:wght@400;500&display=swap');
+        
+        * {
+            margin: 0;
+            padding: 0;
+            box-sizing: border-box;
+        }
+        
+        html {
+            scroll-behavior: smooth;
+        }
+        
+        body {
+            font-family: 'Noto Sans KR', 'Apple SD Gothic Neo', 'Malgun Gothic', sans-serif !important;
+            line-height: 1.9;
+            color: #1a1a2e;
+            max-width: 850px;
+            margin: 0 auto;
+            padding: 50px 40px 80px;
+            background: linear-gradient(180deg, #fafbff 0%, #ffffff 100%);
+            font-size: 16px;
+            -webkit-font-smoothing: antialiased;
+        }
+        
+        /* ===== 헤더 ===== */
+        h1 {
+            font-size: 2.2em;
+            font-weight: 900;
+            color: #2d3436;
+            margin: 60px 0 30px;
+            padding-bottom: 15px;
+            border-bottom: 4px solid #6c5ce7;
+            letter-spacing: -1px;
+            position: relative;
+        }
+        
+        h1::after {
+            content: '';
+            position: absolute;
+            bottom: -4px;
+            left: 0;
+            width: 80px;
+            height: 4px;
+            background: linear-gradient(90deg, #a29bfe, #6c5ce7);
+        }
+        
+        h1:first-of-type {
+            margin-top: 0;
+            font-size: 2.5em;
+            text-align: center;
+            border-bottom: none;
+            background: linear-gradient(135deg, #6c5ce7 0%, #a29bfe 50%, #fd79a8 100%);
+            -webkit-background-clip: text;
+            -webkit-text-fill-color: transparent;
+            background-clip: text;
+            padding: 30px 0 40px;
+            letter-spacing: -2px;
+        }
+        
+        h1:first-of-type::after {
+            display: none;
+        }
+        
+        h2 {
+            font-size: 1.6em;
+            font-weight: 700;
+            color: #2d3436;
+            margin: 55px 0 22px;
+            padding: 12px 0 12px 18px;
+            border-left: 5px solid #6c5ce7;
+            background: linear-gradient(90deg, #f8f9ff 0%, transparent 100%);
+        }
+        
+        h3 {
+            font-size: 1.3em;
+            font-weight: 600;
+            color: #2d3436;
+            margin: 40px 0 18px;
+            padding-left: 12px;
+            border-left: 3px solid #a29bfe;
+        }
+        
+        h4 {
+            font-size: 1.1em;
+            font-weight: 600;
+            color: #636e72;
+            margin: 30px 0 14px;
+        }
+        
+        /* ===== 텍스트 ===== */
+        p {
+            margin: 18px 0;
+            text-align: justify;
+            word-break: keep-all;
+            color: #2d3436;
+        }
+        
+        strong {
+            color: #2d3436;
+            font-weight: 700;
+            background: linear-gradient(180deg, transparent 60%, #fff3cd 60%);
+            padding: 0 2px;
+        }
+        
+        em {
+            color: #636e72;
+            font-style: italic;
+        }
+        
+        /* ===== 인용문 ===== */
+        blockquote {
+            background: linear-gradient(135deg, #f8f9ff 0%, #fff5f8 100%);
+            border-left: 5px solid #6c5ce7;
+            padding: 22px 28px;
+            margin: 28px 0;
+            border-radius: 0 16px 16px 0;
+            color: #2d3436;
+            font-size: 0.98em;
+            box-shadow: 0 4px 15px rgba(108, 92, 231, 0.08);
+        }
+        
+        blockquote p {
+            margin: 10px 0;
+        }
+        
+        blockquote p:first-child {
+            margin-top: 0;
+        }
+        
+        blockquote p:last-child {
+            margin-bottom: 0;
+        }
+        
+        /* ===== 코드 ===== */
+        code {
+            background: #f1f3f8;
+            padding: 3px 8px;
+            border-radius: 6px;
+            font-family: 'JetBrains Mono', 'D2Coding', Consolas, monospace !important;
+            font-size: 0.88em;
+            color: #e74c3c;
+            border: 1px solid #e9ecef;
+        }
+        
+        pre {
+            background: linear-gradient(145deg, #2d3436, #1e272e);
+            color: #dfe6e9;
+            padding: 28px;
+            border-radius: 16px;
+            overflow-x: auto;
+            margin: 28px 0;
+            font-size: 0.9em;
+            line-height: 1.8;
+            box-shadow: 0 15px 50px rgba(0,0,0,0.15), inset 0 1px 0 rgba(255,255,255,0.1);
+            border: 1px solid #3d3d3d;
+        }
+        
+        pre code {
+            background: none !important;
+            color: inherit;
+            padding: 0;
+            border: none;
+            font-size: 1em;
+        }
+        
+        /* ===== 테이블 ===== */
+        table {
+            width: 100%;
+            border-collapse: separate;
+            border-spacing: 0;
+            margin: 35px 0;
+            font-size: 0.95em;
+            border-radius: 16px;
+            overflow: hidden;
+            box-shadow: 0 8px 30px rgba(108, 92, 231, 0.12);
+            border: 1px solid #e9ecef;
+        }
+        
+        th {
+            background: linear-gradient(135deg, #6c5ce7 0%, #a29bfe 100%);
+            color: #fff;
+            padding: 16px 20px;
+            text-align: left;
+            font-weight: 600;
+            font-size: 0.95em;
+            letter-spacing: 0.3px;
+            text-shadow: 0 1px 2px rgba(0,0,0,0.1);
+        }
+        
+        td {
+            padding: 15px 20px;
+            border-bottom: 1px solid #f1f3f8;
+            vertical-align: top;
+            background: #fff;
+        }
+        
+        tr:last-child td {
+            border-bottom: none;
+        }
+        
+        tr:nth-child(even) td {
+            background: #fafbff;
+        }
+        
+        tr:hover td {
+            background: #f0f3ff;
+        }
+        
+        /* ===== 리스트 ===== */
+        ul, ol {
+            margin: 20px 0;
+            padding-left: 28px;
+        }
+        
+        li {
+            margin: 12px 0;
+            line-height: 1.8;
+            color: #2d3436;
+        }
+        
+        li::marker {
+            color: #6c5ce7;
+            font-weight: 700;
+        }
+        
+        ul li {
+            list-style-type: none;
+            position: relative;
+            padding-left: 8px;
+        }
+        
+        ul li::before {
+            content: '•';
+            color: #6c5ce7;
+            font-weight: 900;
+            position: absolute;
+            left: -20px;
+            font-size: 1.2em;
+        }
+        
+        /* ===== 구분선 ===== */
+        hr {
+            border: none;
+            height: 3px;
+            background: linear-gradient(90deg, #6c5ce7, #a29bfe, #fd79a8, #fdcb6e);
+            margin: 60px 0;
+            border-radius: 3px;
+        }
+        
+        /* ===== 링크 ===== */
+        a {
+            color: #6c5ce7;
+            text-decoration: none;
+            border-bottom: 2px solid transparent;
+            transition: all 0.2s ease;
+            font-weight: 500;
+        }
+        
+        a:hover {
+            border-bottom-color: #6c5ce7;
+            color: #5f4fcf;
+        }
+        
+        /* ===== 이미지 ===== */
+        img {
+            max-width: 100%;
+            height: auto;
+            border-radius: 16px;
+            margin: 25px 0;
+            box-shadow: 0 10px 40px rgba(0,0,0,0.12);
+        }
+        
+        /* ===== 이모지 강조 ===== */
+        p:has(> strong:first-child) {
+            background: linear-gradient(90deg, #f8f9ff 0%, transparent 100%);
+            padding: 12px 16px;
+            border-radius: 8px;
+            margin: 20px 0;
+        }
+        
+        /* ===== 프린트 ===== */
+        @media print {
+            body {
+                padding: 15mm;
+                max-width: none;
+                font-size: 11pt;
+                background: #fff;
+            }
+            
+            h1:first-of-type {
+                -webkit-text-fill-color: #6c5ce7;
+                color: #6c5ce7;
+            }
+            
+            pre {
+                white-space: pre-wrap;
+                word-wrap: break-word;
+                box-shadow: none;
+                border: 1px solid #ddd;
+            }
+            
+            table {
+                box-shadow: none;
+            }
+            
+            h1, h2, h3 {
+                page-break-after: avoid;
+            }
+            
+            table, pre, blockquote, img {
+                page-break-inside: avoid;
+            }
+        }
+        
+        /* ===== 모바일 ===== */
+        @media (max-width: 768px) {
+            body {
+                padding: 25px 18px 50px;
+                font-size: 15px;
+            }
+            
+            h1 { font-size: 1.8em; }
+            h1:first-of-type { font-size: 2em; }
+            h2 { font-size: 1.4em; padding-left: 14px; }
+            h3 { font-size: 1.2em; }
+            
+            table { font-size: 0.85em; }
+            th, td { padding: 12px 14px; }
+            
+            blockquote { padding: 18px 20px; }
+            pre { padding: 20px; }
+        }
+    </style>
+</head>
+<body>
+<div style="background: linear-gradient(135deg, #f8f9ff 0%, #e8f4f8 100%); border-radius: 16px; padding: 30px; margin-bottom: 30px; box-shadow: 0 4px 15px rgba(0,139,213,0.1);">
+  <p align="center" style="margin: 0 0 15px 0;">
+    <img src="data:image/svg+xml;base64,<?xml version="1.0" encoding="utf-8"?>
<!-- Generator: Adobe Illustrator 24.1.2, SVG Export Plug-In . SVG Version: 6.00 Build 0)  -->
<svg version="1.1" id="레이어_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
	 y="0px" viewBox="0 0 400 150" style="enable-background:new 0 0 400 150;" xml:space="preserve">
<style type="text/css">
	.st0{fill:#008BD5;}
	.st1{fill:#231815;}
</style>
<g>
	<g>
		<path class="st0" d="M58.3,116.86c0-6.77-5.49-12.21-12.26-12.21h-9.12c-3.18,0-6.14-0.94-8.64-2.54
			c-4.36-2.78-7.28-7.6-7.44-13.1c0-0.16-0.02-0.31-0.02-0.47c0-5.74,3.02-10.79,7.56-13.64c1.39-0.87,2.41-2.23,2.64-3.85
			c0.55-3.86,1.85-7.48,3.75-10.72c5.68-9.64,16.64-15.82,28.89-14.42c1.97,0.22,3.89,0.66,5.73,1.27c2.73,0.91,5.71-0.23,7.03-2.79
			l0,0c1.89-3.67,0.22-7.68-3.71-8.94c-3.87-1.24-7.97-1.92-12.2-1.95c-19.48-0.13-35.87,13.08-40.63,31.03
			c-0.3,1.13-0.93,2.12-1.8,2.9c-7.6,6.79-11.54,17.59-8.38,29.1c3.35,12.2,14.91,20.34,27.56,20.34L58.3,116.86z"/>
	</g>
</g>
<g>
	<g>
		<path class="st0" d="M45.48,73.68c0,2.16-1.76,3.92-3.92,3.92c-2.17,0-3.92-1.76-3.92-3.92c0-2.17,1.76-3.92,3.92-3.92
			C43.73,69.76,45.48,71.52,45.48,73.68z"/>
	</g>
</g>
<g>
	<g>
		<path class="st0" d="M108.86,33.5l-2.39,0c-15.94,0-28.87,12.93-28.87,28.87v54.46c0,0.01,0.01,0.03,0.03,0.03
			c6.73-0.01,12.19-5.48,12.19-12.21v-4.32V78.02v-13c0-10.58,8.5-19.16,19.05-19.3c8.71-0.11,16.44,6.41,16.97,15.1
			c0.57,9.34-6.86,17.12-16.08,17.12h-8.74c-3.38,0-6.12,2.74-6.12,6.12l0,0c0,3.37,2.73,6.1,6.1,6.1h8.76
			c16.07,0,29.01-13.38,28.29-29.61C137.37,45.26,124.16,33.5,108.86,33.5z"/>
	</g>
</g>
<g>
	<g>
		<path class="st1" d="M114.59,101.52v3.3h8.51v1.2h-4.27v2.06h6.73v1.16h-14.84v-1.16h6.8v-2.06h-4.27v-5.67h9.78v1.18H114.59z
			 M118.15,117.12c-2.77,0-4.44-1.5-4.44-3.38c0-1.87,1.67-3.4,4.44-3.4c2.77,0,4.44,1.53,4.44,3.4
			C122.59,115.62,120.92,117.12,118.15,117.12z M118.15,111.48c-1.85,0-3.07,0.99-3.07,2.26c0,1.3,1.22,2.27,3.07,2.27
			s3.07-0.97,3.07-2.27C121.22,112.46,120,111.48,118.15,111.48z"/>
	</g>
	<g>
		<path class="st1" d="M129.39,116.76v-4.02h8.53v-1.59h-8.53v-1.18h4.34v-1.67h-6.79v-1.18h14.84v1.18h-6.75v1.67h4.18v3.97h-8.53
			v1.66h9.01v1.16H129.39z M129.48,105.59v-5.48h9.76v5.48H129.48z M137.92,101.29h-7.12v3.1h7.12V101.29z"/>
	</g>
	<g>
		<path class="st1" d="M147.45,108.29c-2.36,0-4.12-1.62-4.12-3.79c0-2.13,1.76-3.74,4.12-3.74c2.34,0,4.13,1.59,4.13,3.74
			C151.57,106.67,149.79,108.29,147.45,108.29z M147.45,101.91c-1.62,0-2.75,1.2-2.75,2.59c0,1.38,1.13,2.63,2.75,2.63
			c1.64,0,2.77-1.25,2.77-2.63C150.21,103.1,149.09,101.91,147.45,101.91z M154.5,116.48v-5h-8.07v-1.2h9.4v6.2H154.5z
			 M155.82,103.53v2.15h2.55v1.2h-2.55v2.47h-1.32v-9.36h1.32v2.34h2.55v1.2H155.82z"/>
	</g>
	<g>
		<path class="st1" d="M170.64,110.75c-1.94,0.21-4.37,0.41-6.08,0.48c-1.59,0.07-3.72,0.12-5.15,0.12l-0.14-1.2
			c1.25,0.02,3.4-0.04,5.01-0.09c1.87-0.07,4.53-0.19,6.26-0.42L170.64,110.75z M168.59,104.34c0,2.1-1.64,3.72-4.13,3.72
			c-2.4,0-4.16-1.62-4.16-3.72c0-2.13,1.76-3.7,4.16-3.7C166.79,100.64,168.59,102.21,168.59,104.34z M164.47,101.82
			c-1.76,0-2.84,1.08-2.84,2.52c0,1.41,1.06,2.54,2.84,2.54c1.73,0,2.75-1.13,2.75-2.54C167.22,102.89,166.19,101.82,164.47,101.82z
			 M171.59,114.7v-14.68h1.3v14.68H171.59z"/>
	</g>
	<g>
		<path class="st1" d="M189.66,109.4c-1.96-0.6-3.47-1.9-4.16-3.49c-0.67,1.64-1.96,2.91-4.11,3.74l-0.65-1.09
			c2.34-0.9,4.05-2.61,4.05-5.25v-0.95h-3.65v-1.16h8.46v1.16h-3.44v0.92c0,2.54,1.82,4.3,4.11,5.04L189.66,109.4z M185.08,116.11
			v-5.53h1.3v4.32h8.21v1.22H185.08z M192.99,111.55v-5.97h-3.81v-1.16h3.81V100h1.3v11.54H192.99z"/>
	</g>
	<g>
		<path class="st1" d="M203.81,112.99v-3.38h-7.1v-1.18h14.84v1.18h-6.45v3.38H203.81z M200.49,111.58v3.63h8.64v1.2h-9.96v-4.83
			H200.49z M199.24,106.49v-6.01h9.76v6.01H199.24z M207.69,101.68h-7.12v3.61h7.12V101.68z"/>
	</g>
	<g>
		<path class="st1" d="M221.14,101.13c-0.09,5.39-3.44,8.44-7.42,10.03l-0.78-1.15c3.95-1.5,6.35-4.16,6.73-7.7h-5.9v-1.18H221.14z
			 M225.57,106.19v8.51h-1.32v-14.68h1.32v4.99h2.79v1.18H225.57z"/>
	</g>
	<g>
		<path class="st1" d="M229.12,109.43v-1.18h14.84v1.18H229.12z M232.96,111.2v3.77h8.67v1.2h-9.99v-4.97H232.96z M231.71,105.86
			v-5.62h1.3v4.42h8.62v1.2H231.71z"/>
	</g>
	<g>
		<path class="st1" d="M254.56,108.29c-2.36,0-4.12-1.62-4.12-3.79c0-2.13,1.76-3.74,4.12-3.74c2.34,0,4.13,1.59,4.13,3.74
			C258.68,106.67,256.9,108.29,254.56,108.29z M254.56,101.91c-1.62,0-2.75,1.2-2.75,2.59c0,1.38,1.13,2.63,2.75,2.63
			c1.64,0,2.77-1.25,2.77-2.63C257.33,103.1,256.2,101.91,254.56,101.91z M261.61,116.48v-5h-8.07v-1.2h9.4v6.2H261.61z
			 M262.93,103.53v2.15h2.55v1.2h-2.55v2.47h-1.32v-9.36h1.32v2.34h2.55v1.2H262.93z"/>
	</g>
	<g>
		<path class="st1" d="M274.93,110.65c-1.66-0.95-3.45-3.06-3.88-4.81c-0.37,1.85-1.92,4.09-3.97,5.18l-0.85-0.95
			c2.38-1.27,4.07-3.9,4.07-7.26v-2.13h1.41v2.08c0,3.3,1.82,5.71,4.04,6.91L274.93,110.65z M279.14,106.19v8.51h-1.31v-14.68h1.31
			v4.99h2.78v1.18H279.14z"/>
	</g>
	<g>
		<path class="st1" d="M287.52,108.36c-2.38,0-4.18-1.62-4.18-3.86c0-2.24,1.8-3.82,4.18-3.82c2.43,0,4.21,1.59,4.21,3.82
			C291.73,106.73,289.97,108.36,287.52,108.36z M287.52,101.84c-1.69,0-2.84,1.23-2.84,2.66c0,1.41,1.15,2.68,2.84,2.68
			c1.78,0,2.89-1.27,2.89-2.68C290.41,103.07,289.3,101.84,287.52,101.84z M287.1,116.62v-6.84h1.3v2.08h6.77v-2.08h1.32v6.84H287.1
			z M295.17,113.03h-6.77v2.41h6.77V113.03z M295.17,108.8v-8.81h1.32v8.81H295.17z"/>
	</g>
	<g>
		<path class="st1" d="M301.3,108.9c3.1,0,5.76-0.21,7.83-0.67l0.19,1.16c-2.38,0.53-5.66,0.71-9.36,0.71v-9.13h1.34V108.9z
			 M311.13,100.04h1.32v14.67h-1.32V100.04z"/>
	</g>
	<g>
		<path class="st1" d="M324.94,109.78c-2.66,0.42-5.82,0.62-9.22,0.49v-9.22h7.31v1.16h-5.97v6.86c2.01,0.11,5.62-0.12,7.74-0.51
			L324.94,109.78z M327.74,105.01h2.79v1.18h-2.79v8.51h-1.3v-14.68h1.3V105.01z"/>
	</g>
</g>
<g>
	<path class="st1" d="M153.8,52.47c0-3.53,0.86-6.64,2.58-9.33c1.72-2.69,4.01-4.8,6.89-6.34c2.88-1.53,6.03-2.3,9.47-2.3
		c3.43,0,6.59,0.77,9.47,2.3c2.88,1.53,5.2,3.64,6.96,6.34c1.76,2.69,2.65,5.8,2.65,9.33c0,3.62-0.88,6.8-2.65,9.54
		c-1.76,2.74-4.09,4.87-6.96,6.41c-2.88,1.53-6.04,2.3-9.47,2.3c-3.44,0-6.59-0.77-9.47-2.3c-2.88-1.53-5.18-3.67-6.89-6.41
		C154.66,59.27,153.8,56.09,153.8,52.47z M165.5,52.47c0,2.23,0.72,3.97,2.16,5.22c1.44,1.25,3.13,1.88,5.08,1.88
		c2.13,0,3.9-0.63,5.29-1.88c1.39-1.25,2.09-2.99,2.09-5.22c0-2.13-0.7-3.83-2.09-5.08c-1.39-1.25-3.16-1.88-5.29-1.88
		c-1.95,0-3.64,0.63-5.08,1.88C166.21,48.64,165.5,50.34,165.5,52.47z M229.69,75.86c0,1.76-0.54,3.2-1.6,4.32
		c-1.07,1.11-2.39,1.67-3.97,1.67c-1.76,0-3.16-0.56-4.18-1.67c-1.02-1.11-1.53-2.55-1.53-4.32V63.05c0-0.74-0.26-1.46-0.77-2.16
		c-0.51-0.7-1.28-1.05-2.3-1.05h-1.81c-0.93,0.09-1.62,0.44-2.09,1.05c-0.47,0.6-0.7,1.32-0.7,2.16v12.53c0,1.77-0.51,3.2-1.53,4.32
		c-1.02,1.11-2.41,1.67-4.18,1.67c-1.67,0-3.02-0.56-4.04-1.67c-1.02-1.12-1.53-2.55-1.53-4.32V38.97c0-1.76,0.49-3.18,1.46-4.25
		c0.97-1.07,2.34-1.6,4.11-1.6c1.86,0,3.18,0.42,3.97,1.25c0.79,0.83,1.27,1.69,1.46,2.58c0.19,0.88,0.28,1.56,0.28,2.02v7.1
		c0,0.84,0.16,1.72,0.49,2.65c0.32,0.93,1.09,1.39,2.3,1.39h1.95c1.11,0,1.88-0.46,2.3-1.39c0.42-0.93,0.63-1.81,0.63-2.65v-7.1
		c0-0.46,0.09-1.14,0.28-2.02c0.19-0.88,0.7-1.74,1.53-2.58c0.84-0.84,2.13-1.25,3.9-1.25c1.67,0,3.02,0.54,4.04,1.6
		c1.02,1.07,1.53,2.48,1.53,4.25V75.86z"/>
	<path class="st1" d="M247.08,41.61c0-1.58,0.5-2.9,1.51-3.97c1.01-1.07,2.3-1.6,3.9-1.6c1.42,0,2.66,0.54,3.71,1.6
		c1.05,1.07,1.57,2.39,1.57,3.97v11.98c0,1.49,0.36,2.78,1.07,3.9c0.71,1.11,1.91,1.67,3.58,1.67H276c1.51,0,2.78,0.47,3.83,1.39
		c1.05,0.93,1.57,2.28,1.57,4.04c0,1.67-0.52,3.04-1.57,4.11c-1.05,1.07-2.33,1.6-3.83,1.6h-20.87c-2.18,0-4.07-0.77-5.66-2.3
		c-1.59-1.53-2.39-3.69-2.39-6.48V41.61z M297.99,75.45c0,1.76-0.48,3.2-1.45,4.32c-0.96,1.11-2.2,1.67-3.71,1.67
		c-1.51,0-2.81-0.56-3.9-1.67c-1.09-1.11-1.63-2.55-1.63-4.32V38.83c0-0.46,0.15-1.14,0.44-2.02c0.29-0.88,0.84-1.74,1.63-2.58
		c0.8-0.83,1.95-1.25,3.46-1.25c1.59,0,2.85,0.53,3.77,1.6c0.92,1.07,1.38,2.48,1.38,4.25V75.45z"/>
	<path class="st1" d="M320.68,70.16c-1.76,0-3.18-0.51-4.25-1.53c-1.07-1.02-1.6-2.37-1.6-4.04c0-1.76,0.53-3.11,1.6-4.04
		c1.07-0.93,2.48-1.39,4.25-1.39h1.67c1.39,0,2.09-0.83,2.09-2.51v-6.82c0-1.95-0.7-2.92-2.09-2.92h-1.39
		c-1.67,0-3.04-0.46-4.11-1.39c-1.07-0.93-1.6-2.27-1.6-4.04c0-1.58,0.53-2.86,1.6-3.83c1.07-0.97,2.39-1.51,3.97-1.6h35.23
		c1.67,0,3.04,0.51,4.11,1.53c1.07,1.02,1.6,2.32,1.6,3.9c0,1.76-0.54,3.11-1.6,4.04c-1.07,0.93-2.44,1.39-4.11,1.39h-0.98
		c-0.65,0-1.25,0.21-1.81,0.63c-0.56,0.42-0.84,1.09-0.84,2.02v7.1c0,1.67,0.74,2.51,2.23,2.51h1.81c1.58,0,2.92,0.47,4.04,1.39
		c1.11,0.93,1.67,2.28,1.67,4.04c0,1.67-0.56,3.02-1.67,4.04c-1.11,1.02-2.46,1.53-4.04,1.53H320.68z M342.13,50.38
		c0-1.58-0.35-2.55-1.04-2.93c-0.7-0.37-1.42-0.56-2.16-0.56h-0.83c-0.74,0-1.46,0.19-2.16,0.56c-0.7,0.37-1.04,1.3-1.04,2.79v6.27
		c0,0.93,0.3,1.63,0.91,2.09c0.6,0.46,1.37,0.7,2.3,0.7h0.83c0.84,0,1.58-0.21,2.23-0.63c0.65-0.42,0.97-1.18,0.97-2.3V50.38z
		 M349.79,117.78c-2.6,0-4.73-0.79-6.41-2.37c-1.67-1.58-2.51-3.67-2.51-6.27V93.69c0-2.6,0.84-4.69,2.51-6.27
		c1.67-1.58,3.81-2.37,6.41-2.37h18.24c2.69,0,4.83,0.79,6.41,2.37c1.58,1.58,2.37,3.67,2.37,6.27v15.46c0,2.6-0.79,4.69-2.37,6.27
		c-1.58,1.58-3.71,2.37-6.41,2.37H349.79z M352.71,102.88c0,1.21,0.18,2.18,0.56,2.92c0.37,0.74,1.25,1.11,2.65,1.11h5.29
		c1.48,0,2.48-0.37,2.99-1.11c0.51-0.74,0.77-1.72,0.77-2.92V99.4c0-1.11-0.26-1.97-0.77-2.58c-0.51-0.6-1.56-0.91-3.13-0.91h-4.87
		c-1.3,0-2.21,0.35-2.72,1.05c-0.51,0.7-0.77,1.55-0.77,2.58V102.88z M368.86,39.1c0-1.86,0.56-3.29,1.67-4.32
		c1.11-1.02,2.55-1.53,4.32-1.53c1.76,0,3.04,0.42,3.83,1.25c0.79,0.84,1.32,1.7,1.6,2.58c0.28,0.88,0.42,1.56,0.42,2.02v6.96
		c0,2.51,1.16,3.76,3.48,3.76h3.62c2.13,0,3.62,0.56,4.46,1.67c0.84,1.11,1.25,2.37,1.25,3.76c0,1.58-0.51,2.9-1.53,3.97
		c-1.02,1.07-2.41,1.6-4.18,1.6h-3.62c-2.32,0-3.48,1.02-3.48,3.06v12.11c0,1.76-0.58,3.2-1.74,4.32c-1.16,1.11-2.53,1.67-4.11,1.67
		c-1.76,0-3.2-0.56-4.32-1.67c-1.11-1.11-1.67-2.55-1.67-4.32V39.1z"/>
</g>
</svg>
" alt="애니팜 로고" width="220">
+  </p>
+  <p align="center" style="margin: 0; color: #666; font-size: 0.9em;">동물약의 전문가는 약사입니다</p>
+</div>
+
+<h1 style="text-align: center; margin-bottom: 5px; font-size: 1.3em; color: #666; font-weight: 500;">시골약사의 동물약 이야기</h1>
+<h2 style="text-align: center; margin-top: 0; font-size: 2em; color: #2d3436; border: none; background: none; padding: 0;">#1 복합 개시딘 겔</h2>
+<p style="text-align: center; color: #888; font-size: 0.95em; margin-top: 5px;">🐕 세균성 피부염·농피증 치료제 | 퓨시드산 + 베타메타손 | 비처방대상 동물용의약품</p>
+
+<blockquote>
+<p>"사람 후시딘 개한테 발라도 돼요?"</p>
+</blockquote>
+<p>약국에서 한 번쯤 들어보셨죠? 저도 처음엔 "뭐... 되지 않을까?" 했는데, 알고 보니 꽤 복잡한 이야기가 숨어 있더라고요. 오늘은 이 질문에 <strong>제대로 답할 수 있는</strong> 약사가 되어봅시다! 🎯</p>
+<hr />
+<h2 id="-">💊 약사와 동물약 - 우리가 할 수 있는 것</h2>
+<h3 id="_1">법적으로, 이미 가능합니다</h3>
+<p>혹시 "동물약은 수의사만 줄 수 있는 거 아니야?"라고 생각하셨다면, 그건 오해예요.</p>
+<table>
+<thead>
+<tr>
+<th>구분</th>
+<th>약국 판매</th>
+</tr>
+</thead>
+<tbody>
+<tr>
+<td><strong>처방대상 동물용의약품</strong> (항생제 일부, 호르몬제 등)</td>
+<td>✅ 가능 (수의사 처방 필요)</td>
+</tr>
+<tr>
+<td><strong>비처방대상 동물용의약품</strong> (구충제, 외용제, 소화제 등)</td>
+<td>✅ 가능 (처방 없이)</td>
+</tr>
+</tbody>
+</table>
+<p>👉 <strong>동물약국 개설허가</strong>를 받은 약국은 동물용의약품을 취급할 수 있습니다. 복합 개시딘 겔처럼 <strong>비처방대상 동물용의약품</strong>은 수의사 처방 없이 판매 가능해요.</p>
+<h3 id="_2">수의사와 약사, 다른 전문성</h3>
+<p>수의사를 깎아내리려는 게 아닙니다. <strong>교육 구조 자체가 다르고, 그래서 강점이 다릅니다.</strong></p>
+<table>
+<thead>
+<tr>
+<th>영역</th>
+<th>수의대 (6년)</th>
+<th>약대 (6년)</th>
+</tr>
+</thead>
+<tbody>
+<tr>
+<td><strong>교육 목표</strong></td>
+<td>진단 → 처방 → 수술까지 종합 임상</td>
+<td><strong>약 중심</strong> 전문가</td>
+</tr>
+<tr>
+<td><strong>약물학</strong></td>
+<td>종별 차이 + 임상 적용 중심</td>
+<td>Receptor, signaling pathway 수준 심화</td>
+</tr>
+<tr>
+<td><strong>약동학</strong></td>
+<td>기본 PK + 종간 차이</td>
+<td>Compartment model, Clearance, TDM, Modeling</td>
+</tr>
+<tr>
+<td><strong>제제학·제형</strong></td>
+<td>사용자 입장 (tablet, injection 이해)</td>
+<td><strong>설계자 입장</strong> (서방형, 나노, 생체이용률)</td>
+</tr>
+<tr>
+<td><strong>약물 상호작용</strong></td>
+<td>임상 빈용 조합 중심</td>
+<td>CYP, Transporter, Mechanism 분석</td>
+</tr>
+</tbody>
+</table>
+<p><strong>종간 차이</strong> — 특히 대동물(소, 말)과 소동물(개, 고양이)의 용량 체계, 종별 독성 프로파일, 그리고 진단에서 수술까지 이어지는 <strong>임상 판단</strong>은 수의사의 전문 영역이에요. 6년간 그걸 집중적으로 훈련받은 분들이니까요.</p>
+<p>물론 우리도 고양이 acetaminophen 독성 같은 건 알고 있죠. 하지만 "말에게는 이 용량, 소에게는 저 용량" 같은 <strong>대동물 임상 디테일</strong>까지는 솔직히 깊지 않아요.</p>
+<p>반면, <strong>"이 약이 왜 이런 제형인지", "왜 이 농도인지", "왜 이 기간만 써야 하는지"</strong> — 이건 우리가 평소 인체약으로 매일 하고 있는 설명이잖아요? 동물약도 마찬가지예요. 약의 원리를 깊이 있게 전달하는 건 <strong>약사가 잘할 수 있는 영역</strong>입니다.</p>
+<h3 id="_3">반려인이 약국에 오는 이유</h3>
+<p>반려인들은 수의사 가기 전, 또는 처방받고 나서도 <strong>약국에 와요</strong>.</p>
+<ul>
+<li>💬 "이거 개한테 발라도 돼요?"</li>
+<li>💬 "수의사 선생님이 준 약인데, 어떻게 먹이는 거예요?"</li>
+<li>💬 "항생제 언제까지 먹여야 해요?"</li>
+</ul>
+<p>이때 <strong>정확한 정보 + 전문가다운 설명</strong>을 해주면?<br />
+→ 신뢰가 쌓이고, "약 관련은 약국에 물어봐야지"가 됩니다.</p>
+<p>우리는 법적 테두리 안에서 충분히 전문가로서 역할할 수 있어요. 항생제 남용 문제, 제형 선택 이유, 투약 기간의 근거 — 이런 건 <strong>약사가 더 잘 전달할 수 있는 영역</strong>입니다.</p>
+<blockquote>
+<p>💡 이 연재의 목표: 이미 알고 있는 동물약, <strong>더 깊이 알고 더 잘 설명하자.</strong></p>
+</blockquote>
+<hr />
+<h2 id="vs-">🔬 개시딘 vs 사람 후시딘 - 뭐가 다른데?</h2>
+<p align="center">
+  <img src="https://cdn-saas-web-218-79.cdn-nhncommerce.com/anypharm70_godomall_com/data/img/product/resized/0231093520106_F_600_wm.jpg" alt="복합 개시딘 겔" width="200">
+  <br>
+  <em>복합 개시딘 겔 (퓨시드산 0.5% + 베타메타손 0.1%)</em>
+</p>
+
+<p>"어차피 퓨시드산 아니야?" 맞아요. 근데 <strong>결정적 차이가 3가지</strong> 있어요.</p>
+<h3 id="1-vs">1️⃣ 제형: 겔 vs 크림</h3>
+<table>
+<thead>
+<tr>
+<th>구분</th>
+<th>개시딘</th>
+<th>사람 후시딘</th>
+</tr>
+</thead>
+<tbody>
+<tr>
+<td>제형</td>
+<td><strong>겔</strong></td>
+<td>크림</td>
+</tr>
+<tr>
+<td>털 침투</td>
+<td>✅ 우수</td>
+<td>❌ 불량</td>
+</tr>
+<tr>
+<td>잔여감</td>
+<td>깔끔</td>
+<td>번들거림</td>
+</tr>
+</tbody>
+</table>
+<p>개는 <strong>털이 있어요</strong>. (너무 당연한가요? ㅋㅋ) 크림은 털 위에서 뭉치는데, 겔은 털 사이로 <strong>쭉쭉 스며들어요</strong>. 이게 생각보다 큰 차이예요.</p>
+<h3 id="2-ph">2️⃣ pH 최적화</h3>
+<ul>
+<li>개 피부 pH: <strong>4.4~8.2</strong> (넓은 범위)</li>
+<li>사람 피부 pH: 4.5~5.5 (좁은 범위)</li>
+</ul>
+<p>개시딘은 <strong>개 피부 pH 범위에 맞게</strong> 제형화되어 있어요. 사람용은 사람 피부에 최적화되어 있고요.</p>
+<h3 id="3">3️⃣ 농도 &amp; 스테로이드 차이</h3>
+<p align="center">
+  <img src="https://www.dong-wha.co.kr/product/pimage/85_img2.jpg" alt="인체용 후시딘" width="150">
+  &nbsp;&nbsp;&nbsp;
+  <img src="https://image.coupangcdn.com/image/vendor_inventory/7818/e8cbd8d566d87bfbde019baff9f7c4c3da5da9d4517dfe915589e40398b3.jpg" alt="후시딘H" width="150">
+  <br>
+  <em>후시딘 연고 (퓨시드산 2%) &nbsp;|&nbsp; 후시딘H 크림 (퓨시드산 2% + 하이드로코르티손 1%)</em>
+</p>
+
+<h4 id="_4">후시딘 제품별 성분 비교</h4>
+<table>
+<thead>
+<tr>
+<th>제품</th>
+<th>퓨시드산</th>
+<th>스테로이드</th>
+<th>스테로이드 강도</th>
+</tr>
+</thead>
+<tbody>
+<tr>
+<td><strong>개시딘 겔</strong> (동물용)</td>
+<td>0.5%</td>
+<td>베타메타손발레레이트 0.1%</td>
+<td><strong>Class IV</strong> (중등도)</td>
+</tr>
+<tr>
+<td>후시딘 연고/크림 (인체용)</td>
+<td>2%</td>
+<td>❌ 없음</td>
+<td>-</td>
+</tr>
+<tr>
+<td>후시딘H 크림 (인체용)</td>
+<td>2%</td>
+<td>하이드로코르티손아세테이트 1%</td>
+<td><strong>Class VI</strong> (약함)</td>
+</tr>
+</tbody>
+</table>
+<h4 id="stoughton-cornell-classification">스테로이드 강도 분류 기준 (Stoughton-Cornell Classification)</h4>
+<p>국소 스테로이드 강도는 <strong>혈관수축 분석(Vasoconstriction Assay)</strong>을 기반으로 Class I(초강력)~VII(가장 약함)로 분류됩니다.</p>
+<table>
+<thead>
+<tr>
+<th>Class</th>
+<th>강도</th>
+<th>대표 약물</th>
+</tr>
+</thead>
+<tbody>
+<tr>
+<td>I</td>
+<td>초강력 (Superpotent)</td>
+<td>Clobetasol propionate 0.05%</td>
+</tr>
+<tr>
+<td>II</td>
+<td>강력 (Potent)</td>
+<td>Betamethasone dipropionate 0.05%</td>
+</tr>
+<tr>
+<td>III</td>
+<td>상위 중강도</td>
+<td>Fluticasone propionate 0.005%</td>
+</tr>
+<tr>
+<td><strong>IV</strong></td>
+<td><strong>중등도 (Mid-strength)</strong></td>
+<td><strong>Betamethasone valerate 0.1%</strong> ← 개시딘</td>
+</tr>
+<tr>
+<td>V</td>
+<td>하위 중등도</td>
+<td>Fluticasone propionate 0.05% cream</td>
+</tr>
+<tr>
+<td><strong>VI</strong></td>
+<td><strong>약함 (Mild)</strong></td>
+<td><strong>Hydrocortisone 1%</strong> ← 후시딘H</td>
+</tr>
+<tr>
+<td>VII</td>
+<td>가장 약함</td>
+<td>Hydrocortisone 0.5%</td>
+</tr>
+</tbody>
+</table>
+<blockquote>
+<p>📚 <strong>근거</strong>: Stoughton RB. Vasoconstrictor assay—specific applications. In: <em>Maibach HI, Surber C, eds. Topical Corticosteroids.</em> Basel: Karger; 1992:42-53. 및 <a href="https://pubmed.ncbi.nlm.nih.gov/3881106/">PMID 3881106</a> - Jacob SE, Steele T. Corticosteroid classes: a quick reference guide including patch test substances and cross-reactivity. <em>J Am Acad Dermatol.</em> 2006.</p>
+</blockquote>
+<h4 id="ester">베타메타손 "염(Ester)"에 따른 차이</h4>
+<p>같은 베타메타손이라도 <strong>어떤 염(ester)으로 결합</strong>되어 있느냐에 따라 효력이 다릅니다:</p>
+<table>
+<thead>
+<tr>
+<th>베타메타손 염</th>
+<th>스테로이드 등급</th>
+<th>특징</th>
+</tr>
+</thead>
+<tbody>
+<tr>
+<td><strong>Betamethasone valerate</strong> (개시딘)</td>
+<td>Class IV</td>
+<td>중등도, 표피 침투 적당</td>
+</tr>
+<tr>
+<td>Betamethasone dipropionate</td>
+<td>Class I~II</td>
+<td>초강력, 깊은 침투</td>
+</tr>
+<tr>
+<td>Betamethasone sodium phosphate</td>
+<td>주사용</td>
+<td>수용성, 전신 투여</td>
+</tr>
+</tbody>
+</table>
+<blockquote>
+<p>💡 <strong>약사 포인트</strong>: 개시딘의 베타메타손발레레이트(Class IV)는 후시딘H의 하이드로코르티손(Class VI)보다 <strong>약 10~15배 강력</strong>합니다. 그래서 개시딘은 <strong>최대 7일</strong>로 사용 기간이 제한되어 있어요.</p>
+</blockquote>
+<h4 id="_5">왜 개시딘이 낮은 농도인데 괜찮을까?</h4>
+<p>"어? 퓨시드산이 0.5%밖에 안 돼?" 맞아요. 근데 여기서 <strong>약사의 시선</strong>이 필요해요.</p>
+<p>겔 제형은 피부 침투가 좋아서 낮은 농도로도 <strong>피부 내 MIC의 67,000배</strong> 농도를 달성해요! (<a href="https://pubmed.ncbi.nlm.nih.gov/29162115/">PMID 29162115</a>) </p>
+<p>높은 농도가 항상 좋은 게 아닙니다:<br />
+- 크림 2% → 털에 흡착되어 실제 피부 도달량 ↓<br />
+- 겔 0.5% → 털 통과 + 피부 직접 도달 → 유효 농도 충분</p>
+<hr />
+<h2 id="_6">🧪 약제학 깊이 보기: 왜 겔이어야 하는가?</h2>
+<p>대학 시절 약제학 시간에 배웠던 에멀전, Henderson-Hasselbalch 방정식... 기억나시죠? 개시딘이 왜 <strong>겔</strong>인지, 그 과학적 이유를 파헤쳐봅시다.</p>
+<h3 id="ow-vs-wo">에멀전의 기초: O/W vs W/O</h3>
+<table>
+<thead>
+<tr>
+<th>구분</th>
+<th>O/W (수중유형)</th>
+<th>W/O (유중수형)</th>
+<th>Gel (수성 겔)</th>
+</tr>
+</thead>
+<tbody>
+<tr>
+<td>연속상</td>
+<td>물</td>
+<td>오일</td>
+<td>물</td>
+</tr>
+<tr>
+<td>분산상</td>
+<td>오일</td>
+<td>물</td>
+<td>(없음)</td>
+</tr>
+<tr>
+<td>촉감</td>
+<td>산뜻함</td>
+<td>유성/무거움</td>
+<td>가장 산뜻</td>
+</tr>
+<tr>
+<td>털 침투</td>
+<td>보통</td>
+<td>나쁨</td>
+<td><strong>우수</strong></td>
+</tr>
+<tr>
+<td>증발 후</td>
+<td>약간 잔여</td>
+<td>기름막</td>
+<td>깔끔</td>
+</tr>
+</tbody>
+</table>
+<p>크림(O/W)이나 연고(W/O)는 <strong>지용성 기제</strong>가 털 위에서 뭉쳐요. 반면 겔은 수성 기반이라 털 사이로 <strong>쭉쭉 퍼지고</strong>, 증발 후 약물만 피부에 남깁니다.</p>
+<h3 id="ph-henderson-hasselbalch">pH와 약물 흡수: Henderson-Hasselbalch로 이해하기</h3>
+<p>퓨시드산은 <strong>약산(pKa ≈ 6.0)</strong>입니다. 약산의 이온화는 pH에 따라 달라지죠:</p>
+<pre><code>Henderson-Hasselbalch 방정식:
+pH = pKa + log([A⁻]/[HA])
+
+비이온화율(%) = 100 / (1 + 10^(pH-pKa))
+</code></pre>
+<table>
+<thead>
+<tr>
+<th>피부 환경</th>
+<th>pH</th>
+<th>비이온화(HA)</th>
+<th>이온화(A⁻)</th>
+<th>지용성</th>
+</tr>
+</thead>
+<tbody>
+<tr>
+<td>사람 피부</td>
+<td>5.0</td>
+<td><strong>91%</strong></td>
+<td>9%</td>
+<td>높음</td>
+</tr>
+<tr>
+<td>개 피부(귀/발)</td>
+<td>6.0</td>
+<td>50%</td>
+<td>50%</td>
+<td>중간</td>
+</tr>
+<tr>
+<td>개 피부(체간)</td>
+<td>7.0</td>
+<td><strong>9%</strong></td>
+<td>91%</td>
+<td>낮음</td>
+</tr>
+</tbody>
+</table>
+<p><strong>핵심 포인트:</strong><br />
+- 사람 피부(pH 5): 비이온화↑ → 지용성 크림이 각질층 확산에 유리<br />
+- 개 피부(pH 7): 이온화↑ → <strong>수성 겔 기제</strong>가 이온화된 약물을 피부 표면에 효율적으로 전달 후, 피부 pH에서 약물 방출</p>
+<h3 id="_7">겔 제형의 과학: 털 있는 피부에서의 강점</h3>
+<table>
+<thead>
+<tr>
+<th>특성</th>
+<th>크림/연고</th>
+<th>겔</th>
+</tr>
+</thead>
+<tbody>
+<tr>
+<td>Spreading coefficient</td>
+<td>낮음</td>
+<td><strong>높음</strong></td>
+</tr>
+<tr>
+<td>모낭 침투</td>
+<td>털 위에 머묾</td>
+<td>털 사이 침투</td>
+</tr>
+<tr>
+<td>핥았을 때</td>
+<td>기름 맛 = 더 핥음</td>
+<td>무미건조</td>
+</tr>
+<tr>
+<td>약물 잔류</td>
+<td>기제와 함께 제거</td>
+<td>피부 흡착 유지</td>
+</tr>
+</tbody>
+</table>
+<p><a href="https://pubmed.ncbi.nlm.nih.gov/29162115/">PMID 29162115</a> 연구에서 퓨시드산 겔 적용 시, 표피 상층 240μm에서 <strong>2,000 μg/g</strong> 농도 달성 - 이는 MIC(0.03 mg/L)의 약 <strong>67,000배</strong>입니다!</p>
+<blockquote>
+<p>💡 <strong>약사 포인트:</strong> 제형 선택은 <strong>약물의 물리화학적 특성 + 적용 부위의 생리적 조건</strong>을 모두 고려해야 해요. 개시딘이 겔인 건 마케팅이 아니라, 약제학적 근거가 있는 거죠!</p>
+</blockquote>
+<hr />
+<h2 id="_8">🐱 잠깐! 고양이는 왜 안 되나요?</h2>
+<p>개시딘이 "개 전용"인 이유는 제품명에 '개'가 들어가서가 아닙니다. <strong>베타메타손 0.1%</strong>가 포함되어 있기 때문이에요.</p>
+<h3 id="_9">고양이와 스테로이드: 민감한 관계</h3>
+<p>고양이도 스테로이드를 "잘 견딘다"는 오래된 인식이 있지만, 이는 <strong>급성 부작용이 적다</strong>는 의미일 뿐입니다. 진짜 문제는 <strong>대사적 취약성</strong>이에요.</p>
+<p>고양이의 HPA axis(시상하부-뇌하수체-부신 축)는 외인성 글루코코르티코이드에 의해 억제될 수 있으며, 특히 <strong>고양이의 당뇨 발생 기전</strong>이 개와 근본적으로 다릅니다. 고양이는 사람의 제2형 당뇨와 유사한 <strong>췌도 아밀로이드 침착(islet amyloidosis)</strong> 기전을 가지고 있어, 스테로이드에 의한 인슐린 저항성이 비가역적 당뇨로 진행할 위험이 높아요 (<a href="https://pubmed.ncbi.nlm.nih.gov/11106586/">PMID 11106586</a>).</p>
+<h3 id="_10">약동학으로 보는 차이</h3>
+<table>
+<thead>
+<tr>
+<th>항목</th>
+<th>개</th>
+<th>고양이</th>
+</tr>
+</thead>
+<tbody>
+<tr>
+<td>Glucuronidation</td>
+<td>활발</td>
+<td><strong>미숙</strong> (UGT 효소 결핍)</td>
+</tr>
+<tr>
+<td>스테로이드 대사</td>
+<td>상대적 빠름</td>
+<td><strong>지연</strong></td>
+</tr>
+<tr>
+<td>당뇨 발생 기전</td>
+<td>Type 1 유사</td>
+<td><strong>Type 2 유사</strong> (amyloid)</td>
+</tr>
+<tr>
+<td>인슐린 저항성</td>
+<td>가역적 경향</td>
+<td><strong>비가역적 위험↑</strong></td>
+</tr>
+</tbody>
+</table>
+<p>고양이는 <strong>glucuronidation</strong> 경로가 미숙하여 여러 약물의 대사가 느립니다. 베타메타손 같은 강력한 fluorocorticoid(C-16 치환, mineralocorticoid 활성 無)는 외용제라도 피부를 통해 전신 흡수되어 <strong>HPA axis 억제</strong>를 유발할 수 있습니다.</p>
+<h3 id="_11">임상적 위험: 숫자로 보면 무섭습니다</h3>
+<p>2021년 J Feline Med Surg 연구(<a href="https://pubmed.ncbi.nlm.nih.gov/32716236/">PMID 32716236</a>):<br />
+- Prednisolone ≥1.9mg/kg/day 투여 고양이 143마리 중 <strong>14마리(9.7%)에서 당뇨 발생</strong><br />
+- 85.7%가 <strong>투약 3개월 이내</strong> 발생</p>
+<p>2022년 브라질 연구(<a href="https://pubmed.ncbi.nlm.nih.gov/35202848/">PMID 35202848</a>):<br />
+- <strong>MPA 단회 주사</strong>만으로도 혈당·인슐린 상승, HOMA-IR 지표 악화<br />
+- 메트포르민이나 당뇨식이로도 예방 실패</p>
+<table>
+<thead>
+<tr>
+<th>고양이 스테로이드 부작용</th>
+</tr>
+</thead>
+<tbody>
+<tr>
+<td><strong>당뇨병 유발</strong> (특히 비만묘, 버미즈 품종)</td>
+</tr>
+<tr>
+<td>의인성 쿠싱 증후군</td>
+</tr>
+<tr>
+<td>피부 위축, 상처 치유 지연</td>
+</tr>
+<tr>
+<td>면역억제 → 감염 취약</td>
+</tr>
+</tbody>
+</table>
+<h3 id="_12">그럼 고양이는 뭘 써요?</h3>
+<p>고양이 피부 세균 감염 시:<br />
+1. <strong>퓨시드산 단독 제품</strong> (스테로이드 無) - 사람용 후시딘 연고 off-label<br />
+2. <strong>클로르헥시딘 세정제</strong> - 1차 관리<br />
+3. <strong>전신 항생제</strong> - 세팔렉신, 아목시실린-클라불란산 등<br />
+4. <strong>수의사 처방</strong> - 고양이 허가 제품 또는 off-label 사용 판단</p>
+<blockquote>
+<p>⚠️ <strong>복약상담 포인트</strong>: "고양이 키우시는 분들 많으시죠? 개시딘은 <strong>스테로이드 성분</strong> 때문에 고양이에게 당뇨를 유발할 수 있어요. 퓨시드산만 필요하시면 스테로이드 없는 제품을 찾거나, 수의사 선생님과 상의해 보세요."</p>
+</blockquote>
+<hr />
+<h2 id="_13">📋 약사의 꿀팁: 이렇게 설명하세요!</h2>
+<h3 id="3-5-7">🎯 3-5-7 법칙</h3>
+<pre><code>┌─────────────────────────────────────────┐
+│  3일: 효과 체크 (안 나으면 수의사!)     │
+│  5일: 최소 사용 기간                    │
+│  7일: 최대 사용 기간 (이상 사용 금지)   │
+└─────────────────────────────────────────┘
+</code></pre>
+<p>반려인에게 이렇게 말해주세요:</p>
+<blockquote>
+<p>"3일 발랐는데 전혀 안 나아지면 수의사 선생님께 가세요. 효과 있으면 5~7일 꾸준히! 근데 7일 넘기면 안 돼요~"</p>
+</blockquote>
+<h3 id="_14">🐶 핥기 방지 필수!</h3>
+<p>이거 꼭 강조하세요:</p>
+<blockquote>
+<p>"바르고 나서 <strong>10~15분</strong>은 핥지 못하게 해주세요. 엘리자베스 칼라 있으면 씌우시고, 없으면 안고 계시거나 간식으로 관심 돌리세요!"</p>
+</blockquote>
+<h3 id="_15">🍄 곰팡이(진균) 감별 포인트</h3>
+<p>퓨시드산은 <strong>세균성</strong> 피부염에 써요. 진균이면 안 들어요!</p>
+<table>
+<thead>
+<tr>
+<th>세균성 (개시딘 OK)</th>
+<th>진균성 (터비덤 or 수의사)</th>
+</tr>
+</thead>
+<tbody>
+<tr>
+<td>부분적, 붉은 병변</td>
+<td>동그란 링 모양</td>
+</tr>
+<tr>
+<td>고름/삼출물</td>
+<td>털 빠짐 + 비듬</td>
+</tr>
+<tr>
+<td>급성 발생</td>
+<td>서서히 퍼짐</td>
+</tr>
+</tbody>
+</table>
+<blockquote>
+<p>💡 <strong>진균이 의심된다면?</strong> 약국에서 바로 추천할 수 있는 제품이 있어요!<br />
+<strong>터비덤 스프레이 큐어</strong> — 테르비나핀(항진균) + 클로르헥시딘(항균) 복합 스프레이<br />
+- Malassezia 피부염, 윤선(Microsporum), 표재성 세균 감염까지 커버<br />
+- 1일 1~2회 분무, 증상 소실 후 7일 추가 사용<br />
+- 개 전용 비처방대상 동물용의약품</p>
+<p>확실하지 않거나, 윤선(링웜) 의심 시에는 <strong>수의사 진료</strong>도 함께 권유하세요. 윤선은 인수공통이라 가족에게도 전파될 수 있거든요!</p>
+</blockquote>
+<hr />
+<h2 id="-_1">⚠️ 항생제 스튜어드십 - 이건 진지하게!</h2>
+<p><strong>한국 퓨시드산 내성률: 27%</strong> (<a href="https://pubmed.ncbi.nlm.nih.gov/32115810/">PMID 32115810</a>)</p>
+<p>4마리 중 1마리 이상에서 내성균이 나온다는 거예요. 이게 왜 중요하냐면:</p>
+<h3 id="_16">항생제 스튜어드십이란?</h3>
+<blockquote>
+<p>항생제를 <strong>꼭 필요할 때, 적절한 용량으로, 적절한 기간만</strong> 쓰자는 원칙</p>
+</blockquote>
+<p>국소 항생제라고 막 쓰면 안 되는 이유:<br />
+- 피부 상재균에 내성 유발<br />
+- 나중에 <strong>전신 감염</strong> 시 치료 옵션 감소<br />
+- 사람에게도 내성균 전파 가능 (One Health 개념)</p>
+<h3 id="_17">그래서 우리가 할 일</h3>
+<ol>
+<li><strong>7일 넘게 쓰지 말라고 안내</strong> (정말 중요!)</li>
+<li><strong>호전 안 되면 수의사 가라고</strong> (배양검사 필요할 수 있음)</li>
+<li><strong>예방 목적 사용 금지</strong> (상처 없는데 미리 바르기 ❌)</li>
+</ol>
+<hr />
+<h2 id="_18">🌟 마무리: 약사의 자부심</h2>
+<p>우리는 <strong>약의 전문가</strong>예요. 수의사가 진단하면, 우리는 <strong>그 약이 어떻게 작용하고, 어떻게 써야 효과적인지</strong> 설명할 수 있어요.</p>
+<p>동물약도 결국 <strong>약리학, 약동학, 제제학</strong>의 연장선이에요. 사람약 공부하며 쌓은 내공이 여기서도 빛을 발하는 거죠! ✨</p>
+<p>다음에 "사람 후시딘 발라도 돼요?" 질문 받으면, 이렇게 답해보세요:</p>
+<blockquote>
+<p>"쓸 수는 있는데, <strong>개 전용 개시딘</strong>이 더 좋아요. 겔이라 털 사이로 잘 스며들고, 개 피부에 맞게 만들어졌거든요. 3일 발라서 효과 없으면 수의사 선생님 가시고, 효과 있으면 5~7일 꾸준히 바르세요. 7일 넘기면 안 돼요!"</p>
+</blockquote>
+<p><strong>전문가다운 답변</strong>, 멋지지 않나요? 😎</p>
+<hr />
+<p><em>다음 편 예고: 귀 세정제의 과학 - 왜 클로르헥시딘은 귀에 안 될까?</em></p>
+<hr />
+<!-- 플로팅 챗봇 버튼 - 애니팜 도매상 링크 -->
+<p><a href="https://www.anipharm.kr/" target="_blank" title="애니팜 도매상 바로가기" style="position: fixed; bottom: 20px; right: 20px; width: 56px; height: 56px; background: linear-gradient(135deg, #008BD5 0%, #00a8e8 100%); border-radius: 50%; box-shadow: 0 4px 16px rgba(0, 139, 213, 0.4); cursor: pointer; z-index: 9999; transition: transform 0.2s ease, box-shadow 0.2s ease; text-decoration: none;" onmouseover="this.style.transform='scale(1.1)'; this.style.boxShadow='0 6px 24px rgba(0,139,213,0.5)';" onmouseout="this.style.transform='scale(1)'; this.style.boxShadow='0 4px 16px rgba(0,139,213,0.4)';"><svg width="32" height="32" viewBox="50 20 300 180" style="fill: white; position: absolute; top: 50%; left: 50%; transform: translate(-50%, -50%);"><path d="M173.48,196.64c0-13.86-11.24-24.99-25.1-24.99h-18.66c-6.51,0-12.57-1.92-17.69-5.19c-8.92-5.7-14.91-15.55-15.24-26.81c-0.01-0.33-0.05-0.64-0.05-0.97c0-11.76,6.19-22.09,15.47-27.93c2.84-1.79,4.94-4.57,5.41-7.89c1.13-7.91,3.78-15.32,7.68-21.94c11.62-19.74,34.05-32.38,59.14-29.52c4.04,0.46,7.96,1.34,11.73,2.59c5.59,1.85,11.69-0.48,14.39-5.71l0,0c3.88-7.51,0.45-15.72-7.6-18.3c-7.93-2.53-16.32-3.93-24.98-3.99c-39.87-0.27-73.43,26.77-83.16,63.51c-0.61,2.31-1.9,4.35-3.69,5.94c-15.56,13.89-23.62,36-17.16,59.57c6.85,24.98,30.51,41.63,56.41,41.63L173.48,196.64z"/><circle cx="139.21" cy="108.25" r="8.02"/><path d="M276.96,26.01l-4.9,0c-32.64,0.01-59.09,26.47-59.09,59.1v111.48c0,0.03,0.03,0.05,0.06,0.05c13.78-0.03,24.94-11.21,24.94-25v-8.85v-45.67v-26.6c0-21.65,17.41-39.23,38.99-39.51c17.83-0.23,33.65,13.11,34.75,30.91c1.17,19.12-14.05,35.05-32.92,35.05h-17.88c-6.91,0-12.52,5.6-12.52,12.52l0,0c0,6.89,5.59,12.48,12.48,12.48h17.92c32.89,0,59.39-27.39,57.92-60.61C335.33,50.07,308.29,26,276.96,26.01z"/></svg></a></p>
+<p>📚 <strong>참고문헌</strong><br />
+- Fusidic acid resistance in S. pseudintermedius (Korea): <a href="https://pubmed.ncbi.nlm.nih.gov/32115810/">PMID 32115810</a><br />
+- Topical fusidic acid skin concentration: <a href="https://pubmed.ncbi.nlm.nih.gov/29162115/">PMID 29162115</a><br />
+- Feline islet amyloidosis model: <a href="https://pubmed.ncbi.nlm.nih.gov/11106586/">PMID 11106586</a><br />
+- Prednisolone-induced diabetes in cats: <a href="https://pubmed.ncbi.nlm.nih.gov/32716236/">PMID 32716236</a><br />
+- MPA insulin resistance in cats: <a href="https://pubmed.ncbi.nlm.nih.gov/35202848/">PMID 35202848</a><br />
+- 복합 개시딘 겔 제품 설명서</p>
+</body>
+</html>
\ No newline at end of file
diff --git a/static/nexgard_spectra.jpg b/static/nexgard_spectra.jpg
new file mode 100644
index 0000000..bdd1b60
Binary files /dev/null and b/static/nexgard_spectra.jpg differ
diff --git a/templates/anipharm_logo.svg b/templates/anipharm_logo.svg
new file mode 100644
index 0000000..a0184ec
--- /dev/null
+++ b/templates/anipharm_logo.svg
@@ -0,0 +1,137 @@
+<?xml version="1.0" encoding="utf-8"?>
+<!-- Generator: Adobe Illustrator 24.1.2, SVG Export Plug-In . SVG Version: 6.00 Build 0)  -->
+<svg version="1.1" id="레이어_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
+	 y="0px" viewBox="0 0 400 150" style="enable-background:new 0 0 400 150;" xml:space="preserve">
+<style type="text/css">
+	.st0{fill:#008BD5;}
+	.st1{fill:#231815;}
+</style>
+<g>
+	<g>
+		<path class="st0" d="M58.3,116.86c0-6.77-5.49-12.21-12.26-12.21h-9.12c-3.18,0-6.14-0.94-8.64-2.54
+			c-4.36-2.78-7.28-7.6-7.44-13.1c0-0.16-0.02-0.31-0.02-0.47c0-5.74,3.02-10.79,7.56-13.64c1.39-0.87,2.41-2.23,2.64-3.85
+			c0.55-3.86,1.85-7.48,3.75-10.72c5.68-9.64,16.64-15.82,28.89-14.42c1.97,0.22,3.89,0.66,5.73,1.27c2.73,0.91,5.71-0.23,7.03-2.79
+			l0,0c1.89-3.67,0.22-7.68-3.71-8.94c-3.87-1.24-7.97-1.92-12.2-1.95c-19.48-0.13-35.87,13.08-40.63,31.03
+			c-0.3,1.13-0.93,2.12-1.8,2.9c-7.6,6.79-11.54,17.59-8.38,29.1c3.35,12.2,14.91,20.34,27.56,20.34L58.3,116.86z"/>
+	</g>
+</g>
+<g>
+	<g>
+		<path class="st0" d="M45.48,73.68c0,2.16-1.76,3.92-3.92,3.92c-2.17,0-3.92-1.76-3.92-3.92c0-2.17,1.76-3.92,3.92-3.92
+			C43.73,69.76,45.48,71.52,45.48,73.68z"/>
+	</g>
+</g>
+<g>
+	<g>
+		<path class="st0" d="M108.86,33.5l-2.39,0c-15.94,0-28.87,12.93-28.87,28.87v54.46c0,0.01,0.01,0.03,0.03,0.03
+			c6.73-0.01,12.19-5.48,12.19-12.21v-4.32V78.02v-13c0-10.58,8.5-19.16,19.05-19.3c8.71-0.11,16.44,6.41,16.97,15.1
+			c0.57,9.34-6.86,17.12-16.08,17.12h-8.74c-3.38,0-6.12,2.74-6.12,6.12l0,0c0,3.37,2.73,6.1,6.1,6.1h8.76
+			c16.07,0,29.01-13.38,28.29-29.61C137.37,45.26,124.16,33.5,108.86,33.5z"/>
+	</g>
+</g>
+<g>
+	<g>
+		<path class="st1" d="M114.59,101.52v3.3h8.51v1.2h-4.27v2.06h6.73v1.16h-14.84v-1.16h6.8v-2.06h-4.27v-5.67h9.78v1.18H114.59z
+			 M118.15,117.12c-2.77,0-4.44-1.5-4.44-3.38c0-1.87,1.67-3.4,4.44-3.4c2.77,0,4.44,1.53,4.44,3.4
+			C122.59,115.62,120.92,117.12,118.15,117.12z M118.15,111.48c-1.85,0-3.07,0.99-3.07,2.26c0,1.3,1.22,2.27,3.07,2.27
+			s3.07-0.97,3.07-2.27C121.22,112.46,120,111.48,118.15,111.48z"/>
+	</g>
+	<g>
+		<path class="st1" d="M129.39,116.76v-4.02h8.53v-1.59h-8.53v-1.18h4.34v-1.67h-6.79v-1.18h14.84v1.18h-6.75v1.67h4.18v3.97h-8.53
+			v1.66h9.01v1.16H129.39z M129.48,105.59v-5.48h9.76v5.48H129.48z M137.92,101.29h-7.12v3.1h7.12V101.29z"/>
+	</g>
+	<g>
+		<path class="st1" d="M147.45,108.29c-2.36,0-4.12-1.62-4.12-3.79c0-2.13,1.76-3.74,4.12-3.74c2.34,0,4.13,1.59,4.13,3.74
+			C151.57,106.67,149.79,108.29,147.45,108.29z M147.45,101.91c-1.62,0-2.75,1.2-2.75,2.59c0,1.38,1.13,2.63,2.75,2.63
+			c1.64,0,2.77-1.25,2.77-2.63C150.21,103.1,149.09,101.91,147.45,101.91z M154.5,116.48v-5h-8.07v-1.2h9.4v6.2H154.5z
+			 M155.82,103.53v2.15h2.55v1.2h-2.55v2.47h-1.32v-9.36h1.32v2.34h2.55v1.2H155.82z"/>
+	</g>
+	<g>
+		<path class="st1" d="M170.64,110.75c-1.94,0.21-4.37,0.41-6.08,0.48c-1.59,0.07-3.72,0.12-5.15,0.12l-0.14-1.2
+			c1.25,0.02,3.4-0.04,5.01-0.09c1.87-0.07,4.53-0.19,6.26-0.42L170.64,110.75z M168.59,104.34c0,2.1-1.64,3.72-4.13,3.72
+			c-2.4,0-4.16-1.62-4.16-3.72c0-2.13,1.76-3.7,4.16-3.7C166.79,100.64,168.59,102.21,168.59,104.34z M164.47,101.82
+			c-1.76,0-2.84,1.08-2.84,2.52c0,1.41,1.06,2.54,2.84,2.54c1.73,0,2.75-1.13,2.75-2.54C167.22,102.89,166.19,101.82,164.47,101.82z
+			 M171.59,114.7v-14.68h1.3v14.68H171.59z"/>
+	</g>
+	<g>
+		<path class="st1" d="M189.66,109.4c-1.96-0.6-3.47-1.9-4.16-3.49c-0.67,1.64-1.96,2.91-4.11,3.74l-0.65-1.09
+			c2.34-0.9,4.05-2.61,4.05-5.25v-0.95h-3.65v-1.16h8.46v1.16h-3.44v0.92c0,2.54,1.82,4.3,4.11,5.04L189.66,109.4z M185.08,116.11
+			v-5.53h1.3v4.32h8.21v1.22H185.08z M192.99,111.55v-5.97h-3.81v-1.16h3.81V100h1.3v11.54H192.99z"/>
+	</g>
+	<g>
+		<path class="st1" d="M203.81,112.99v-3.38h-7.1v-1.18h14.84v1.18h-6.45v3.38H203.81z M200.49,111.58v3.63h8.64v1.2h-9.96v-4.83
+			H200.49z M199.24,106.49v-6.01h9.76v6.01H199.24z M207.69,101.68h-7.12v3.61h7.12V101.68z"/>
+	</g>
+	<g>
+		<path class="st1" d="M221.14,101.13c-0.09,5.39-3.44,8.44-7.42,10.03l-0.78-1.15c3.95-1.5,6.35-4.16,6.73-7.7h-5.9v-1.18H221.14z
+			 M225.57,106.19v8.51h-1.32v-14.68h1.32v4.99h2.79v1.18H225.57z"/>
+	</g>
+	<g>
+		<path class="st1" d="M229.12,109.43v-1.18h14.84v1.18H229.12z M232.96,111.2v3.77h8.67v1.2h-9.99v-4.97H232.96z M231.71,105.86
+			v-5.62h1.3v4.42h8.62v1.2H231.71z"/>
+	</g>
+	<g>
+		<path class="st1" d="M254.56,108.29c-2.36,0-4.12-1.62-4.12-3.79c0-2.13,1.76-3.74,4.12-3.74c2.34,0,4.13,1.59,4.13,3.74
+			C258.68,106.67,256.9,108.29,254.56,108.29z M254.56,101.91c-1.62,0-2.75,1.2-2.75,2.59c0,1.38,1.13,2.63,2.75,2.63
+			c1.64,0,2.77-1.25,2.77-2.63C257.33,103.1,256.2,101.91,254.56,101.91z M261.61,116.48v-5h-8.07v-1.2h9.4v6.2H261.61z
+			 M262.93,103.53v2.15h2.55v1.2h-2.55v2.47h-1.32v-9.36h1.32v2.34h2.55v1.2H262.93z"/>
+	</g>
+	<g>
+		<path class="st1" d="M274.93,110.65c-1.66-0.95-3.45-3.06-3.88-4.81c-0.37,1.85-1.92,4.09-3.97,5.18l-0.85-0.95
+			c2.38-1.27,4.07-3.9,4.07-7.26v-2.13h1.41v2.08c0,3.3,1.82,5.71,4.04,6.91L274.93,110.65z M279.14,106.19v8.51h-1.31v-14.68h1.31
+			v4.99h2.78v1.18H279.14z"/>
+	</g>
+	<g>
+		<path class="st1" d="M287.52,108.36c-2.38,0-4.18-1.62-4.18-3.86c0-2.24,1.8-3.82,4.18-3.82c2.43,0,4.21,1.59,4.21,3.82
+			C291.73,106.73,289.97,108.36,287.52,108.36z M287.52,101.84c-1.69,0-2.84,1.23-2.84,2.66c0,1.41,1.15,2.68,2.84,2.68
+			c1.78,0,2.89-1.27,2.89-2.68C290.41,103.07,289.3,101.84,287.52,101.84z M287.1,116.62v-6.84h1.3v2.08h6.77v-2.08h1.32v6.84H287.1
+			z M295.17,113.03h-6.77v2.41h6.77V113.03z M295.17,108.8v-8.81h1.32v8.81H295.17z"/>
+	</g>
+	<g>
+		<path class="st1" d="M301.3,108.9c3.1,0,5.76-0.21,7.83-0.67l0.19,1.16c-2.38,0.53-5.66,0.71-9.36,0.71v-9.13h1.34V108.9z
+			 M311.13,100.04h1.32v14.67h-1.32V100.04z"/>
+	</g>
+	<g>
+		<path class="st1" d="M324.94,109.78c-2.66,0.42-5.82,0.62-9.22,0.49v-9.22h7.31v1.16h-5.97v6.86c2.01,0.11,5.62-0.12,7.74-0.51
+			L324.94,109.78z M327.74,105.01h2.79v1.18h-2.79v8.51h-1.3v-14.68h1.3V105.01z"/>
+	</g>
+</g>
+<g>
+	<path class="st1" d="M153.8,52.47c0-3.53,0.86-6.64,2.58-9.33c1.72-2.69,4.01-4.8,6.89-6.34c2.88-1.53,6.03-2.3,9.47-2.3
+		c3.43,0,6.59,0.77,9.47,2.3c2.88,1.53,5.2,3.64,6.96,6.34c1.76,2.69,2.65,5.8,2.65,9.33c0,3.62-0.88,6.8-2.65,9.54
+		c-1.76,2.74-4.09,4.87-6.96,6.41c-2.88,1.53-6.04,2.3-9.47,2.3c-3.44,0-6.59-0.77-9.47-2.3c-2.88-1.53-5.18-3.67-6.89-6.41
+		C154.66,59.27,153.8,56.09,153.8,52.47z M165.5,52.47c0,2.23,0.72,3.97,2.16,5.22c1.44,1.25,3.13,1.88,5.08,1.88
+		c2.13,0,3.9-0.63,5.29-1.88c1.39-1.25,2.09-2.99,2.09-5.22c0-2.13-0.7-3.83-2.09-5.08c-1.39-1.25-3.16-1.88-5.29-1.88
+		c-1.95,0-3.64,0.63-5.08,1.88C166.21,48.64,165.5,50.34,165.5,52.47z M229.69,75.86c0,1.76-0.54,3.2-1.6,4.32
+		c-1.07,1.11-2.39,1.67-3.97,1.67c-1.76,0-3.16-0.56-4.18-1.67c-1.02-1.11-1.53-2.55-1.53-4.32V63.05c0-0.74-0.26-1.46-0.77-2.16
+		c-0.51-0.7-1.28-1.05-2.3-1.05h-1.81c-0.93,0.09-1.62,0.44-2.09,1.05c-0.47,0.6-0.7,1.32-0.7,2.16v12.53c0,1.77-0.51,3.2-1.53,4.32
+		c-1.02,1.11-2.41,1.67-4.18,1.67c-1.67,0-3.02-0.56-4.04-1.67c-1.02-1.12-1.53-2.55-1.53-4.32V38.97c0-1.76,0.49-3.18,1.46-4.25
+		c0.97-1.07,2.34-1.6,4.11-1.6c1.86,0,3.18,0.42,3.97,1.25c0.79,0.83,1.27,1.69,1.46,2.58c0.19,0.88,0.28,1.56,0.28,2.02v7.1
+		c0,0.84,0.16,1.72,0.49,2.65c0.32,0.93,1.09,1.39,2.3,1.39h1.95c1.11,0,1.88-0.46,2.3-1.39c0.42-0.93,0.63-1.81,0.63-2.65v-7.1
+		c0-0.46,0.09-1.14,0.28-2.02c0.19-0.88,0.7-1.74,1.53-2.58c0.84-0.84,2.13-1.25,3.9-1.25c1.67,0,3.02,0.54,4.04,1.6
+		c1.02,1.07,1.53,2.48,1.53,4.25V75.86z"/>
+	<path class="st1" d="M247.08,41.61c0-1.58,0.5-2.9,1.51-3.97c1.01-1.07,2.3-1.6,3.9-1.6c1.42,0,2.66,0.54,3.71,1.6
+		c1.05,1.07,1.57,2.39,1.57,3.97v11.98c0,1.49,0.36,2.78,1.07,3.9c0.71,1.11,1.91,1.67,3.58,1.67H276c1.51,0,2.78,0.47,3.83,1.39
+		c1.05,0.93,1.57,2.28,1.57,4.04c0,1.67-0.52,3.04-1.57,4.11c-1.05,1.07-2.33,1.6-3.83,1.6h-20.87c-2.18,0-4.07-0.77-5.66-2.3
+		c-1.59-1.53-2.39-3.69-2.39-6.48V41.61z M297.99,75.45c0,1.76-0.48,3.2-1.45,4.32c-0.96,1.11-2.2,1.67-3.71,1.67
+		c-1.51,0-2.81-0.56-3.9-1.67c-1.09-1.11-1.63-2.55-1.63-4.32V38.83c0-0.46,0.15-1.14,0.44-2.02c0.29-0.88,0.84-1.74,1.63-2.58
+		c0.8-0.83,1.95-1.25,3.46-1.25c1.59,0,2.85,0.53,3.77,1.6c0.92,1.07,1.38,2.48,1.38,4.25V75.45z"/>
+	<path class="st1" d="M320.68,70.16c-1.76,0-3.18-0.51-4.25-1.53c-1.07-1.02-1.6-2.37-1.6-4.04c0-1.76,0.53-3.11,1.6-4.04
+		c1.07-0.93,2.48-1.39,4.25-1.39h1.67c1.39,0,2.09-0.83,2.09-2.51v-6.82c0-1.95-0.7-2.92-2.09-2.92h-1.39
+		c-1.67,0-3.04-0.46-4.11-1.39c-1.07-0.93-1.6-2.27-1.6-4.04c0-1.58,0.53-2.86,1.6-3.83c1.07-0.97,2.39-1.51,3.97-1.6h35.23
+		c1.67,0,3.04,0.51,4.11,1.53c1.07,1.02,1.6,2.32,1.6,3.9c0,1.76-0.54,3.11-1.6,4.04c-1.07,0.93-2.44,1.39-4.11,1.39h-0.98
+		c-0.65,0-1.25,0.21-1.81,0.63c-0.56,0.42-0.84,1.09-0.84,2.02v7.1c0,1.67,0.74,2.51,2.23,2.51h1.81c1.58,0,2.92,0.47,4.04,1.39
+		c1.11,0.93,1.67,2.28,1.67,4.04c0,1.67-0.56,3.02-1.67,4.04c-1.11,1.02-2.46,1.53-4.04,1.53H320.68z M342.13,50.38
+		c0-1.58-0.35-2.55-1.04-2.93c-0.7-0.37-1.42-0.56-2.16-0.56h-0.83c-0.74,0-1.46,0.19-2.16,0.56c-0.7,0.37-1.04,1.3-1.04,2.79v6.27
+		c0,0.93,0.3,1.63,0.91,2.09c0.6,0.46,1.37,0.7,2.3,0.7h0.83c0.84,0,1.58-0.21,2.23-0.63c0.65-0.42,0.97-1.18,0.97-2.3V50.38z
+		 M349.79,117.78c-2.6,0-4.73-0.79-6.41-2.37c-1.67-1.58-2.51-3.67-2.51-6.27V93.69c0-2.6,0.84-4.69,2.51-6.27
+		c1.67-1.58,3.81-2.37,6.41-2.37h18.24c2.69,0,4.83,0.79,6.41,2.37c1.58,1.58,2.37,3.67,2.37,6.27v15.46c0,2.6-0.79,4.69-2.37,6.27
+		c-1.58,1.58-3.71,2.37-6.41,2.37H349.79z M352.71,102.88c0,1.21,0.18,2.18,0.56,2.92c0.37,0.74,1.25,1.11,2.65,1.11h5.29
+		c1.48,0,2.48-0.37,2.99-1.11c0.51-0.74,0.77-1.72,0.77-2.92V99.4c0-1.11-0.26-1.97-0.77-2.58c-0.51-0.6-1.56-0.91-3.13-0.91h-4.87
+		c-1.3,0-2.21,0.35-2.72,1.05c-0.51,0.7-0.77,1.55-0.77,2.58V102.88z M368.86,39.1c0-1.86,0.56-3.29,1.67-4.32
+		c1.11-1.02,2.55-1.53,4.32-1.53c1.76,0,3.04,0.42,3.83,1.25c0.79,0.84,1.32,1.7,1.6,2.58c0.28,0.88,0.42,1.56,0.42,2.02v6.96
+		c0,2.51,1.16,3.76,3.48,3.76h3.62c2.13,0,3.62,0.56,4.46,1.67c0.84,1.11,1.25,2.37,1.25,3.76c0,1.58-0.51,2.9-1.53,3.97
+		c-1.02,1.07-2.41,1.6-4.18,1.6h-3.62c-2.32,0-3.48,1.02-3.48,3.06v12.11c0,1.76-0.58,3.2-1.74,4.32c-1.16,1.11-2.53,1.67-4.11,1.67
+		c-1.76,0-3.2-0.56-4.32-1.67c-1.11-1.11-1.67-2.55-1.67-4.32V39.1z"/>
+</g>
+</svg>
diff --git a/templates/anipharm_logo_base64.txt b/templates/anipharm_logo_base64.txt
new file mode 100644
index 0000000..e757915
Binary files /dev/null and b/templates/anipharm_logo_base64.txt differ
diff --git a/templates/medication_guide_v2.html b/templates/medication_guide_v2.html
index d16266f..b841008 100644
--- a/templates/medication_guide_v2.html
+++ b/templates/medication_guide_v2.html
@@ -2,7 +2,7 @@
 <html lang="ko">
 <head>
     <meta charset="UTF-8">
-    <title>동물약 복약안내문 v2</title>
+    <title>애니팜 투약지도서</title>
     <style>
         @import url('https://fonts.googleapis.com/css2?family=Noto+Sans+KR:wght@300;400;500;700;900&display=swap');
         
@@ -23,6 +23,7 @@
             padding: 5mm;
             page-break-after: always;
             box-sizing: border-box;
+            position: relative;  /* 푸터 absolute 위치 기준 */
         }
         
         .page:last-child {
@@ -31,35 +32,68 @@
         
         /* 헤더 */
         .header {
+            position: relative;
             display: flex;
             justify-content: space-between;
-            align-items: center;
-            border-bottom: 2px solid #1565C0;
+            align-items: flex-end;
+            border-bottom: 1.5px solid #008BD5;
             padding-bottom: 2mm;
             margin-bottom: 3mm;
-            height: 15mm;
+            height: 18mm;
+        }
+        
+        .header-left {
+            display: flex;
+            flex-direction: column;
+            gap: 1mm;
+            width: 50mm;
         }
         
         .header-left .patient-name {
-            font-size: 14pt;
+            font-size: 16pt;
             font-weight: 700;
-            color: #0D47A1;
+            color: #1a1a1a;
+            letter-spacing: -0.5pt;
         }
         
         .header-left .patient-info {
-            font-size: 7pt;
-            color: #666;
+            font-size: 8pt;
+            color: #555;
+            font-weight: 400;
+        }
+        
+        .header-center {
+            position: absolute;
+            left: 50%;
+            transform: translateX(-50%);
+            bottom: 2mm;
+            text-align: center;
         }
         
         .header-center .pharmacy-name {
-            font-size: 12pt;
-            font-weight: 700;
-            color: #1565C0;
+            font-size: 22pt;
+            font-weight: 900;
+            color: #008BD5;
+            letter-spacing: -1pt;
+        }
+        
+        .header-center .pharmacy-sub {
+            font-size: 7pt;
+            color: #666;
+            margin-top: 0.5mm;
         }
         
         .header-right {
-            font-size: 7pt;
-            color: #666;
+            text-align: right;
+            font-size: 8pt;
+            color: #333;
+            font-weight: 500;
+            width: 50mm;
+        }
+        
+        .header-right .tel-label {
+            font-size: 6pt;
+            color: #888;
         }
         
         /* 카드 그리드 영역 */
@@ -89,14 +123,36 @@
         }
         
         .drug-icon {
-            width: 7mm;
-            height: 7mm;
+            width: 10mm;
+            height: 10mm;
             background: white;
             border-radius: 1mm;
             display: flex;
             align-items: center;
             justify-content: center;
             font-size: 10pt;
+            overflow: hidden;
+        }
+        
+        .drug-icon img {
+            width: 100%;
+            height: 100%;
+            object-fit: cover;
+        }
+        
+        .drug-icon-fallback {
+            width: 100%;
+            height: 100%;
+            background: #f5f5f5;
+            display: flex;
+            align-items: center;
+            justify-content: center;
+        }
+        
+        .drug-icon-fallback svg {
+            width: 70%;
+            height: 70%;
+            fill: #bdbdbd;
         }
         
         .drug-name {
@@ -279,10 +335,34 @@
             color: #9E9E9E;
             border-top: 0.5px solid #E0E0E0;
             padding-top: 1mm;
-            height: 7mm;
+            height: 10mm;
+            display: flex;
+            justify-content: space-between;
+            align-items: center;
         }
         
-        .footer-logo { font-weight: 700; color: #1565C0; font-size: 6pt; }
+        .footer-left {
+            display: flex;
+            align-items: center;
+            gap: 2mm;
+        }
+        
+        .footer-logo { font-weight: 700; color: #008BD5; font-size: 7pt; letter-spacing: 0.5px; }
+        
+        .footer-right {
+            display: flex;
+            align-items: center;
+            gap: 1.5mm;
+        }
+        
+        .footer-right img {
+            height: 6mm;
+        }
+        
+        .footer-provider {
+            font-size: 5pt;
+            color: #666;
+        }
     </style>
 </head>
 <body>
@@ -295,13 +375,18 @@
     <!-- 헤더 (첫 페이지만) -->
     <div class="header">
         <div class="header-left">
-            <div class="patient-name">{{ patient_name }} 보호자님</div>
-            <div class="patient-info">🐾 {{ pet_name }} ({{ pet_species }}, {{ pet_age }}) | 📅 {{ issue_date }}</div>
+            <div class="patient-name">{{ patient_name }} 반려인님</div>
+            <div class="patient-info">{{ pet_name }} · {{ pet_species }} · {{ pet_age }}</div>
         </div>
         <div class="header-center">
-            <div class="pharmacy-name">🏥 {{ pharmacy_name }}</div>
+            <div class="pharmacy-name">{{ pharmacy_name }}</div>
+            <div class="pharmacy-sub">동물약 전문 상담</div>
+        </div>
+        <div class="header-right">
+            <div class="tel-label">TEL</div>
+            <div>{{ pharmacy_tel }}</div>
+            <div style="font-size:6pt; color:#888; margin-top:1mm;">{{ issue_date }}</div>
         </div>
-        <div class="header-right">{{ pharmacy_tel }}</div>
     </div>
     {% endif %}
     
@@ -312,7 +397,27 @@
         {% for drug in drugs[start_idx:end_idx] %}
         <div class="drug-card">
             <div class="drug-card-header">
-                <div class="drug-icon">💊</div>
+                <div class="drug-icon">
+                    {% if drug.image_url %}
+                    <img src="{{ drug.image_url }}" 
+                         alt="{{ drug.name }}"
+                         onerror="this.style.display='none'; this.nextElementSibling.style.display='flex';" />
+                    <span class="drug-icon-fallback" style="display:none;">
+                        <svg viewBox="0 0 24 24"><path d="M20 6h-4V4c0-1.1-.9-2-2-2h-4c-1.1 0-2 .9-2 2v2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h16c1.1 0 2-.9 2-2V8c0-1.1-.9-2-2-2zm-6 0h-4V4h4v2z"/></svg>
+                    </span>
+                    {% elif drug.apc_code is not none and drug.apc_code and (drug.apc_code|string)[:4] != '0519' and (drug.apc_code|string)[:4] != 'None' %}
+                    <img src="https://cdn-saas-web-218-79.cdn-nhncommerce.com/anypharm70_godomall_com/data/img/product/resized/{{ drug.apc_code }}_F_600_wm.jpg" 
+                         alt="{{ drug.name }}"
+                         onerror="this.style.display='none'; this.nextElementSibling.style.display='flex';" />
+                    <span class="drug-icon-fallback" style="display:none;">
+                        <svg viewBox="0 0 24 24"><path d="M20 6h-4V4c0-1.1-.9-2-2-2h-4c-1.1 0-2 .9-2 2v2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h16c1.1 0 2-.9 2-2V8c0-1.1-.9-2-2-2zm-6 0h-4V4h4v2z"/></svg>
+                    </span>
+                    {% else %}
+                    <span class="drug-icon-fallback">
+                        <svg viewBox="0 0 24 24"><path d="M20 6h-4V4c0-1.1-.9-2-2-2h-4c-1.1 0-2 .9-2 2v2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h16c1.1 0 2-.9 2-2V8c0-1.1-.9-2-2-2zm-6 0h-4V4h4v2z"/></svg>
+                    </span>
+                    {% endif %}
+                </div>
                 <div>
                     <div class="drug-name">{{ drug.name }}</div>
                     <div class="drug-subtitle">{{ drug.english_name }}</div>
@@ -399,11 +504,49 @@
                 {% elif drug.category == 'antibiotic' %}
                 <!-- 항생제 -->
                 <div class="dosing-section">
-                    <div class="dosing-title">📋 {{ drug.indication[:30] }}...</div>
-                    <div class="dosing-main">{{ drug.dosage.standard }}</div>
+                    <div class="dosing-title">📋 {{ drug.indication[:40] if drug.indication is string else drug.indication }}...</div>
+                    <div class="dosing-main">{{ drug.dosage.standard if drug.dosage.standard is defined else drug.dosage }}</div>
+                    {% if drug.dosage.duration is defined %}
                     <div class="dosing-note">기간: {{ drug.dosage.duration }}</div>
+                    {% endif %}
                 </div>
                 
+                {% if drug.dosage_table %}
+                <div class="coverage-title">⚖️ 체중별 용량</div>
+                <div class="dosage-grid">
+                    {% for row in drug.dosage_table[:6] %}
+                    <div class="dosage-cell">
+                        <div class="dosage-weight">{{ row.weight }}</div>
+                        <div class="dosage-amount">{{ row.tablets_per_dose if row.tablets_per_dose is defined else (row.tablets if row.tablets is defined else row.dose) }}</div>
+                    </div>
+                    {% endfor %}
+                </div>
+                {% endif %}
+                
+                {% if drug.treatment_timeline %}
+                <div class="gap-warning">
+                    <span class="gap-warning-title">📅 효과 시기</span><br>
+                    {% if drug.treatment_timeline.phases is defined %}
+                    {% for phase in drug.treatment_timeline.phases[:4] %}
+                    <span class="gap-solution">• {{ phase.week }}: {{ phase.expected[:30] }}...</span><br>
+                    {% endfor %}
+                    {% else %}
+                    {% for key, val in drug.treatment_timeline.items() %}
+                    {% if key not in ['realistic_expectation', 'important_note', 'description', 'phases'] %}
+                    <span class="gap-solution">• {{ key }}: {{ val }}</span><br>
+                    {% endif %}
+                    {% endfor %}
+                    {% endif %}
+                </div>
+                {% endif %}
+                
+                {% if drug.clinical_notes %}
+                <div class="gap-warning">
+                    <span class="gap-warning-title">💡 임상 참고</span><br>
+                    {% for note in drug.clinical_notes[:3] %}<span class="gap-solution">• {{ note }}</span><br>{% endfor %}
+                </div>
+                {% endif %}
+                
                 {% if drug.cat_warning %}
                 <div class="contraindication-box">
                     <div class="contraindication-title">🐱 고양이 주의</div>
@@ -495,7 +638,51 @@
                 <div class="usage-box">
                     {% if drug.dosage.frequency %}<b>빈도:</b> {{ drug.dosage.frequency }}<br>{% endif %}
                     {% if drug.dosage.duration %}<b>기간:</b> {{ drug.dosage.duration }}<br>{% endif %}
-                    {% if drug.dosage.contact_time %}<b>접촉:</b> {{ drug.dosage.contact_time }}{% endif %}
+                    {% if drug.dosage.max_duration %}<b>최대:</b> {{ drug.dosage.max_duration }}<br>{% endif %}
+                    {% if drug.dosage.application %}<b>방법:</b> {{ drug.dosage.application }}{% endif %}
+                </div>
+                {% endif %}
+                
+                {% if drug.application_method %}
+                <div class="gap-warning">
+                    <span class="gap-warning-title">🖐️ 도포 방법</span>
+                    <div style="display:flex; flex-wrap:wrap; gap:1mm; margin-top:1mm;">
+                    {% for key, val in drug.application_method.items() %}
+                    {% if key.startswith('step') and val.action is defined %}
+                    <span style="background:#E3F2FD; padding:0.5mm 1.5mm; border-radius:1mm; font-size:5pt;">{{ loop.index }}. {{ val.action[:12] }}</span>
+                    {% endif %}
+                    {% endfor %}
+                    </div>
+                </div>
+                {% endif %}
+                
+                {% if drug.progress_monitoring %}
+                <div class="gap-warning">
+                    <span class="gap-warning-title">📅 경과 관찰</span><br>
+                    {% for key, val in drug.progress_monitoring.items() %}
+                    {% if val.description is defined %}
+                    <span class="gap-solution">• {{ key.replace('_', ' ') }}: {{ val.description }}</span><br>
+                    {% endif %}
+                    {% endfor %}
+                </div>
+                {% endif %}
+                
+                {% if drug.pharmacy_tips %}
+                <div class="gap-warning" style="background:#E8F5E9;">
+                    <span class="gap-warning-title">💡 약사 꿀팁</span><br>
+                    {% if drug.pharmacy_tips.human_vs_animal %}
+                    <span class="gap-solution">• {{ drug.pharmacy_tips.human_vs_animal }}</span><br>
+                    {% endif %}
+                    {% if drug.pharmacy_tips.ph_tip %}
+                    <span class="gap-solution">• {{ drug.pharmacy_tips.ph_tip }}</span><br>
+                    {% endif %}
+                </div>
+                {% endif %}
+                
+                {% if drug.clinical_notes %}
+                <div class="gap-warning">
+                    <span class="gap-warning-title">💡 임상 참고</span><br>
+                    {% for note in drug.clinical_notes[:3] %}<span class="gap-solution">• {{ note }}</span><br>{% endfor %}
                 </div>
                 {% endif %}
                 {% endif %}
@@ -514,13 +701,17 @@
         {% endfor %}
     </div>
     
-    {% if loop.last %}
-    <!-- 푸터 (마지막 페이지만) -->
+    <!-- 푸터 (모든 페이지) -->
     <div class="footer">
-        <div class="footer-logo">🐾 동물약 복약안내 v2</div>
-        ※ 참고용 안내문입니다. 정확한 투약은 수의사 지시에 따르세요.
+        <div class="footer-left">
+            <div class="footer-logo">애니팜 투약지도서</div>
+            <span>※ 참고용 안내문입니다. 정확한 투약은 약사님과 함께 허가사항 해석과, 수의사 지시에 따릅니다.</span>
+        </div>
+        <div class="footer-right">
+            <span class="footer-provider">투약정보 제공</span>
+            <img src="data:image/svg+xml;base64,<?xml version="1.0" encoding="utf-8"?>
<!-- Generator: Adobe Illustrator 24.1.2, SVG Export Plug-In . SVG Version: 6.00 Build 0)  -->
<svg version="1.1" id="레이어_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
	 y="0px" viewBox="0 0 400 150" style="enable-background:new 0 0 400 150;" xml:space="preserve">
<style type="text/css">
	.st0{fill:#008BD5;}
	.st1{fill:#231815;}
</style>
<g>
	<g>
		<path class="st0" d="M58.3,116.86c0-6.77-5.49-12.21-12.26-12.21h-9.12c-3.18,0-6.14-0.94-8.64-2.54
			c-4.36-2.78-7.28-7.6-7.44-13.1c0-0.16-0.02-0.31-0.02-0.47c0-5.74,3.02-10.79,7.56-13.64c1.39-0.87,2.41-2.23,2.64-3.85
			c0.55-3.86,1.85-7.48,3.75-10.72c5.68-9.64,16.64-15.82,28.89-14.42c1.97,0.22,3.89,0.66,5.73,1.27c2.73,0.91,5.71-0.23,7.03-2.79
			l0,0c1.89-3.67,0.22-7.68-3.71-8.94c-3.87-1.24-7.97-1.92-12.2-1.95c-19.48-0.13-35.87,13.08-40.63,31.03
			c-0.3,1.13-0.93,2.12-1.8,2.9c-7.6,6.79-11.54,17.59-8.38,29.1c3.35,12.2,14.91,20.34,27.56,20.34L58.3,116.86z"/>
	</g>
</g>
<g>
	<g>
		<path class="st0" d="M45.48,73.68c0,2.16-1.76,3.92-3.92,3.92c-2.17,0-3.92-1.76-3.92-3.92c0-2.17,1.76-3.92,3.92-3.92
			C43.73,69.76,45.48,71.52,45.48,73.68z"/>
	</g>
</g>
<g>
	<g>
		<path class="st0" d="M108.86,33.5l-2.39,0c-15.94,0-28.87,12.93-28.87,28.87v54.46c0,0.01,0.01,0.03,0.03,0.03
			c6.73-0.01,12.19-5.48,12.19-12.21v-4.32V78.02v-13c0-10.58,8.5-19.16,19.05-19.3c8.71-0.11,16.44,6.41,16.97,15.1
			c0.57,9.34-6.86,17.12-16.08,17.12h-8.74c-3.38,0-6.12,2.74-6.12,6.12l0,0c0,3.37,2.73,6.1,6.1,6.1h8.76
			c16.07,0,29.01-13.38,28.29-29.61C137.37,45.26,124.16,33.5,108.86,33.5z"/>
	</g>
</g>
<g>
	<g>
		<path class="st1" d="M114.59,101.52v3.3h8.51v1.2h-4.27v2.06h6.73v1.16h-14.84v-1.16h6.8v-2.06h-4.27v-5.67h9.78v1.18H114.59z
			 M118.15,117.12c-2.77,0-4.44-1.5-4.44-3.38c0-1.87,1.67-3.4,4.44-3.4c2.77,0,4.44,1.53,4.44,3.4
			C122.59,115.62,120.92,117.12,118.15,117.12z M118.15,111.48c-1.85,0-3.07,0.99-3.07,2.26c0,1.3,1.22,2.27,3.07,2.27
			s3.07-0.97,3.07-2.27C121.22,112.46,120,111.48,118.15,111.48z"/>
	</g>
	<g>
		<path class="st1" d="M129.39,116.76v-4.02h8.53v-1.59h-8.53v-1.18h4.34v-1.67h-6.79v-1.18h14.84v1.18h-6.75v1.67h4.18v3.97h-8.53
			v1.66h9.01v1.16H129.39z M129.48,105.59v-5.48h9.76v5.48H129.48z M137.92,101.29h-7.12v3.1h7.12V101.29z"/>
	</g>
	<g>
		<path class="st1" d="M147.45,108.29c-2.36,0-4.12-1.62-4.12-3.79c0-2.13,1.76-3.74,4.12-3.74c2.34,0,4.13,1.59,4.13,3.74
			C151.57,106.67,149.79,108.29,147.45,108.29z M147.45,101.91c-1.62,0-2.75,1.2-2.75,2.59c0,1.38,1.13,2.63,2.75,2.63
			c1.64,0,2.77-1.25,2.77-2.63C150.21,103.1,149.09,101.91,147.45,101.91z M154.5,116.48v-5h-8.07v-1.2h9.4v6.2H154.5z
			 M155.82,103.53v2.15h2.55v1.2h-2.55v2.47h-1.32v-9.36h1.32v2.34h2.55v1.2H155.82z"/>
	</g>
	<g>
		<path class="st1" d="M170.64,110.75c-1.94,0.21-4.37,0.41-6.08,0.48c-1.59,0.07-3.72,0.12-5.15,0.12l-0.14-1.2
			c1.25,0.02,3.4-0.04,5.01-0.09c1.87-0.07,4.53-0.19,6.26-0.42L170.64,110.75z M168.59,104.34c0,2.1-1.64,3.72-4.13,3.72
			c-2.4,0-4.16-1.62-4.16-3.72c0-2.13,1.76-3.7,4.16-3.7C166.79,100.64,168.59,102.21,168.59,104.34z M164.47,101.82
			c-1.76,0-2.84,1.08-2.84,2.52c0,1.41,1.06,2.54,2.84,2.54c1.73,0,2.75-1.13,2.75-2.54C167.22,102.89,166.19,101.82,164.47,101.82z
			 M171.59,114.7v-14.68h1.3v14.68H171.59z"/>
	</g>
	<g>
		<path class="st1" d="M189.66,109.4c-1.96-0.6-3.47-1.9-4.16-3.49c-0.67,1.64-1.96,2.91-4.11,3.74l-0.65-1.09
			c2.34-0.9,4.05-2.61,4.05-5.25v-0.95h-3.65v-1.16h8.46v1.16h-3.44v0.92c0,2.54,1.82,4.3,4.11,5.04L189.66,109.4z M185.08,116.11
			v-5.53h1.3v4.32h8.21v1.22H185.08z M192.99,111.55v-5.97h-3.81v-1.16h3.81V100h1.3v11.54H192.99z"/>
	</g>
	<g>
		<path class="st1" d="M203.81,112.99v-3.38h-7.1v-1.18h14.84v1.18h-6.45v3.38H203.81z M200.49,111.58v3.63h8.64v1.2h-9.96v-4.83
			H200.49z M199.24,106.49v-6.01h9.76v6.01H199.24z M207.69,101.68h-7.12v3.61h7.12V101.68z"/>
	</g>
	<g>
		<path class="st1" d="M221.14,101.13c-0.09,5.39-3.44,8.44-7.42,10.03l-0.78-1.15c3.95-1.5,6.35-4.16,6.73-7.7h-5.9v-1.18H221.14z
			 M225.57,106.19v8.51h-1.32v-14.68h1.32v4.99h2.79v1.18H225.57z"/>
	</g>
	<g>
		<path class="st1" d="M229.12,109.43v-1.18h14.84v1.18H229.12z M232.96,111.2v3.77h8.67v1.2h-9.99v-4.97H232.96z M231.71,105.86
			v-5.62h1.3v4.42h8.62v1.2H231.71z"/>
	</g>
	<g>
		<path class="st1" d="M254.56,108.29c-2.36,0-4.12-1.62-4.12-3.79c0-2.13,1.76-3.74,4.12-3.74c2.34,0,4.13,1.59,4.13,3.74
			C258.68,106.67,256.9,108.29,254.56,108.29z M254.56,101.91c-1.62,0-2.75,1.2-2.75,2.59c0,1.38,1.13,2.63,2.75,2.63
			c1.64,0,2.77-1.25,2.77-2.63C257.33,103.1,256.2,101.91,254.56,101.91z M261.61,116.48v-5h-8.07v-1.2h9.4v6.2H261.61z
			 M262.93,103.53v2.15h2.55v1.2h-2.55v2.47h-1.32v-9.36h1.32v2.34h2.55v1.2H262.93z"/>
	</g>
	<g>
		<path class="st1" d="M274.93,110.65c-1.66-0.95-3.45-3.06-3.88-4.81c-0.37,1.85-1.92,4.09-3.97,5.18l-0.85-0.95
			c2.38-1.27,4.07-3.9,4.07-7.26v-2.13h1.41v2.08c0,3.3,1.82,5.71,4.04,6.91L274.93,110.65z M279.14,106.19v8.51h-1.31v-14.68h1.31
			v4.99h2.78v1.18H279.14z"/>
	</g>
	<g>
		<path class="st1" d="M287.52,108.36c-2.38,0-4.18-1.62-4.18-3.86c0-2.24,1.8-3.82,4.18-3.82c2.43,0,4.21,1.59,4.21,3.82
			C291.73,106.73,289.97,108.36,287.52,108.36z M287.52,101.84c-1.69,0-2.84,1.23-2.84,2.66c0,1.41,1.15,2.68,2.84,2.68
			c1.78,0,2.89-1.27,2.89-2.68C290.41,103.07,289.3,101.84,287.52,101.84z M287.1,116.62v-6.84h1.3v2.08h6.77v-2.08h1.32v6.84H287.1
			z M295.17,113.03h-6.77v2.41h6.77V113.03z M295.17,108.8v-8.81h1.32v8.81H295.17z"/>
	</g>
	<g>
		<path class="st1" d="M301.3,108.9c3.1,0,5.76-0.21,7.83-0.67l0.19,1.16c-2.38,0.53-5.66,0.71-9.36,0.71v-9.13h1.34V108.9z
			 M311.13,100.04h1.32v14.67h-1.32V100.04z"/>
	</g>
	<g>
		<path class="st1" d="M324.94,109.78c-2.66,0.42-5.82,0.62-9.22,0.49v-9.22h7.31v1.16h-5.97v6.86c2.01,0.11,5.62-0.12,7.74-0.51
			L324.94,109.78z M327.74,105.01h2.79v1.18h-2.79v8.51h-1.3v-14.68h1.3V105.01z"/>
	</g>
</g>
<g>
	<path class="st1" d="M153.8,52.47c0-3.53,0.86-6.64,2.58-9.33c1.72-2.69,4.01-4.8,6.89-6.34c2.88-1.53,6.03-2.3,9.47-2.3
		c3.43,0,6.59,0.77,9.47,2.3c2.88,1.53,5.2,3.64,6.96,6.34c1.76,2.69,2.65,5.8,2.65,9.33c0,3.62-0.88,6.8-2.65,9.54
		c-1.76,2.74-4.09,4.87-6.96,6.41c-2.88,1.53-6.04,2.3-9.47,2.3c-3.44,0-6.59-0.77-9.47-2.3c-2.88-1.53-5.18-3.67-6.89-6.41
		C154.66,59.27,153.8,56.09,153.8,52.47z M165.5,52.47c0,2.23,0.72,3.97,2.16,5.22c1.44,1.25,3.13,1.88,5.08,1.88
		c2.13,0,3.9-0.63,5.29-1.88c1.39-1.25,2.09-2.99,2.09-5.22c0-2.13-0.7-3.83-2.09-5.08c-1.39-1.25-3.16-1.88-5.29-1.88
		c-1.95,0-3.64,0.63-5.08,1.88C166.21,48.64,165.5,50.34,165.5,52.47z M229.69,75.86c0,1.76-0.54,3.2-1.6,4.32
		c-1.07,1.11-2.39,1.67-3.97,1.67c-1.76,0-3.16-0.56-4.18-1.67c-1.02-1.11-1.53-2.55-1.53-4.32V63.05c0-0.74-0.26-1.46-0.77-2.16
		c-0.51-0.7-1.28-1.05-2.3-1.05h-1.81c-0.93,0.09-1.62,0.44-2.09,1.05c-0.47,0.6-0.7,1.32-0.7,2.16v12.53c0,1.77-0.51,3.2-1.53,4.32
		c-1.02,1.11-2.41,1.67-4.18,1.67c-1.67,0-3.02-0.56-4.04-1.67c-1.02-1.12-1.53-2.55-1.53-4.32V38.97c0-1.76,0.49-3.18,1.46-4.25
		c0.97-1.07,2.34-1.6,4.11-1.6c1.86,0,3.18,0.42,3.97,1.25c0.79,0.83,1.27,1.69,1.46,2.58c0.19,0.88,0.28,1.56,0.28,2.02v7.1
		c0,0.84,0.16,1.72,0.49,2.65c0.32,0.93,1.09,1.39,2.3,1.39h1.95c1.11,0,1.88-0.46,2.3-1.39c0.42-0.93,0.63-1.81,0.63-2.65v-7.1
		c0-0.46,0.09-1.14,0.28-2.02c0.19-0.88,0.7-1.74,1.53-2.58c0.84-0.84,2.13-1.25,3.9-1.25c1.67,0,3.02,0.54,4.04,1.6
		c1.02,1.07,1.53,2.48,1.53,4.25V75.86z"/>
	<path class="st1" d="M247.08,41.61c0-1.58,0.5-2.9,1.51-3.97c1.01-1.07,2.3-1.6,3.9-1.6c1.42,0,2.66,0.54,3.71,1.6
		c1.05,1.07,1.57,2.39,1.57,3.97v11.98c0,1.49,0.36,2.78,1.07,3.9c0.71,1.11,1.91,1.67,3.58,1.67H276c1.51,0,2.78,0.47,3.83,1.39
		c1.05,0.93,1.57,2.28,1.57,4.04c0,1.67-0.52,3.04-1.57,4.11c-1.05,1.07-2.33,1.6-3.83,1.6h-20.87c-2.18,0-4.07-0.77-5.66-2.3
		c-1.59-1.53-2.39-3.69-2.39-6.48V41.61z M297.99,75.45c0,1.76-0.48,3.2-1.45,4.32c-0.96,1.11-2.2,1.67-3.71,1.67
		c-1.51,0-2.81-0.56-3.9-1.67c-1.09-1.11-1.63-2.55-1.63-4.32V38.83c0-0.46,0.15-1.14,0.44-2.02c0.29-0.88,0.84-1.74,1.63-2.58
		c0.8-0.83,1.95-1.25,3.46-1.25c1.59,0,2.85,0.53,3.77,1.6c0.92,1.07,1.38,2.48,1.38,4.25V75.45z"/>
	<path class="st1" d="M320.68,70.16c-1.76,0-3.18-0.51-4.25-1.53c-1.07-1.02-1.6-2.37-1.6-4.04c0-1.76,0.53-3.11,1.6-4.04
		c1.07-0.93,2.48-1.39,4.25-1.39h1.67c1.39,0,2.09-0.83,2.09-2.51v-6.82c0-1.95-0.7-2.92-2.09-2.92h-1.39
		c-1.67,0-3.04-0.46-4.11-1.39c-1.07-0.93-1.6-2.27-1.6-4.04c0-1.58,0.53-2.86,1.6-3.83c1.07-0.97,2.39-1.51,3.97-1.6h35.23
		c1.67,0,3.04,0.51,4.11,1.53c1.07,1.02,1.6,2.32,1.6,3.9c0,1.76-0.54,3.11-1.6,4.04c-1.07,0.93-2.44,1.39-4.11,1.39h-0.98
		c-0.65,0-1.25,0.21-1.81,0.63c-0.56,0.42-0.84,1.09-0.84,2.02v7.1c0,1.67,0.74,2.51,2.23,2.51h1.81c1.58,0,2.92,0.47,4.04,1.39
		c1.11,0.93,1.67,2.28,1.67,4.04c0,1.67-0.56,3.02-1.67,4.04c-1.11,1.02-2.46,1.53-4.04,1.53H320.68z M342.13,50.38
		c0-1.58-0.35-2.55-1.04-2.93c-0.7-0.37-1.42-0.56-2.16-0.56h-0.83c-0.74,0-1.46,0.19-2.16,0.56c-0.7,0.37-1.04,1.3-1.04,2.79v6.27
		c0,0.93,0.3,1.63,0.91,2.09c0.6,0.46,1.37,0.7,2.3,0.7h0.83c0.84,0,1.58-0.21,2.23-0.63c0.65-0.42,0.97-1.18,0.97-2.3V50.38z
		 M349.79,117.78c-2.6,0-4.73-0.79-6.41-2.37c-1.67-1.58-2.51-3.67-2.51-6.27V93.69c0-2.6,0.84-4.69,2.51-6.27
		c1.67-1.58,3.81-2.37,6.41-2.37h18.24c2.69,0,4.83,0.79,6.41,2.37c1.58,1.58,2.37,3.67,2.37,6.27v15.46c0,2.6-0.79,4.69-2.37,6.27
		c-1.58,1.58-3.71,2.37-6.41,2.37H349.79z M352.71,102.88c0,1.21,0.18,2.18,0.56,2.92c0.37,0.74,1.25,1.11,2.65,1.11h5.29
		c1.48,0,2.48-0.37,2.99-1.11c0.51-0.74,0.77-1.72,0.77-2.92V99.4c0-1.11-0.26-1.97-0.77-2.58c-0.51-0.6-1.56-0.91-3.13-0.91h-4.87
		c-1.3,0-2.21,0.35-2.72,1.05c-0.51,0.7-0.77,1.55-0.77,2.58V102.88z M368.86,39.1c0-1.86,0.56-3.29,1.67-4.32
		c1.11-1.02,2.55-1.53,4.32-1.53c1.76,0,3.04,0.42,3.83,1.25c0.79,0.84,1.32,1.7,1.6,2.58c0.28,0.88,0.42,1.56,0.42,2.02v6.96
		c0,2.51,1.16,3.76,3.48,3.76h3.62c2.13,0,3.62,0.56,4.46,1.67c0.84,1.11,1.25,2.37,1.25,3.76c0,1.58-0.51,2.9-1.53,3.97
		c-1.02,1.07-2.41,1.6-4.18,1.6h-3.62c-2.32,0-3.48,1.02-3.48,3.06v12.11c0,1.76-0.58,3.2-1.74,4.32c-1.16,1.11-2.53,1.67-4.11,1.67
		c-1.76,0-3.2-0.56-4.32-1.67c-1.11-1.11-1.67-2.55-1.67-4.32V39.1z"/>
</g>
</svg>
" alt="애니팜" />
+        </div>
     </div>
-    {% endif %}
 </div>
 {% endfor %}
 </body>